Cancer Research

14.09.2026

Epigenetic Repression of Type I Interferon Signaling by RUNX2 Drives Immune Checkpoint Blockade Resistance in Osteosarcoma

Abstract Interferon (IFN) signaling plays a pivotal role in orchestrating antitumor immunity and shaping the response to immune checkpoint blockade (ICB). Although genetic alterations that impair the IFN pathway have been reported, such events are relatively rare, suggesting a po …

14.09.2026

Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer

Abstract High levels of immune suppression are a common intrinsic mechanism of resistance in metastatic breast cancer that calls for developing immunotherapeutic combinations to broaden treatment responses. Histone deacetylase (HDAC) inhibitors can sensitize tumors to dual checkp …

14.09.2026

The mRNA-Based Therapeutic Vaccine NTX250 Induces Potent Antitumor Immunity in HPV-Driven Cancers

Abstract Human papillomavirus (HPV) plays a pivotal role in various malignancies, including cervical, anogenital, head, and neck cancers. Despite the availability of highly effective prophylactic vaccines, many individuals remain susceptible to HPV-driven cancers due to barriers …

10.09.2026

YAP1-Driven PLCβ1 Impairs MHC-I Antigen Presentation and Limits Antitumor Immunity in Gastrointestinal Cancer

Abstract Immune checkpoint blockade (ICB) has revolutionized cancer treatment, yet its efficacy in gastrointestinal malignancies is often limited by an immunosuppressive tumor microenvironment. In this study, we identified phospholipase C beta 1 (PLCβ1) as a central driver of pat …

10.09.2026

Oral Fungal Infection Impacts Epithelial Innate Immunity to Promote Local and Distal Squamous Cell Carcinoma Progression

Abstract Fungi have been detected within human tumors and shown to support tumor progression. A better understanding of how intratumoral fungi evade innate immunity, remodel the tumor microenvironment (TME), and promote tumorigenesis may provide insights into cancer pathogenesis …

10.09.2026

Regression-Associated Macrophages Recruit Natural Killer Cells That Constrain Targeted Therapy Resistance

Abstract Targeted kinase inhibitors induce marked tumor regressions but are limited by the emergence of drug-tolerant residual disease and resistance. Although tumor-intrinsic and adaptive immune mechanisms have been extensively studied, a better understanding of the contribution …

08.09.2026

Targeting Both Oncogenic Signaling and Dependence Receptor Function is Required to Fully Suppress MET Exon 14 Skipping-Driven tumorigenesis

Abstract Receptor tyrosine kinases (RTKs) classically function as oncogenic drivers that promote survival and proliferation upon ligand binding. A subset of RTKs can also function as dependence receptors, inducing apoptosis in the absence of their ligands. Genetic alterations tha …

08.09.2026

Extracellular Matrix Remodeling in Tumors: Forces Beyond Fibroblasts

Abstract Aberrant extracellular matrix (ECM) remodeling in tumors is characterized by altered deposition, enzymatic cross-linking, degradation, and organization of matrix molecules that in turn can contribute directly to tumor invasiveness, immune evasion, and resistance to thera …

08.09.2026

Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response

Abstract Single-stranded DNA (ssDNA) gaps represent an underappreciated vulnerability that directly shapes therapeutic response in BRCA-deficient models. Current clinical biomarkers remain anchored to the double-strand break (DSB) centric model of homologous recombination deficie …

04.09.2026

Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression

Abstract Current immunotherapies often fail in immunologically “cold”, macrophage-rich tumor microenvironments (TMEs). Multi-targeting approaches that modulate innate-adaptive immune activation represent a promising frontier in cancer immunotherapy. Here, we developed phagocytic …

04.09.2026

Chemotherapy Reawakens Dormant Disseminated Pancreatic Cancer Cells in the Liver by Promoting Senescent Hepatocyte-Induced Neutrophil Extracellular Traps

Abstract Chemotherapy remains a cornerstone treatment for pancreatic ductal adenocarcinoma (PDAC), yet it paradoxically promotes metastatic recurrence. Elucidation of the underlying mechanisms mediating chemotherapy-induced metastasis could help identify improved combination trea …

03.09.2026

RASA2 Promotes Pancreatic Cancer Metastasis by Activating TGFβ-Dependent Noncanonical Hedgehog Signaling

Abstract KRAS mutations are a major driver of pancreatic ductal adenocarcinoma (PDAC). RASA2, a RAS GTPase-activating protein, modulates KRAS protein levels in wild-type (WT) contexts, suggesting that it could play a potential role in PDAC. In this study, we systematically invest …

03.09.2026

Histone Lactylation in Cancer-Associated Fibroblasts Induces Extracellular Matrix Remodeling and Immunosuppression to Promote Colorectal Cancer Progression

Abstract Cancer-associated fibroblasts (CAF) drive key aspects of tumor malignancy. However, the profound heterogeneity in cytokine secretion and cell–cell communication orchestrated by CAFs renders therapeutic strategies targeting these molecules largely ineffective against canc …

03.09.2026

Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression

Abstract The Tn antigen, a truncated O-glycan, is frequently elevated in pancreatic ductal adenocarcinoma (PDAC). Multiple therapeutic approaches targeting Tn have been developed, but they have not demonstrated clear efficacy signals in early-phase clinical studies. Improving Tn- …

03.09.2026

Transcriptomic Profiling of Mouse Mammary Tumors Enables Prognostic and Predictive Biomarker Discovery for Human Breast Cancer

Abstract The development and validation of prognostic and predictive biomarkers in breast cancer are limited by the availability of well-annotated datasets linking tumor molecular features to treatment response and survival outcomes. To address this need, we generated an extensiv …

03.09.2026

CDState Resolves Malignant Cell Heterogeneity from Bulk Tumor RNA Sequencing Data

Abstract Intratumor transcriptional heterogeneity (ITTH), defined as the coexistence of diverse cell states within a single tumor, complicates cancer treatment and contributes to variable therapeutic responses. Although single-cell RNA sequencing (scRNA-seq) can resolve this comp …

03.09.2026

Single-Cell Analysis Guides Organoid CRISPR Screening to Reveal NF1 as a Gatekeeper of Cervical Squamous Malignant Transformation

Abstract Cervical cancer progresses from high-grade squamous intraepithelial lesions driven by persistent HPV infection. Identifying the gatekeepers restraining malignant transformation could reveal strategies to prevent and treat cervical cancer. Here, we integrated single-cell …

01.09.2026

Histone Lactylation Mediated by circRNA-Facilitated FXR1 Phase Separation Promotes Colorectal Cancer Progression

Abstract Histone lactylation is an epigenetic modification triggered by lactate produced during glycolysis. In cancer, histone lactylation can coordinate metabolic and epigenetic states to promote tumor development and progression. In this study, we identified circ2891 as a drive …

01.09.2026

Targeting GEM Reprograms Macrophages and Overcomes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma

Abstract Esophageal squamous cell carcinoma (ESCC) exhibits heterogeneous responses to immune checkpoint blockade, highlighting the need to define tumor-intrinsic mechanisms driving resistance to PD-L1 inhibition. In this study, we identified GTP-binding protein overexpressed in …

01.09.2026

Fasting-Mimicking Diets Reprogram Cancer-Associated Fibroblasts to Reverse the Immunosuppressive Tumor Microenvironment in Breast Cancer

Abstract Fasting-mimicking diets (FMD) have been reported to increase the antitumor efficacy in preclinical studies in various cancers. FMD can affect the tumor microenvironment (TME), and elucidating the mechanisms and cells mediating the effects of FMD may uncover combination t …

01.09.2026

The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Minimal Toxicity

Abstract Potent and sustained inhibition of epidermal growth factor receptor (EGFR) signaling is critical for suppressing colorectal cancer (CRC) growth, yet current EGFR therapies are often limited by incomplete EGFR blockade and on-target/off-tumor toxicities, particularly skin …

31.08.2026

Microenvironmental Prostaglandin F2α Antagonizes FSP1 in Cancer Cells to Sensitize Tumors to Ferroptosis and Immunotherapy

Abstract Induction of ferroptosis is a potential strategy for treating cancer and improving the efficacy of immunotherapy. Ferroptosis is driven by excessive peroxidation of polyunsaturated fatty acid–containing phospholipids, suggesting that microenvironmental lipid metabolites …

28.08.2026

Mechanosensors Collaborate to Regulate DNA Damage Repair in Hepatocellular Carcinoma

Abstract Increased matrix stiffness is a biomechanical feature of hepatocellular carcinoma (HCC) that functions as an important promoting factor driving tumor progression. Characterization of the mechanosensors and the underlying downstream mechanisms driving HCC could help ident …

28.08.2026

Antibody–Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors

Abstract Antibody–drug conjugates (ADC) show clinical efficacy against several solid malignancies, inducing cytotoxic effects in malignant cells accompanied by changes in the composition of the tumor stroma. The therapeutic effects of some ADCs have been shown to be potentiated b …

27.08.2026

Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer

Abstract Clinical-grade RAS inhibitors raise an unresolved question as to whether KRAS alleles impose constraints on adaptive resistance that can be exploited therapeutically. Using daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor, we compared resistance mechanisms be …

27.08.2026

KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer

Abstract KRAS mutations, present in about 40% of colorectal cancers, are strongly associated with an immunosuppressive tumor microenvironment characterized by restricted immune infiltration and poor responses to immunotherapy. In this study, we found that KRAS mutations remodel t …

27.08.2026

Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma

Abstract Metastasis remains a leading cause of mortality in patients with esophageal squamous cell carcinoma (ESCC), underscoring the urgent need to elucidate the molecular mechanisms driving disease progression. In this study, we delineated that zinc finger BED-type containing 2 …

27.08.2026

Chronic Stress–Induced m7G Cap Modification of ADRB2 Dysregulates the Pentose Phosphate Pathway to Promote Esophageal Squamous Cell Carcinoma Progression

Abstract Chronic stress is increasingly recognized as a driver of cancer metabolism, highlighting the need to elucidate the mechanism linking chronic stress to metabolic reprogramming. In this study, we performed untargeted metabolomics on serum samples from patients with esophag …

27.08.2026

A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells

Abstract Casein kinase 1α (CK1α) is a multifunctional serine/threonine kinase, serving as an upstream regulator of the p53 pathway and a potential therapeutic target for acute myeloid leukemia (AML). Small-molecule degraders show preclinical promise in AML by selectively degradin …

27.08.2026

Cross-talk between Schwann Cells and CD4+ T Cells Promotes Perineural Invasion in Colorectal Cancer

Abstract Perineural invasion (PNI) is a common pathologic feature associated with poor prognosis in colorectal cancer. A better understanding of the mechanisms underlying PNI formation could help identify potential strategies to inhibit tumor progression. In this study, we reveal …

26.08.2026 · 1 Zitationen

Single-Cell Analysis of Residual Esophageal Squamous Cell Carcinoma after Neoadjuvant Immunochemotherapy Reveals TFAM-Mediated Immunoregulation in Dendritic Cells

Abstract Neoadjuvant immunochemotherapy (nICT) has emerged as a promising neoadjuvant strategy for esophageal squamous cell carcinoma (ESCC). Identification of the factors affecting responsiveness to nICT could help further improve treatment efficacy. In this study, we performed …

25.08.2026

ETV6 Rearrangement Suppresses CDKN1B Transcription by Disrupting an Intragenic Super-enhancer in Acute Lymphoblastic Leukemia

Abstract ETV6-rearranged acute lymphoblastic leukemia (ALL) is associated with poor prognosis in adults. Previously, a super-enhancer (SE) located within the ETV6 intragenic region (ETV6-SE) was identified in a rare fusion gene, ETV6::ACSL6; however, further work is needed to det …

25.08.2026

Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance

Abstract Poly (ADP-ribose) polymerase inhibitors (PARPi) are a first-line treatment for patients with epithelial ovarian cancer (EOC), but the development of resistance limits long-term therapeutic efficacy. Tumor acidosis is a hallmark of the tumor microenvironment (TME) that ha …

24.08.2026

Cystine Restriction Alleviates T-cell Exhaustion and Enhances CAR T-cell Potency

Abstract Although chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant efficacy in treating hematologic malignancies, its application in solid tumors remains challenging. A major limitation of CAR T-cell efficacy in solid tumors is the functional exhaustion …

24.08.2026

Oncogenic KRAS Rewires mRNA Stability and Translation through AGO2-Mediated Disruption of the miRNA pathway

Abstract KRAS mutations occur in over 90% of pancreatic ductal adenocarcinomas (PDACs). Despite recent advances in targeting oncogenic KRAS, tumors eventually acquire resistance. A more comprehensive understanding of the mechanisms connecting KRAS signaling to tumor progression c …

24.08.2026

Neutrophil Extracellular Trap-Derived DNA Activates the ITGB1/FAK Pathway to Promote Lung Adenocarcinoma Metastasis

Abstract Neutrophil extracellular traps (NETs) have recently emerged as key modulators of cancer progression and metastasis. However, a more comprehensive understanding of the underlying mechanisms could help identify effective strategies to prevent and treat NET-mediated metasta …

21.08.2026

Motherhood’s Sentinels: Pregnancy Induces Tissue-Resident Memory T Cells to Curb Breast Cancer Growth

Women who carry a pregnancy to term have long been known to have a reduced lifetime risk of breast cancer, yet the mechanisms underlying this protection remain poorly understood. Although parity-induced differentiation and hormonal remodeling of the mammary epithelium have been c …

21.08.2026

PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway

Abstract Noncanonical metabolic functions of signaling molecules contribute to cancer plasticity and metastatic progression. In this study, we demonstrated that phosphodiesterase type 5A (PDE5A) inhibitors, including sildenafil (Sild; Viagra), induced lysosomal cholesterol accumu …

20.08.2026

Exercise modulates microbial metabolites and induces stromal remodeling in pancreatic cancer

Abstract Exercise induces a variety of changes in the tumor microenvironment with beneficial effects in several tumor types. However, a better understanding of the clinical effects of exercise and mediating mechanisms is needed to maximize the utility of exercise for patients. In …

20.08.2026

Mathematical and Mouse Models Identify Regulatory T Cell Influx as A Key Determinant of Acquired Resistance to PD-1 Immunotherapy

Abstract The immune system can eradicate cancer, but various immunosuppressive mechanisms active within a tumor curb this beneficial response. However, unraveling the effects of multimodal interactions between tumor and immune cells and their contributions to tumor control using …

20.08.2026

Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity

Abstract Although checkpoint inhibitors have revolutionized cancer treatment, responses are largely restricted to targeting CTLA-4 and PD-(L)1. TNFR2 has been identified as a promising target, but further therapeutic development requires a better understanding of whether agonists …

19.08.2026

SEZ6-Targeted PET Imaging and Alpha-Particle Radioimmunotherapy is Effective for Detection and Treatment of Small Cell Lung Cancer

Abstract Small cell lung cancer (SCLC) remains one of the most lethal malignancies, with a 5-year survival of <10% despite advances in treatment. Seizure-related gene 6 (SEZ6), a type I transmembrane protein preferentially expressed in neuroendocrine tumors, has recently emerged …

19.08.2026

Serine Starvation Modulates mRNA Splicing through Translational Inhibition of SRSF Proteins

Abstract Serine is a critical nutrient for cancer cell proliferation due to its numerous downstream biosynthetic functions. Given the ongoing clinical efforts to utilize dietary serine starvation as a potential therapy for serine auxotrophic tumors, it is important to understand …

19.08.2026

High-Risk Rhabdomyosarcomas Feature a Convergent Cell State

Abstract Somatic mutations often predict survival in childhood cancers, as exemplified in rhabdomyosarcoma (RMS), in which FOXO1 gene fusion status is a key prognostic feature. In this study, we examined single-cell transcriptomes and discovered that cancer cells of lethal diseas …

19.08.2026

The Multimodal Pretraining Framework CarHE Predicts Spatial Transcriptomics in Tumors from Routine Pathology Images

Abstract Spatial transcriptomic analyses provide spatially resolved gene expression data that can provide insights into complex biological processes. However, current spatial transcriptomics approaches remain financially prohibitive and restricted in resolution, scalability, and …

18.08.2026

ARID1A Stimulates Notch-TLL1 Signaling to Induce Cancer-Associated Fibroblast Activation and Intrahepatic Cholangiocarcinoma Development

Abstract Intrahepatic cholangiocarcinoma (ICC) is a lethal hepatic malignancy characterized by a prominent desmoplastic stroma. In this study, we demonstrated that AT-rich interactive domain-containing protein 1A (ARID1A), a core component of the Switch/Sucrose (SWI/SNF) protein …

17.08.2026

Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer

Abstract Limited intratumoral persistence and insufficient proliferative capacity severely restrict the efficacy of chimeric antigen receptor (CAR) T-cell therapies in solid tumors. In this study, we demonstrated that DLL3-targeting CAR T cells co-expressing a CD56 chimeric switc …

13.08.2026

Micropharmacology beyond Target Expression: Mapping Barriers to Intratumoral Drug Delivery

High-dimension spatial technologies are broadly being used to map the cellular and molecular organization of human cancers including tumor antigens and drug targets. This has revealed extensive spatial heterogeneity of target proteins but does not quantify drug distribution itsel …

11.08.2026

CRISPR Screening Identifies SMARCAL1 and MRN as Modulators of WRN Dependency in MSI-H Colorectal Cancer

Abstract Microsatellite instability–high (MSI-H) colorectal cancer cells depend on the Werner syndrome helicase (WRN) to resolve cruciform DNA structures that arise from expanded TA-dinucleotide repeats. Loss of WRN induces replication stress and double-strand breaks, a vulnerabi …

11.08.2026

Spatial Profiling Reveals Immune Escape Pathways and Therapeutic Vulnerabilities in Prostate Cancer Bone Metastases

Abstract Prostate cancer (PCa) frequently metastasizes to bone, marking incurable disease. This progression is driven by an immunologically cold bone tumor microenvironment that fosters resistance to therapy. To define the mechanisms underlying this uniquely immunosuppressive nic …

06.08.2026

Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release

Abstract Colorectal cancer with microsatellite instability (MSI) is often treated with immune checkpoint inhibitors (ICI), such as anti–PD-1 antibodies. However, a substantial fraction of MSI colorectal cancers do not respond to ICIs. Recent studies have identified the DNA helica …

05.08.2026

Obesity and Age Elevate Tissue-Resident Microbiota Akkermansia muciniphila to Induce Oxidative Stress and Promote Breast Cancer Risk

Abstract Obesity is a modifiable risk factor for postmenopausal breast cancer. As obesity–gut microbiome interactions are well known, obesity might also affect tissue-resident microbiome populations as a mechanism promoting breast cancer. Using noncancerous breast tissue samples, …

05.08.2026

Matrix Stiffness-Encoded Mechanical Memory Maintains Proliferative Dominance in Metastatic Tumors

Abstract Primary and metastatic lesions share similar biological properties despite existing in different microenvironments. A better understanding of the mechanisms underlying the maintenance of phenotypic homogeneity in heterogeneous microenvironments could help identify strate …

04.08.2026

Co-targeting Deregulated WNT and MAPK Signaling Pathways Limits Phenotypic Reprogramming of Intestinal Stem Cell Progeny in KRAS-Hyperactivated Colorectal Cancer

In their recent article, Moore and colleagues demonstrate that, upon KRAS hyperactivation, colorectal cancer growth is driven by a reprogramming of Lgr5+ intestinal stem cell (ISC) progeny towards the acquisition of a regenerative phenotype. They find that this phenotype is regul …

04.08.2026

ALKBH5 in Cancer-Associated Fibroblasts Governs an Epitranscriptomic Axis That Drives Pancreatic Cancer Metastasis

Abstract Cancer-associated fibroblasts (CAF) are principal determinants of pancreatic ductal adenocarcinoma (PDAC) progression. CAFs can shape tumor behavior via multiple pathways, underscoring the need for a complete understanding of the regulatory mechanisms that govern CAF fun …

04.08.2026 · 1 Zitationen

TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis

Abstract Adoptive T-cell transfer (ACT) therapy offers curative potential for some patients with cancer. Toll-like receptor (TLR) agonists improve the efficacy of ACT therapy, and elucidating the underlying mechanism of potency could help determine the best way to maximize the be …

04.08.2026

IL-1α Expands SLC2A1HighSPP1HighIFNLow Myeloid Cells to Drive Immune Escape and Malignant Transformation of Precancers

Abstract Head and neck squamous cell carcinomas (HNSCC) are preceded by potentially malignant precursor lesions, highlighting the need for strategies to discern which precancerous lesions harbor a high risk for malignant transformation. In this study, we developed a unique geneti …

04.08.2026

Context-Dependent Cancer Vulnerabilities: CRISPR Screening under Inflammatory Stress

Genome-wide CRISPR screens have systematically identified genes required for cancer cell survival, yet these studies are typically performed under standardized conditions that do not fully recapitulate the physiologic stresses encountered within the tumor microenvironment. In a r …

03.08.2026

Multiomics Dissection Reveals Natural Killer Cell–CD8+ T-cell Cooperation in Shaping an Immunostimulatory Tumor Microenvironment

Abstract Immune evasion remains a major barrier to effective immunotherapy in cancer. Coordinated activation of different immune cell types shapes immune responses within the tumor microenvironment (TME). In this study, we uncovered a spatiotemporal synergy between cytotoxic T ly …

31.07.2026

From Tissue Specificity to Systemic Cues: Shaping MYC-Driven Tumor Metabolism

Abstract The proto-oncogene MYC acts as a master regulator of diverse metabolic programs that fuel tumor initiation and progression, but the exact programs it activates depend heavily on context, tissue type, accompanying mutations, and the tumor microenvironment (TME). Furthermo …

31.07.2026

Macrophage-Induced Senescent Cancer-Associated Fibroblasts Promote SASP-Mediated Chemoresistance in Colorectal Cancer

Abstract Cancer-associated fibroblasts (CAF) play a crucial role in the tumor microenvironment (TME) by influencing tumor progression, metastasis, and therapy resistance. Accumulating evidence suggests that CAFs undergo senescence, which can affect their effects on the TME. In th …

30.07.2026

Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS - and RAF -Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass

Abstract Inappropriate activation of the mitogen-activated protein kinase (MAPK) pathway, often stemming from activating mutations in RAS or RAF, represents one of the most common oncogenic events in human cancer. However, currently approved RAS/RAF inhibitors target specific mut …

30.07.2026

The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers

Abstract Cancer is the leading cause of disease-related deaths among children in high-income countries. Tumor heterogeneity and the lack of mechanism of action–based therapeutic options are key challenges to overcome to improve the survival of pediatric patients with cancer. To a …

30.07.2026

Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non–Small Cell Lung Cancer

Abstract The disease burden from non–small cell lung cancer (NSCLC) adenocarcinoma is substantial, with a million new cases diagnosed globally each year and a 5-year survival rate of less than 20%. The lack of therapeutic options personalized to individual patients leads to high …

28.07.2026

Comprehensive Genomic Analysis of Normal and Cancer Cells Elucidates the Elevated Mutational Burden in Cancer

Abstract Self-renewing normal tissues generate several somatic mutations at each division. Previous studies have reported that cancer cells have more mutations than their normal counterparts. It is not obvious why dramatic differences in mutational burdens between normal tissues …

28.07.2026

SEPTIN7 Enhances Tumorgenesis and Therapeutic Resistance in Hepatocellular Carcinoma by Promoting FGFR4 Stabilization and Recycling

Abstract Hepatocellular carcinoma (HCC) is a highly lethal malignancy with rapid onset of drug resistance and high recurrence rate, partly driven by cancer stem cells (CSC). In this study, we identified a small GTPases SEPTIN7 as a critical regulator of tumorigenesis and therapeu …

28.07.2026

Targeting Cystine Addiction Suppresses Breast Cancer Lung Metastasis

Abstract Metastatic disease remains a major cause of cancer-related mortality. Recent studies suggest that dissemination to other organs comes with metabolic changes that allow the metastasizing cancer cells to adapt to new microenvironments. A deeper knowledge of these specific …

27.07.2026

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies

Abstract Preclinical translational research has increasingly utilized patient-derived xenograft (PDX) models for mechanistic and experimental therapeutic studies, yet most existing models have been developed from adult cancer types. We describe the establishment of a PDX program …

23.07.2026

Non-kinase Orchestrated VEGFR2–ERK Signaling is a Dependency and Pharmacological Target for Antiangiogenic Immunotherapy

Abstract Antiangiogenic immunotherapy represents a promising cancer treatment strategy. However, the efficacy of this combination approach is hindered by inadequate vascular normalization. While the fundamental role of canonical kinase-centric VEGFR–ERK signaling in angiogenesis …

23.07.2026

Lactylation Orchestrates Immune Evasion in Gastric Cancer through KDM5B-Mediated Histone Demethylation

Abstract Immune evasion driven by the tumor microenvironment is a major obstacle to effective immunotherapy in gastric cancer. To overcome this barrier, a detailed understanding of the mechanisms by which gastric cancer circumvents antitumor immunity is essential. In this study, …

21.07.2026

Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer

Abstract Small cell lung cancer (SCLC) is an aggressive malignancy marked by rapid progression, early dissemination, and a pronounced propensity for brain metastases (BM), which develop in up to 80% of patients. SCLC is defined by profound genomic instability, lineage plasticity, …

21.07.2026

Inhibiting PPM1D Perturbs Mitochondrial Integrity to Stimulate cGAS-STING Signaling and Antitumor Immunity

Abstract Immune checkpoint blockade (ICB) represents an important therapeutic approach for hepatocellular carcinoma (HCC). However, resistance to ICB treatment remains challenging. In this study, we identified protein phosphatase magnesium–dependent 1δ (PPM1D) as a driver of HCC …

20.07.2026

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor–Resistant HR+/HER2− Breast Cancer

Abstract Intrinsic and acquired resistance to CDK4/6 inhibitors (CDK4/6i) is a critical challenge in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) metastatic breast cancer (MBC). CDK2 inhibitors (CDK2i) show promise in this context, wi …

17.07.2026

Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma

Abstract High-grade serous (tubo-ovarian) carcinoma (HGSC) is the most lethal gynecologic malignancy and the most common form of ovarian cancer. Most patients (75%) are diagnosed at advanced disease stages, with widespread peritoneal dissemination leading to a poor prognosis. In …

16.07.2026

EGFR N-Glycosylation Catalyzed by NDST2 Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Abstract The clinical efficacy of lenvatinib, a multitarget tyrosine kinase inhibitor used as a first-line treatment for advanced hepatocellular carcinoma (HCC), is frequently compromised by the development of drug resistance. Elucidating the molecular mechanisms underlying this …

15.07.2026

Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones

Abstract Cancer treatment using immune checkpoint blockade (ICB) with anti–programmed cell death protein 1 (αPD-1) and anti–cytotoxic T lymphocyte–associated protein 4 (αCTLA-4) has been successful. However, primary and acquired resistance limits clinical benefit. To improve the …

15.07.2026

KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma

Abstract Lung squamous cell carcinoma (LUSC) is a basal-like subtype of lung cancer with limited treatment options. Although prior studies have identified tumor-propagating cell (TPC) states in squamous tumors, further work is needed to elucidate the broader landscape of intratum …

13.07.2026

Label-Free Prediction of EGFR Mutation Status Using Fluorescence Lifetime Imaging and Deep Learning in Lung Adenocarcinoma

Abstract Accurate prediction of epidermal growth factor receptor (EGFR) mutations is essential for guiding targeted therapy in non–small cell lung cancer (NSCLC) and is routinely performed in clinical pathology samples. Current diagnostic practices rely on molecular techniques su …

10.07.2026 · 1 Zitationen

BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma

Abstract Synovial sarcoma incorporates the SS18::SSX fusion oncoprotein into GLTSCR1-containing BRG1/BRM and associated factors (GBAF) complexes, which confers a dependency on the GBAF subunit BRD9. However, synovial sarcoma clinical trials with multiple BRD9 degraders failed to …

08.07.2026

PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance

Abstract Gastric cancer is a lethal malignancy with limited targeted therapeutic options, particularly for HER2-negative disease. Through integrated bioinformatic analysis of multiple gastric cancer cohorts, we identified poly(ADP-ribose) glycohydrolase (PARG) as a DNA damage res …

30.06.2026

SMARCB1 Deficiency in Tumors Confers Vulnerability to H3K27 Demethylase Inhibitors via Autophagy Disruption

Abstract Inactivation of the Switch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling complex is a hallmark of multiple human cancers. In this study, we showed that SMARCB1-deficient cells, including highly aggressive pediatric malignant rhabdoid tumors (MRT), display aberra …

25.06.2026 · 1 Zitationen

Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma

Abstract Multiple myeloma is marked by recurrent cytogenetic abnormalities and mutations that accumulate as the disease progresses. In this study, we sought to elucidate the transitions driving tumorigenesis and therapy resistance in multiple myeloma using a unique cohort of near …

22.06.2026

Longitudinal Single-Cell RNA-Sequencing Reveals Evolution of Micro- and Macro-states in Chronic Myeloid Leukemia

Abstract Single-cell RNA-sequencing (scRNA-seq) has revolutionized our understanding of cancer. However, identifying meaningful disease states from single-cell data remains challenging due to the complex continuum of transcriptional alterations, which may obscure clear phenotype …

30.04.2026 · 1 Zitationen

CRISPR Screening Reveals SAA1-Driven Neutrophil Extracellular Traps Promote CD8⁺ T Cell Dysfunction in Renal Cell Carcinoma

Abstract Immune checkpoint inhibitors are a frontline treatment for metastatic renal cell carcinoma (RCC), one of the most common malignancies of the urinary system. However, a large proportion of patients exhibit poor responses or develop resistance, which severely limits the th …

02.09.2026

Editor’s Note: miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells

02.09.2026

Varying Cancer Drug Doses to Balance Tumor Control and Resistance Evolution

The effectiveness of any cancer therapy depends on its dose and its treatment schedule. A potential third dimension of regimen design is whether intentional fluctuations in administered dose might improve treatment outcomes. In this issue, West and colleagues demonstrate that dos …

02.09.2026

Editor’s Note: Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2 -Amplified Breast Cancers

23.06.2026

Opportunities to Enhance Cancer Research through Advocate–Researcher Partnerships

Abstract People who have experienced cancer are integral partners in the research process and improving standard-of-care treatments. Advocates contribute insights from lived experience that help researchers identify impactful scientific priorities, improve study design, and enhan …

18.06.2026

Aerobic Exercise Activates S1PR1 Signaling in Tumor Endothelial Cells to Promote Vascular Function in Pancreatic Cancer

Abstract Pancreatic ductal adenocarcinoma (PDAC) is characterized by high resistance to anticancer therapies, which is caused in part by hypovascularization and dysfunctional vessels that inefficiently deliver chemotherapy. Exercise has been shown to improve tumor vascular functi …

18.06.2026

HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation–Mediated TXNRD1 Stabilization to Suppress Ferroptosis

Abstract The development of therapy resistance compromises the long-term efficacy of lenvatinib in advanced hepatocellular carcinoma (HCC), highlighting the need to characterize the molecular drivers of resistance. Through integrated multiomics analysis combining genome-wide CRIS …

17.06.2026

Counterfactual Diffusion Models Provide Interpretable Explanations of Artificial Intelligence Models in Pathology

Abstract Deep learning can extract predictive and prognostic biomarkers from histopathology whole-slide images. However, explainable artificial intelligence approaches widely used in digital pathology, such as attention heatmaps and class activation mapping, provide limited insig …

16.06.2026

Mapping the Divergence and Convergence of Mouse and Human Tumor Immunity

Mouse models remain the premier preclinical model organisms for cancer immunotherapy, yet how they faithfully recapitulate the human tumor microenvironment has remained poorly defined. In a recent Nature Immunology study, Courau and colleagues addressed this gap through a systema …

15.06.2026

Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells

Abstract Chemotherapy induces cancer cell apoptosis and the release of apoptotic bodies (AB) that are poorly immunogenic or immunosuppressive, creating a major barrier to the success of coadministered or second-line immunotherapies. In this study, we found reduced circulating lev …

10.06.2026

TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy

Abstract Epigenetic silencing of interferon (IFN) signaling contributes to the resistance of tumors to programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immune checkpoint blockade. In this study, we conducted a fluorescence-activated cell sorting (FACS …

10.06.2026

Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer

Abstract The management of metastatic breast cancer (mBC) relies on tissue-based immunohistochemical subtypes. However, biopsies are invasive and may not capture metastatic heterogeneity, and subtypes can change over time under treatment pressure. In this study, we developed cell …

08.06.2026

Deficiency in POLE Exonuclease Causes Synthetic Lethality in Highly Aneuploid Cancer Cells

Abstract Aneuploidy is a hallmark of cancer and is associated with drug resistance and poor clinical outcomes across diverse cancer types. However, no therapies have been clinically established to target highly aneuploid tumors. By analyzing nearly half a million tumor samples su …

08.06.2026

Spatial Analysis Reveals Gene Expression and Microenvironmental Changes in the Transition of Nevus to Melanoma

Abstract A third of melanomas originate from benign melanocytic nevi, representing a transition between distinct stages of melanocytic neoplasia. To gain insight into the transcriptional and microenvironmental changes accompanying this transition, we used spatially resolved, tran …

08.06.2026

KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones

Abstract The clinical benefit of therapies targeting the KRAS G12C mutation is substantially limited by the development of resistance through multiple mechanisms. Therefore, to achieve lasting benefit with these therapies, effective strategies to tackle the evolution of drug resi …

08.06.2026

PARK7-Mediated Delactylation of SF3B Reprograms RNA Splicing to Attenuate Fibrosis and Promote Antitumor Immunity

Abstract Lactylation, an emerging posttranslational modification, plays a crucial role in epigenetic regulation and tumorigenesis. Characterization of the key enzymes governing lactylation in tumors, including writers, erasers, and readers, could help identify potential therapeut …

08.06.2026

A Co-opted Developmental Gene Regulatory Program in Endothelial Progenitors Promotes Tumor Angiogenic Phenotypes

Abstract The transition of endothelial cells (EC) to tumor-associated ECs (TEC) is a critical process in tumor progression. The underlying mechanisms driving this angiogenic state could represent potential therapeutic targets. In this study, we revealed that a co-opted gene regul …

08.06.2026 · 2 Zitationen

Lactate-Activated GPR132 Signaling Drives a Tumor Microenvironmental Autocrine Metabolic Loop in Kidney Cancer

Abstract Despite the presence of oxygen, tumors frequently preferentially perform fermentative glycolysis, producing lactate and acidifying the tumor microenvironment (TME). Although studies have observed that high concentrations of lactate in the TME help tumors gain a prolifera …

29.05.2026

JUN Specifies the Local Differentiation and Maintenance of Pro-tumoral Monocyte-Derived Macrophages

Abstract Tumor-associated macrophages (TAMs) play important roles in cancer progression and resistance to therapy. Recent studies have shown that TAMs include both long-lived resident tissue macrophages (RTMs) and short-lived monocyte-derived macrophages (MDMs) with limited proli …

21.05.2026 · 1 Zitationen

Evolutionary Antifragile Therapy Is a Treatment Strategy to Suppress Drug Resistance by Exploiting Dose–Response Convexity

Abstract A population of cells within a tumor can be described as antifragile (the opposite of fragile) if they derive a benefit from fluctuations or perturbations in environmental conditions induced by treatment. Treatment fluctuations could either promote (antifragile tumor) or …

14.08.2026

Retraction: CYP3A5 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Regulating mTORC2/Akt Signaling

14.08.2026

KRASG12V Degraders Provide a Potential Therapeutic Opportunity in Lung Adenocarcinoma

Mutant KRAS inhibition has revolutionized the treatment of lung adenocarcinoma. Unfortunately, responses to this form of targeted therapy are often of limited duration because of the development of resistance. Targeted protein degradation, including using PROTACs (PROteolysis-TAr …

15.06.2026 · 1 Zitationen

Reprogramming of TLR–Ferroptosis Signaling and Immunometabolic Pathways Overcomes Myeloid Suppression to Improve Checkpoint Blockade in Prostate Cancer

Abstract The limited efficacy of immunotherapies in advanced prostate cancer stems from a tumor microenvironment (TME) in which myeloid-driven immune suppression, stromal remodeling, and metabolic barriers converge to limit antitumor immunity. In this study, we characterized the …

11.06.2026

Seeing Is Believing: Intercellular Transfer of DNA between Human Cells

Genomic insults in the form of DNA damage and mitotic errors can result in mislocalization of nuclear DNA into the cytoplasm in the form of micronuclei or as fragmented chromosomal elements. Recent work from the Ly lab has demonstrated that cytoplasmic DNAs can undergo intercellu …

08.06.2026

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors

Abstract Gastrointestinal stromal tumor (GIST) is the most common gastrointestinal mesenchymal tumor, driven by tyrosine–protein kinase (KIT) and platelet-derived growth factor receptor A (PDGFRA) mutations. Specific variants, such as KIT exon 11 deletions, carry prognostic and t …

02.06.2026

Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity

Abstract Regulatory T cells (Treg) infiltrate most tumors, and increased Treg infiltration is correlated with reduced survival in patients with cancer. Although Tregs suppress antitumor immunity, they are also integral for preventing harmful inflammation in nontumor tissues, hind …

02.06.2026

Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination

Abstract Breast cancer is the most commonly diagnosed malignancy and a leading cause of cancer-related mortality. Hormone receptor–positive (HR+) tumors represent the most prevalent metastatic subtype, and early dissemination remains a major clinical challenge. Commensal dysbiosi …

01.06.2026 · 2 Zitationen

Autophagy Inhibition Reprograms the Tumor Microenvironment of Pancreatic Cancer to Promote Macrophage Phagocytosis of Tumor Cells

Abstract Pancreatic ductal adenocarcinoma (PDAC) relies on elevated autophagy to support metabolism, proliferation, and immune evasion. Inhibiting autophagy has been reported to improve response rates in patients with PDAC. In this work, we identified a mechanism to explain how t …

01.06.2026

Stage-Specific Degradation of Cyclin D3 Orchestrates Myelopoiesis and Restrains Myeloproliferative Neoplasm Development

Abstract Accumulation of D cyclins during the G1-phase of the cell cycle is a key regulatory step that derepresses the transcriptional program required for DNA replication, facilitating S-phase entry. Among the three D cyclins, cyclin D3 predominates in hematopoietic cells. Accor …

29.05.2026 · 1 Zitationen

Alcohol-Induced Metabolic Stress Sensed by m6A-Modified ChREBP Drives Immune Evasion in Esophageal Carcinogenesis

Abstract Chronic alcohol consumption is an established risk factor for esophageal squamous cell carcinoma (ESCC). Elucidating the underlying mechanisms linking metabolic stress to esophageal carcinogenesis could help identify prevention and treatment strategies. Through a transan …

28.05.2026 · 1 Zitationen

ICAM1high Neutrophils Sculpt Tumor Evolution and Metastasis Through Symbiotic Adhesion and Reverse Migration

Abstract Neutrophils are a prominent component of the tumor microenvironment (TME) that can have both pro- and antitumor functions. By analyzing neutrophils across different human cancers, we revealed an ICAM1high subset enriched in the TME, which was also observed in murine trip …

28.05.2026

GDF15 Reprograms the Microenvironment to Drive Liver Metastasis of Uveal Melanoma

Abstract Uveal melanoma is an aggressive tumor type that frequently results in fatal liver metastasis. A better understanding of the interactions between uveal melanoma and host cells in the tumor microenvironment that promote liver metastasis could lead to the development of the …

27.05.2026

Fusobacterium nucleatum Promotes Exosomal LncRNA MANCR Secretion from Colorectal Cancer Cells to Induce PD-L1 Expression in Macrophages

Abstract Fusobacterium nucleatum is a key microbial driver of colorectal cancer progression. In this study, we identified an intercellular signaling axis through which F. nucleatum remodels the immune microenvironment. Analysis of 54 clinical colorectal cancer specimens revealed …

27.05.2026 · 2 Zitationen

Targeted KRASG12V Degradation In Vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis

Abstract Recent drug discovery breakthroughs have led to the approval of KRASG12C inhibitors in lung adenocarcinoma. Unfortunately, clinical responses are often hampered by the rapid onset of resistance. Proteolysis-targeting chimeras (PROTAC) have emerged as promising alternativ …

27.05.2026

eIF4G2-Dependent Translation Restrains Pancreatic Cancer Progression

Abstract The lethality of pancreatic ductal adenocarcinoma (PDAC) is driven, in part, by cellular plasticity that facilitates dedifferentiation and dissemination. Although transcriptional programs underlying these processes are well characterized, the contribution of translationa …

27.05.2026 · 1 Zitationen

Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer

Abstract Pancreatic cancer remains one of the deadliest malignancies, with gemcitabine-based chemotherapy as the mainstay treatment for most patients, yet resistance emerges almost universally. A defining feature of pancreatic cancer is its dense, fibroblast-rich stroma, in which …

22.05.2026 · 1 Zitationen

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS -Mutated Melanoma

Abstract Most patients with advanced BRAF- or NRAS-driven melanoma receive first-line immunotherapy. However, if immunotherapy fails, BRAF-mutated patients receive effective second-line therapies, whereas NRAS-mutated patients lack pathway-targeted options. Recently, RAS(ON) mult …

22.05.2026

Ancestral Genetic Homogeneity in Preclinical Models May Shape Outcome Differences in Pediatric Brain Cancer

Abstract The influence of genetic ancestry on cancer development and treatment response is underappreciated within pediatric neuro-oncology. Pediatric brain tumors (PBT) comprise the deadliest malignancies among childhood cancers. Poorer prognoses are accentuated in minority popu …

19.05.2026

ETS1 Orchestrates a Hybrid EMT Program Driving Metastasis and Immune Evasion

Abstract Transcriptional intratumoral heterogeneity (ITH) is a hallmark of aggressive cancers. Investigation into the ITH programs that drive tumor metastasis and immune evasion could help identify potential treatment and prevention approaches. Through single-cell RNA sequencing …

01.08.2026

Correction: Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells

26.05.2026

Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer

Abstract High-grade serous ovarian cancer (HGSOC) is a lethal malignancy characterized by profound intratumoral heterogeneity and immune evasion. Although previous research has identified 4 molecular subtypes of HGSOC, defining their spatial distribution across anatomic sites cou …

26.05.2026

MPND Loss Epigenetically Activates TGFβ/SMAD3 Signaling to Drive Tumor Progression and Metastasis in Non–Small Cell Lung Cancer

Abstract Although non–small cell lung cancer (NSCLC) is among the most prevalent malignancies, currently available treatments remain largely ineffective, highlighting the need to elucidate the precise mechanisms of tumorigenesis. The Mpr1/Pad1 N-terminal domain-containing protein …

26.05.2026 · 1 Zitationen

GNAQ Induces Melanomagenesis in Mitfa-Independent Melanocyte Progenitors in a Zebrafish Model of Uveal Melanoma

Abstract Melanocytes reside in diverse microenvironments that influence their susceptibility to oncogenic transformation; however, investigation of rare melanoma subsets has been limited by the lack of suitable preclinical animal models. In this study, we developed a primary, imm …

20.05.2026 · 3 Zitationen

Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma

Abstract Chimeric antigen receptor (CAR) T-cell therapy has shown early promise against glioblastoma, which lacks effective treatment options. However, two key challenges curtail efficacy: tumor-antigen heterogeneity and an immunosuppressive tumor microenvironment. CAR T cells en …

18.05.2026 · 1 Zitationen

Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming

Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor outcomes. Obesity increases the risk of PDAC through metabolic dysregulation and inflammation. Ketogenic diet (KD) can alter metabolism and has been evaluated for its effects on tumor progression i …

18.05.2026 · 2 Zitationen

Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer

Abstract Glucocorticoid receptor (GR) signaling is critical to our physiology but is dysregulated in cancer by the pain, psychologic distress, iatrogenic morbidity, and pathology associated with an advanced, invasive disease. Many tumors exploit glucocorticoid signaling to provid …

14.05.2026 · 2 Zitationen

Targeting the αvβ5 Integrin Modifies the TGFβ-Rich Tumor Microenvironment of Pancreatic Cancer

Abstract Pancreatic ductal adenocarcinoma (PDAC) is notorious for its aggressive, therapy-resistant nature that is in part driven by the desmoplastic, hypoperfused, and immunosuppressive tumor microenvironment (TME). In this study, we demonstrated that the αv integrin and neuropi …

14.05.2026

MYO1G Facilitates Caveolin 1–Mediated Endocytosis of the N-Terminal Fragments of Gasdermin E to Restrain Pyroptosis and Chemotherapy Efficacy

Abstract The N-terminal fragments of gasdermin (GSDM-NT) form pores on the plasma membrane that initiate pyroptosis. However, the presence of GSDM-NT pores does not necessarily result in cell death, allowing some cells to survive GSDM-mediated pyroptosis. Understanding the regula …

14.05.2026

Distinct Inflammatory Cytotoxic T Lymphocyte Populations Mediate PD-1 Blockade–Induced Immune-Related Adverse Events in Multiple Organs

Abstract Immune checkpoint blockade–induced immune-related adverse events (irAE) hamper the application of this revolutionary antitumor therapeutic strategy. In this study, we explored the mechanisms driving irAEs by profiling the immune ecosystem of major irAE-affected organs at …

12.05.2026 · 1 Zitationen

Interplay of Glioblastoma Cells with Microglia Shapes Invasive Phenotypes during Long-distance Invasion

Glioblastoma (GBM) infiltration poses a formidable therapeutic challenge, but the mechanisms enabling long-distance tumor invasion remain poorly defined. In a recent study, Nebeling and colleagues have leveraged longitudinal three-photon intravital microscopy to visualize the mig …

06.05.2026 · 1 Zitationen

PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition

Abstract Despite the availability of RAS inhibitors and the dependence of >90% of pancreatic ductal adenocarcinomas (PDAC) on oncogenic KRAS mutations, resistance to KRAS inhibition remains a serious obstacle. We showed here that phosphoinositide 3-kinase (PI3K) plays a major rol …

30.04.2026

SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma

Abstract SETD2 is frequently mutated or deleted in clear cell renal cell carcinoma (ccRCC). Loss of SETD2 could create synthetic lethal dependencies that confer therapeutic vulnerabilities. In this study, we demonstrated that SETD2 deficiency promotes cytoplasmic mitochondrial DN …

29.04.2026

Shaping CDK4/6 Inhibitor Resistance: BRCA2 Germline Alterations Bias toward RB1 Inactivation

The emergence of resistance to CDK4/6 inhibitors (CDK4/6i) is a major barrier to long-term survival in metastatic hormone receptor–positive breast cancer. Mechanisms of CDK4/6i resistance are highly diverse and are currently unpredictable. In a recent issue of Nature, Safonov and …

20.04.2026

SIRT1 Inhibits T-cell Infiltration and Tertiary Lymphoid Structure Formation to Promote Radioimmunotherapy Resistance

Abstract Microsatellite stable (MSS) rectal cancer exhibits intrinsic resistance to immunotherapy. Although radiotherapy is frequently combined with immune checkpoint inhibitors (ICI) to augment immunotherapy responses, numerous immunologically cold tumors remain unresponsive. In …

18.07.2026

Abstract A046: Pre-diagnostic clinical-trajectory signatures of early-onset pancreatic cancer

Abstract Background: Early-onset pancreatic cancer (EOPC; age <50 y at diagnosis) is rare (≈1.3/100,000), biologically distinct, and germline-enriched (BRCA1/2, PALB2, ATM, CDKN2A, Lynch). Despite NCCN and CAPS Consortium recognition, its pre-diagnostic electronic health record ( …

18.07.2026

Abstract A024: LP-184, a novel acylfulvene alkylating agent, demonstrates potent antitumor activity and survival benefit in SMARCB1-deficient tumor models

Abstract SMARCB1 is a subunit of the mammalian SWI/SNF chromatin remodeling complex that plays a critical role in regulating gene transcription, cell differentiation, and DNA repair. Loss of SMARCB1 leads to widespread epigenetic dysregulation and contributes to the aggressive bi …

18.07.2026

Abstract A029: Durvalumab and tremelimumab in patients with metastatic non-adenoid cystic salivary gland cancer treated in the CCTG IND.228 phase II basket trial

Abstract Background: Over two dozen histological types of salivary gland cancers are recognized comprising 3-5% of all head and neck cancers. Response to chemotherapy and actionable target expression in patients with metastatic disease vary by histological type e.g. HER2 and/or a …

18.07.2026

Abstract A022: Uncovering CAR-T targets from the cholangiocarcinoma proteome

Abstract Objective: The project is designed to identify pairs of proteins for CAR-T co-targeting immunotherapy for cholangiocarcinoma (CCA) based on expression of surface proteins in proteomic experiments. Introduction: Cholangiocarcinoma is a rare cancer of the bile duct, with a …

18.07.2026

Abstract B043: Microenvironmental stress programs polyploid giant cancer cell lineages that generate resistant progeny: implications for rare aggressive cancers

Abstract Polyploid giant cancer cells (PGCCs) are increasingly recognized as stress-adaptive tumor states associated with relapse, metastasis, and therapy resistance in aggressive malignancies, yet how distinct microenvironmental stresses program PGCC lineage behavior remains unc …

18.07.2026

Abstract B034: Radical collaboration in rare oncology: Accelerating therapeutic validation through federated learning and remote precision master protocols

Abstract Rare malignancies, defined by an incidence of <6 cases per 100,000 individuals per year, collectively constitute 25% of the global cancer burden. However, progress is hindered by the "diagnostic odyssey" and structural barriers that concentrate clinical trials in urban a …

18.07.2026

Abstract A033: Integrated PET/CT Phenotyping with Novel Hotspot-Weighted Uptake and Spatial Hotspot Descriptors for Risk Stratification in Malignant Pleural Mesothelioma

Abstract Background: Malignant pleural mesothelioma (MPM) is a rare, aggressive thoracic cancer in which tissue biomarkers are limited by sampling bias and marked spatial heterogeneity. We hypothesized that whole tumor phenotyping from baseline 18F-FDG PET/CT could identify a bio …

18.07.2026

Abstract A054: Convergent tumor microenvironment correlates of pembrolizumab response and resistance in advanced rare cancers

Abstract Background: Rare cancers account for ∼25% of cancer deaths, yet remain understudied; MSI-H, TMB-H, and PD-L1 markers capture only a fraction of checkpoint-inhibitor responders. We analyzed pembrolizumab in advanced rare cancers to identify immune correlates of clinical b …

18.07.2026

Abstract B021: Autoimmunity versus apoptosis in some cases of chronic lymphocytic leukemia

Abstract Introduce: Apoptosis, which plays a vital role in regulating the cellular lifespan, is a programmed process distinct from necrosis, which results from physical or chemical injury. The decision to initiate this "cellular suicide" is driven by either intrinsic or extrinsic …

18.07.2026

Abstract A055: Integrative epigenomic characterization of MGMT and LINE-1 methylation in diffuse gliomas and colorectal cancer: insights from rare brain tumors

Abstract Background: MGMT promoter methylation predicts benefit from alkylating agents in diffuse gliomas, while LINE-1 retrotransposon methylation indicates global epigenetic dysregulation in colorectal tumors. The interplay between these two markers in rare brain gliomas and th …

18.07.2026

Abstract B035: A Phase 2 Platform Trial Integrated with Patient Digital Twins to Prioritize and Refine Therapies for Sarcomas: The RAPID Study

Abstract Ewing sarcoma (ES) and desmoplastic small round cell tumor (DSRCT) are rare, aggressive malignancies affecting adolescents and young adults (AYA), with <25% 5-year survival in the relapsed/refractory setting. Drug development in these populations is limited by small pati …

18.07.2026

Abstract A059: MCHR-1 as an emerging immunotherapy target in ovarian clear cell carcinoma: Opportunities and challenges for translational CAR-T development

Abstract Background: Ovarian clear cell carcinoma (OCCC) is a rare and aggressive malignancy characterized by intrinsic chemoresistance and limited responsiveness to current immunotherapies. A major barrier to CAR-T development in solid tumors is the lack of validated tumor restr …

18.07.2026

Abstract B020: Evaluating copy number changes of chromosomally unstable vulvar squamous cell carcinoma and vulvar intraepithelial neoplasia lesions

Abstract Introduction: Vulvar squamous cell carcinoma (VSCC) is a rare gynecological malignancy that accounts for 0.4-0.7% of all cancers and 2-6% of all gynecological malignancies. VSCCs are divided into human papillomavirus associated (HPVa) tumors or HPV independent (HPVi) tum …

18.07.2026

Abstract B028: Repurposing adult clinical trials for rare cancer immune target discovery using the CURE AI foundation model

Abstract Conventional research begins with an observation that is relevant to human health followed by years of testing in a laboratory environment. This type of 'forward translation' research is the basis for most therapeutic development but fails in over 90% of therapeutic cand …

18.07.2026

Abstract B027: RB1 Loss in Pulmonary Large Cell Neuroendocrine Carcinoma is Associated with More Abundant Pro-inflammatory Stromal Immune Cells

Abstract Introduction: Large cell neuroendocrine carcinoma (LCNEC) of the lung is a rare and aggressive malignancy, with uncertain response to immunotherapy. Molecular features of LCNEC are heterogenous. The present study aimed to determine how immune cell infiltration in the LCN …

18.07.2026

Abstract A017: FAP-Activated Prodrugs Target Cancer Stem Cells in Esophageal Adenocarcinoma

Abstract Esophageal adenocarcinoma (EAC) is a rare and lethal malignancy that evolves through a stepwise mucosal progression — from an intestinal metaplasia known as “Barrett's esophagus (BE)” to low-grade dysplasia (LGD), high-grade dysplasia (HGD), and finally invasive carcinom …

18.07.2026

Abstract B038: Multi-omic Analyses in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp

Abstract Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematologic malignancy with mixed cellular states encompassing dendritic, myeloid, and lymphoid features. Presentation of BPDCN is heterogeneous, starting predominantly in the skin before spreading to …

18.07.2026

Abstract B017: TLR4 loss and IKKα haploinsufficiency drive bacterial dysbiosis and IL-4R–mediated squamous carcinogenesis in skin 3D organoids

Abstract Barrier tissues continuously sense and interact with commensal microbes to maintain immune and epithelial homeostasis, and disruption of this finely tuned crosstalk has been increasingly implicated in carcinogenesis. In the skin, Toll-like receptor 4 (TLR4) has been asso …

18.07.2026

Abstract B003: Inflammatory Breast Cancer in Canada: Patient perspectives on diagnostic delays, care gaps, and the need for change

Abstract Inflammatory Breast Cancer (IBC) is a rare and aggressive form of breast cancer that presents significant diagnostic and treatment challenges. Unlike more common breast cancers, IBC often lacks a palpable mass and presents with rapidly developing symptoms that can mimic …

18.07.2026

Abstract A012: Subcutaneous ANtibody-conjugated microGel platform enabling combination immunotherapy for refractory solid tumors

Abstract Background: Drug delivery systems (DDSs) are increasingly utilized to enhance the precision and durability of biologics in oncology. However, current cancer immunotherapies show limited efficacy in solid tumors due to profoundly immunosuppressive tumor microenvironments, …

18.07.2026

Abstract B054: Systemic Therapy and Outcomes in Patients with Intermediate or High-Risk Solitary Fibrous Tumor

Abstract Background: Solitary fibrous tumors (SFT) make up less than 5% of sarcomas. The Demicco model stratifies risk of metastasis based on age, tumor size, mitotic count, and necrosis. Patients (pts) with relapsed disease have limited options. We evaluated outcomes of systemic …

18.07.2026

Abstract B040: Bridging epigenetic mechanisms in brain cancer: A perspective on the interventions of creative arts therapy on patient outcomes

Abstract The aberrant DNA hypomethylation, hypermethylation, histone modifications, and the roles of non-coded RNAs in the tumor-suppressive pathways, are recognized as cancer hallmarks. Particularly in brain tumors. At the recent time, we are adopting to the advancements in epig …

18.07.2026

Abstract B026: RB1 loss is associated with greater PD-1:PD-L1 interaction in Pulmonary Large Cell Neuroendocrine Carcinoma

Abstract Background: Pulmonary large cell neuroendocrine carcinoma (LCNEC) comprises only ∼3% of primary lung cancers. Developing and testing treatment strategies for LCNEC has been complicated by both the rarity and molecular heterogeneity of LCNEC. The role of immunotherapy for …

18.07.2026

Abstract IA012: Gastric pre-malignancy: When is rare not rare?

Abstract Stomach (gastric) cancers have an incidence of ∼30,000 cases annually in the USA, fitting the definition of a rare cancer (<15 cases/100,000 population). However, in many other countries and geographical regions such as East Asia, Latin America, and Eastern Europe, gastr …

18.07.2026

Abstract A003: Application of CRISPR–Cas9 Technology in the Treatment of Chronic Lymphocytic Leukemia with Mutations P53 gene

Abstract Aim: This study proposes the implementation of clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9 (Cas9) technology for gene therapy targeting genetic mutations in human lymphocytes affected by chronic lymphocytic leukemia, (CL …

18.07.2026

Abstract B007: Advocate Engagement Drives Research Priorities in Fanconi Anemia

Abstract Background: Fanconi anemia (FA) is an ultra-rare DNA repair disorder caused by pathogenic variants in at least 23 genes in the FA/BRCA pathway. Individuals with FA have markedly increased cancer risk, with some malignancies occurring up to 1,000-fold more frequently than …

18.07.2026

Abstract A014: Targeting shared metabolic vulnerabilities in IDH-mutant gliomas and colorectal cancer: a new therapeutic angle for rare brain tumors

Abstract Background: Gain-of-function mutations in isocitrate dehydrogenase 1/2 (IDH1/2) produce the oncometabolite 2-hydroxyglutarate (2-HG) and occur in the majority of lower-grade gliomas as well as in a subset of colorectal cancers. We sought to identify conserved metabolic a …

18.07.2026

Abstract IA003: DICER1-related tumor predisposition: genotypes, phenotypes and mechanisms

Abstract DICER1 is an endoribonuclease that plays a critical role in microRNA (miRNA) biogenesis. DICER1 contains two catalytic ribonuclease domains: RNase IIIa and RNase IIIb, which cleave the bound precursor miRNA to generate 3p and 5p strands, respectively, of the miRNA. One s …

18.07.2026

Abstract A056: From Driver Mutations to Liquid Biomarkers: A Bespoke dPCR Platform for Detecting Uveal Melanoma Circulating Tumor DNA

Abstract Background: Uveal melanoma (UM) is a rare and lethal eye cancer with up to 50% of patients at high risk of metastasis. The UM mutational landscape is highly distinctive, with initiating hotspot driver mutations in 1 of 4 genes (GNAQ, GNA11, CYSLTR2, and PLCB4), with GNA1 …

18.07.2026

Abstract A051: Mechanistic synthetic lethality therapy ranking from tumor mutations: A deterministic sequence-pathway floor with evidence augmentation and lineage-aware dependency grounding

Abstract Background: Synthetic lethality (SL) represents a clinically actionable strategy where targeted therapies become selectively lethal in rare DNA damage response (DDR)-deficient cancer subtypes. While BRCA1/2-PARP relationships are established, rare DDR mutations (ATM, PAL …

18.07.2026

Abstract B002: From delayed diagnosis to advocacy: A patient-led approach to addressing equity gaps in rare cancer care

Abstract Rare cancer patients frequently experience delayed diagnosis, limited awareness, and inequities in access to care. These challenges are particularly pronounced among adolescents and young adults (AYA) and culturally diverse populations, including South Asian communities, …

18.07.2026

Abstract B032: Harnessing anti-EGFR immunotherapy in glioblastoma: lessons from the immune microenvironment of colorectal cancer

Abstract Background: Cetuximab and panitumumab, monoclonal antibodies targeting EGFR, have shown clinical benefit in RAS wild-type colorectal cancer, yet anti-EGFR immunotherapy has uniformly failed in EGFR-amplified glioblastoma. We hypothesized that divergent immune microenviro …

18.07.2026

Abstract A019: Immunohistochemical evaluation of membrane surface targets B7-H3 (CD276), PTK7, IL1RAP, ROR1, AQP4, and LRRC15 in pediatric, adolescent and young adult sarcomas

Abstract Context: There is an urgent need for new targeted therapies for many sarcomas. Surface markers can be targeted by antibody-drug conjugates, adoptive T-cell therapies, and radiopharmaceuticals. Agents directed against B7-H3 (CD276), PTK7, IL1RAP, ROR1, AQP4, and LRRC15 ar …

18.07.2026

Abstract A025: Dual NR4A1/2 ligands inhibit PAX3-FOXO1 and promote ferroptosis in Rhabdomyosarcoma

Abstract Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents, with poor outcomes in metastatic and treatment-resistant disease. The alveolar subtype is frequently driven by the PAX3-FOXO1 fusion oncoprotein, which promotes tumor p …

18.07.2026

Abstract B042: A differentiation-driven migration program in rhabdomyosarcoma (RMS) is governed by a BRD1-MYOG transcriptional axis

Abstract Rhabdomyosarcoma (RMS) is a pediatric soft tissue sarcoma marked by cellular heterogeneity along the myogenic differentiation spectrum, yet the relationship between differentiation state and metastatic potential remains poorly defined. In epithelial cancers, metastasis i …

18.07.2026

Abstract B055: A Genome-to-Vaccine: An Integrated Deep learning-Driven Neoantigen Identification and Multi-Epitope Vaccine Construction for Personalized Melanoma Immunotherapy

Abstract Melanoma, a highly aggressive and therapy-resistant skin cancer, is increasingly treated with immunotherapy, driven by advances in molecular biology and cancer immunology. This study aimed to develop an integrated computational method that combines deep learning based so …

18.07.2026

Abstract B018: TLR4 Deficiency Drives Microbiota-Dependent IL-4R Signaling to Promote Squamous Cell Carcinogenesis

Abstract Background: Epithelial cells sense commensal microbiota to maintain barrier integrity and immune homeostasis. Disruption of epithelial–microbial signaling has been increasingly linked to carcinogenesis. Although Toll-like receptors (TLRs) regulate microbial recognition, …

18.07.2026

Abstract A042: A unified computational framework for 3D spatial transcriptomics reconstruction and its application to hereditary diffuse gastric cancer

Abstract Spatial transcriptomics (ST) enables the measurement of gene expression in its native spatial context, yet most ST datasets are acquired as two-dimensional (2D) sections. Consequently, the underlying three-dimensional (3D) organization of tissues is only partially observ …

18.07.2026

Abstract IA006: Chromatin reorganization in chronic active Epstein–Barr virus disease and extranodal NK/T-cell lymphoma

Abstract Epstein-Barr virus (EBV) is the first virus discovered from human neoplastic cells, and 95% adults become EBV carriers. EBV causes T-cell and natural killer (NK) cell disorders, such as chronic active EBV disease and extranodal NK/T-cell lymphoma, which are aggressive an …

18.07.2026

Abstract B024: Immune checkpoint blockade (ICB) in advanced/metastatic leiomyosarcoma (LMS): Real-world cohort from MD Anderson

Abstract Background: LMS is an aggressive soft-tissue sarcoma with an immunologically “cold” tumor microenvironment and historically poor responsiveness to ICB. With limited benefit from cytotoxic therapy beyond first-line and low ICB monotherapy activity, defining real-world ICB …

18.07.2026

Abstract B031: Pan-cancer dissection of TERT promoter mutations in rare gliomas and colorectal cancer: shared vulnerabilities and therapeutic implications

Abstract Background: Telomerase reverse transcriptase promoter (TERTp) mutations represent one of the most common non-coding alterations across cancers, yet their functional convergence between rare brain gliomas and colorectal cancer (CRC) remains poorly defined. We sought to id …

18.07.2026

Abstract B037: Patient-derived organoid biobank of glioblastoma and colorectal cancer for functional

Abstract Background: Patient-derived organoids (PDOs) are firmly established as predictive models in colorectal cancer but remain scarcely available for rare malignant brain tumors. We aimed to build a cross-cancer organoid platform covering glioblastoma, rare gliomas, and CRC to …

18.07.2026

Abstract B030: BRAF Treatment Response Determinants in Anaplastic Thyroid Cancer Studied Through Single Cell DNA and RNA Sequencing

Abstract Treatment responses of BRAFV600E-mutated ATC to BRAF/MEK inhibition varies across patients and treatment resistance inevitably develops, limiting survival. The objective of this study is identifying mechanisms of resistance in BRAFV600E-mutated ATC treated with neoadjuva …

18.07.2026

Abstract B023: Delineating the role of the microbiome and tumor microenvironment interactions driving mucosal melanoma (MM) response and resistance to immune checkpoint inhibitor (ICI) treatment

Abstract MM is a rare melanoma subtype with distinct biology and low response rates to ICIs. We seek to prospectively profile a cohort of MM patients to determine the interplay of gut, mucosal and tumor microbiome and modifiable risk factors on ICI response and resistance. Patien …

18.07.2026

Abstract A052: Genomic landscape and survival outcomes in breast neuroendocrine carcinoma: A descriptive institutional cohort analysis

Abstract Background: Breast neuroendocrine carcinoma (Br-NEC) is an aggressive malignancy that accounts for fewer than 1% of all breast cancers. Given the rarity and under recognition of this entity, data on clinical outcomes and genomic alterations across receptor subtypes has n …

18.07.2026

Abstract B022: A Living Biobank and Functional Precision Oncology Platform for Rare Cancers

Abstract Rare cancers collectively account for ∼25% of all cancer diagnoses, yet they remain disproportionately understudied due to limited patient numbers, biological heterogeneity, and a lack of robust preclinical models. This gap has constrained mechanistic understanding and s …

18.07.2026

Abstract A009: Integrating HER2-Targeted Antibody-Drug Conjugates into Mucinous Ovarian Cancer Treatment: A preclinical Assesstment

Abstract Background: Mucinous ovarian cancer (MOC) is a rare epithelial ovarian cancer. There are currently no systematic therapies in clinical use for MOC that reliably improve patient outcome, therefore new approaches are needed. MOC genetic alterations and the resulting protei …

18.07.2026

Abstract A027: Leveraging genomic copy-number complexity in uveal melanoma to drive novel therapeutic development

Abstract Uveal Melanoma (UM) is a rare tumor characterized by activating mutations in GNAQ or GNA11, followed by a secondary mutation in BAP1, SF3B1 or EIF1AX. Notably, chromosome 3 copy-number loss, enriched among BAP1-mutant patients, is associated with an increased likelihood …

18.07.2026

Abstract B006: Alliance for Rare Cancers: uniting to accelerate progress across rare cancers

Abstract Rare cancers comprise 25% of all cancers, but are treated as isolated diseases, where organizations or physicians often focus on a single rare cancer. Alliance for Rare Cancers’ (ARC) mission is to build an operational coalition of rare cancer advocates, researchers, cli …

18.07.2026

Abstract IA010: On the right TRACK: Operationalizing a national, patient-driven, decentralized trial offering comprehensive genomic profiling and a molecular tumor board for rare cancers

Abstract Collectively, rare cancers account for approximately 20–25% of all malignancies, and the challenges faced by patients and researchers are consistent across all rare cancer tumor types. Notably, patients encounter challenges in access to clinical trials, access to biomark …

18.07.2026

Abstract A034: Integrated multi-omics analysis of uterine mesonephric-like adenocarcinoma identifies novel diagnostic and therapeutic targets

Abstract Introduction: Mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of endometrial cancer (EC) that accounts for around 1% of all EC. During development, both male and female urogenital tracts initially form, but one duct regresses, due to hormonal cues. …

18.07.2026

Abstract A011: Leveraging a High-Throughput 2D Invasin-Based Organoid Platform for Precision Oncology and Clinical Correlation in Small Bowel Adenocarcinoma

Abstract Introduction: Small Bowel Adenocarcinoma (SBA) is a rare malignancy lacking standardized treatment protocols, necessitating more scalable and clinically representative models for drug discovery. In this study, we sought to validate a novel, high-throughput 2D Invasin-coa …

18.07.2026

Abstract A005: Investigating the role of stabilin-2 in hematopoietic stem and progenitor cell emergence and migration in zebrafish

Abstract Hematopoietic stem cell transplantation is a critical yet high risk therapeutic treatment for patients with blood and immune disorders, including those with cancer where the bone marrow can be severely compromised due to malignancy, intensive chemotherapy and radiation. …

18.07.2026

Abstract B049: Rare Melanoma Translational Core: A patient-guided platform for acral and mucosal melanoma PDX model generation, characterization, and distribution

Abstract The objective of the Rare Melanoma Translational Core (RMTC) is to establish a patient-advocate guided, clinically annotated, and molecularly characterized preclinical model resource to accelerate therapeutic discovery for acral melanoma (AM) and mucosal melanoma (MM). A …

18.07.2026

Abstract PR006: Target discovery in rare cancers enabled by transcriptome-based virtual CRISPR screening

Abstract Identifying cancer gene dependencies is essential for nominating new therapeutic targets. However, because most experimental models do not sufficiently represent the full diversity of tumors—especially for rare cancers—it remains challenging to use functional screening o …

18.07.2026

Abstract B004: Rare oncogene driven lung cancer treatment access gap in Canada: A call for equitable, patient-centred care for rare cancers

Abstract Background: Non-small cell lung cancer (NSCLC) driven by rare oncogenic fusions and mutations represents one of the most compelling and rapidly evolving frontiers in precision oncology. While NSCLC is very common, roughly 20% of lung adenocarcinomas harbour a rare driver …

18.07.2026

Abstract A020: Diagnostic and therapeutic challenges of squamous cell carcinoma of the prostate

Abstract Introduction: Prostate cancer (PCa) is the most common cancer in men with most men presenting with adenocarcinoma. Squamous cell carcinoma of the prostate (SCCP) occurs in less than 1% of PCa cases. Due to sporadic presentation, SCCP is poorly understood and treatment pr …

18.07.2026

Abstract A037: Molecular characterization of adult small round blue cell tumors reveals frequent non-classical EWSR1 and related rearrangements

Abstract BACKGROUND / PURPOSE: Small round blue cell tumors (SRBCTs) in adults are frequently classified as Ewing sarcoma (ES) based on morphology and limited molecular testing. However, the emergence of molecularly distinct SRBCT entities raises concern that adult ES diagnoses m …

18.07.2026

Abstract B044: Patient-driven N-of-1 Longitudinal Multi-Omic Study of Uveal Melanoma Identifies Functional Loss of BAP1 VUS and Evolving Tumor-Immune Dynamics

Abstract Uveal melanoma is a rare and aggressive form of melanoma with few treatment options. A 36 year old patient presented with localized uveal (choroidal) melanoma and underwent enucleation followed by an adjuvant vaccine protocol. Clinical tumor genomic sequencing revealed a …

18.07.2026

Abstract A010: Dual estrogen receptor and PKCβ signaling modulation by (Z)-Endoxifen: A mechanism-driven therapeutic strategy for estrogen-driven pathology in McCune–Albright Syndrome

Abstract Purpose: McCune–Albright syndrome (MAS) is a rare mosaic disorder caused by activating GNAS mutations that drive autonomous estrogen production and chronic estrogen receptor (ER) activation. Although current management suppresses estrogen synthesis, persistent ER-depende …

18.07.2026

Abstract B019: Remarkable driver-gene homogeneity in squamous cell carcinoma arising in patients with recessive dystrophic epidermolysis bullosa

Abstract We investigated the molecular basis underlying the aggressive behavior of squamous cell carcinoma (SCC) arising in the skin of patients with recessive dystrophic epidermolysis bullosa (RDEB) using whole-exome and whole-genome sequencing. Our analysis included two metachr …

18.07.2026

Abstract B051: Keratin K6/K14 Fusion Expands Non-Genetic Phenotypic State Space to Drive Cell Fusion, Aggressiveness, and Immune Modulation in Oral Squamous Cell Carcinoma

Abstract Oral squamous cell carcinoma (OSCC) exhibits substantial phenotypic heterogeneity that cannot be fully explained by genetic alterations alone. Here, we identify keratin network remodeling, specifically fusion of keratin 6 (K6) and keratin 14 (K14), as a driver of non-gen …

18.07.2026

Abstract B033: IL1RAP ADCs potently target primary and metastatic disease in multiple oncofusion-driven cancers

Abstract Gene fusions generated by chromosomal rearrangements function as oncogenic drivers in human cancers. We previously showed that EWSR1-ETS oncofusions of Ewing sarcoma (EwS) directly induce surface expression of IL1 receptor accessory protein (IL1RAP), which along with lim …

18.07.2026

Abstract A018: Identifying potential cell-surface targets for therapeutic treatment of DICER1 -related cancers

Abstract INTRODUCTION: Pleuropulmonary blastoma (PPB) and Sertoli-Leydig cell tumor (SLCT) are DICER1-related tumors for which novel therapies are urgently needed. A subset of Wilms tumors are also associated with germline or somatic variants in DICER1. Current therapies include …

18.07.2026

Abstract B015: Clinical-stage ADC target enrichment across angiosarcoma anatomical subsets

Abstract Background: Angiosarcoma (AS) is an anatomically heterogeneous ultra-rare sarcoma with no approved precision therapies. Head/face/neck/scalp (HNFS) AS is the only subset with reported immune checkpoint inhibitor activity. Whether AS subsets express clinically actionable …

18.07.2026

Abstract IA002: From pathognomonic mutation discovery to generalizable impact: rapid translation or arrested development

Abstract Whenever technical or conceptual revolutions create new opportunities for medical research, a disproportionate amount has and will be learned from studying rare diseases, particularly rare cancers. This aphorism proved true when sequencing-by-synthesis enabled the rapid …

18.07.2026

Abstract A053: Specific cancer cell and immune features mediate atezolizumab-regimen clinical benefit in anaplastic thyroid cancer (ATC) independent of BRAF or RAS oncogenic status

Abstract Background: Anaplastic thyroid cancer (ATC) is a rare, highly aggressive malignancy, responsible for a disproportionate share of thyroid cancer–related mortality and with limited therapeutic options. We reported results from a phase II trial (NCT03181100) in which ATC pt …

18.07.2026

Abstract A040: Microphysiological models uncover invasive and proteomic shifts in Ewing sarcoma cell subpopulations

Abstract Background: Epithelial-to-mesenchymal transition (EMT) drives morphological and molecular changes that promote cancer progression. Ewing sarcoma cells, driven by fluctuations in the master oncogene EWS FLI1, can shift along the EMT spectrum. Yet the proteomic changes und …

18.07.2026

Abstract B025: Epimedin A, a plant-based flavonoid, prevents glioblastoma growth and invasion

Abstract Background: Glioblastomas (U87) are an aggressive brain tumor that arises from glial cells and invades surrounding parts of the brain. The prognosis for glioblastoma is poor, with a median survival rate of 15 months with treatment. Treatments are aggressive with severe s …

18.07.2026

Abstract A038: Multi-omics and Mendelian randomization analyses reveal a COLEC11 gene–metabolite–microbiota axis in imatinib-resistant gastrointestinal stromal tumors

Abstract Background: Gastrointestinal stromal tumors (GISTs) initially respond to imatinib, but acquired resistance frequently develops after 24 to 36 months, highlighting the need to define how the tumor immune microenvironment and systemic metabolic networks contribute to resis …

18.07.2026

Abstract IA008: The Ultra-Rare Cancer Treatment Advancement Program (ULTRA): A new public-private partnership to drive development of innovative therapies for ultra-rare cancers

Abstract Background: Ultra-rare cancers (≤1 case per 1,000,000 per year) present unique challenges. Identification of novel targets and development of new therapies is especially difficult due to few sources of funding, lack of interest from biopharmaceutical companies, limited t …

18.07.2026

Abstract IA001: Radical collaboration for rare cancers

Abstract Rare cancer patients have been left behind in the fight against cancer, and this is unacceptable. We have an enormous scientific and clinical opportunity, as well as a moral responsibility, to definitively eliminate this disparity within our lifetimes. And we must act to …

18.07.2026

Abstract A039: Goblet Cell Appendiceal Adenocarcinoma is A Distinct Disease Entity Defined by LGR5/Wnt mediated oncogenesis driving an Immune-Excluded Tumor Microenvironment

Abstract Background: Goblet cell adenocarcinoma (GCA), which comprises ∼15% of metastatic AA cases, is associated with worse survival than non-goblet AA. We have recently identified that the somatic mutation landscape of GCA tumor is vastly different relative to non-GCA with ZFP3 …

18.07.2026

Abstract PR003: Clonally inherited bivalent chromatin states in SS18::SSX–associated synovial sarcoma

Abstract Synovial sarcoma is an aggressive cancer defined by the pathognomonic SS18::SSX fusion oncoprotein and characterized by remarkably few recurrent secondary mutations, implying that tumor evolution is driven primarily by epigenetic rather than genetic diversification. Here …

18.07.2026

Abstract A006: SHMT2 is a novel protein target in the rare malignancy Spindle epithelial tumor with thymus-like elements (SETTLE)

Abstract Here, we present a new therapeutic target, SHMT2, in SETTLE (spindle epithelial tumor with thymus-like elements), a rare and challenging tumor of the mediastinum in pediatric and young adult patients. While the 5-year overall survival of SETTLE exceeds 80%, the cancer ha …

18.07.2026

Abstract PR005: Conditional Reprogramming Enables Rapid Establishment of Patient-Derived Neuroendocrine Tumor Models for Functional Precision Oncology

Abstract Neuroendocrine tumors (NETs), including aggressive subtypes such as neuroendocrine prostate cancer (NEPC) and small cell carcinomas, are characterized by marked heterogeneity, therapeutic resistance, and limited availability of clinically relevant models. The development …

18.07.2026

Abstract A041: Comparative analysis of tertiary lymphoid structures in canine osteosarcoma supports cross-species tumor immunity in a rare malignancy

Abstract Background: Osteosarcoma (OS) is a rare pediatric malignancy (<1,000 cases/year) but occurs frequently in pet dogs (>10,000 cases/year), providing a valuable comparative model. Human and canine OS share molecular, clinical, and histologic features, as well as standard-of …

18.07.2026

Abstract A031: Precision Medicine and Ultra-Rare Cancers: Genomic Insights from a Private Hospital Experience

Abstract Background: Cancer is the second leading cause of death after cardiac disorders in the United States. Rare cancers are defined by an incidence of less than 6 cases per 100,000 per year, though, in aggregate, rare cancers surprisingly account for up to 25% of cancers diag …

18.07.2026

Abstract A032: Disseminated malignant granular cell tumor with multiorgan metastases and PD-L1–negative phenotype: A translational case of an ultra-rare Schwann-cell neoplasm

Abstract Background: Granular cell tumor (GCT) is an uncommon Schwann cell–derived neoplasm, of which <2% exhibit malignant potential. Disseminated malignant GCT (MGCT) is exceptionally rare (fewer than 20 cases reported), and there is no evidence-based systemic standard; managem …

18.07.2026

Abstract B014: Molecular Determinants of Metastatic Melanoma and Repurposed Drugs: A Pathway to Novel Therapeutic Strategies

Abstract Introduction: Metastatic melanoma poses a significant challenge due to its aggressive nature and limited treatment options. Despite advancements in targeted therapies, the development of effective treatments remains a pressing need. This study explores the molecular unde …

18.07.2026

Abstract B053: A randomized controlled trial for hereditary cancer in the cfDNA in Hereditary And High-Risk Malignancies (CHARM) consortium: Neurofibromatosis type 1 cohort

Abstract Introduction: Individuals with a hereditary cancer syndrome are at increased risk of developing multiple cancers throughout their lifetime. They undergo intensive surveillance (i.e. diagnostic imaging), a process that is time-consuming, burdensome and anxiety-provoking. …

18.07.2026

Abstract A057: Advanced preclinical modeling enables comprehensive characterization of cardiac angiosarcoma biology

Abstract Cardiac angiosarcoma (CAS) is an extremely rare and highly aggressive endothelial tumor characterized by infiltrative growth within the myocardial wall. Most cases arise in the right atrium and are notable for early metastatic spread and a poor prognosis. CAS frequency i …

18.07.2026

Abstract IA007: Precision oncology and the N-of-1 revolution: Rare cancers as a paradigm

Abstract Background: Rare cancers have challenged conventional drug development because patient populations are too small for traditional disease-specific trials. Yet rare cancers may provide the paradigm for the future of oncology. Cancer classification has evolved from organ-of …

18.07.2026

Abstract A049: Bap1-driven soft tissue sarcomas: Mouse modeling and therapeutic strategies

Abstract Objective: Soft tissue sarcomas (STS) are rare in both pediatric and adult cancer patients, yet they remain highly lethal and understudied. Many STS subtypes, including undifferentiated pleomorphic sarcoma (UPS), exhibit significant genetic heterogeneity and lack recurre …

18.07.2026

Abstract A058: Genomic Profiling Identifies 19q13 Amplification in Sarcomatoid Bladder Carcinoma

Abstract Sarcomatoid carcinoma of the bladder (CB) is a rare, highly aggressive malignant neoplasm characterized by the presence of both malignant epithelial (carcinomatous) and malignant mesenchymal (sarcomatous) components within the same tumor. Its poor prognosis, high recurre …

18.07.2026

Abstract A002: Bcl-2–Dependent Apoptotic Resistance Overcome by (2-Methylbutyryl) Shikonin Through ROS-Driven Mitochondrial Signaling in Melanoma

Abstract Skin cancer is one of the most common forms of cancer worldwide, among which melanoma represents the most aggressive and lethal subtype due to its high metastatic potential and resistance to apoptosis. A critical factor underlying melanoma progression and survival is the …

18.07.2026

Abstract B056: Intrinsically disordered AF1 domain of glucocorticoid receptor as a novel potential target for triple negative breast cancer

Abstract Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited treatment options that disproportionately affects younger women, particularly African American women. Unlike hormone-responsive breast cancers, currently there is no targeted treatme …

18.07.2026

Abstract B057: Clinical utility and in vitro anti-proliferative activity of a tissue-agnostic multi-target formula (WD-3) in rare malignancies

Abstract Background: Rare malignancies lack standardized therapeutic options and often share convergent metabolic vulnerabilities despite histologic heterogeneity. Our previous mechanistic studies demonstrated that the multi-component formula WD-3 suppresses glycolytic reprogramm …

18.07.2026

Abstract B045: The Efficacy and Safety of Asciminib in the Treatment of Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis

Abstract Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the BCR::ABL1 fusion gene, which drives leukemogenesis through aberrant tyrosine kinase activity. While first- and second-generation tyrosine kinase inhibitors (TKIs) have tr …

18.07.2026

Abstract A035: Integrated Molecular Subtypes and Hormone Receptor Status Improve Outcome Prediction in Rare Ovarian Cancer: Results from the Multi-National Endometrioid Ovarian Cancer (MECC) Study

Abstract Introduction: Endometrioid Ovarian Carcinoma (ENOC) is an under-characterized type of ovarian cancer and represents less than 10% of all ovarian tumors. ENOC research has been historically confounded by histotyping inaccuracies and small cohorts. While pathology diagnose …

18.07.2026

Abstract A008: The anti-diabetic drug Pramlintide modulates osteosarcoma tumor metabolism and improves NK cell therapy

Abstract Osteosarcoma (OS) is the most common primary malignant bone tumor in children with lung metastases representing the leading cause of mortality. Survival rates have remained unchanged for over three decades. Immunotherapy with natural killer (NK) cells has shown limited e …

18.07.2026

Abstract IA009: Turning the tide: How we doubled the survival of patients with SMARCB1-deficient renal medullary carcinoma

Abstract Renal medullary carcinoma (RMC) is a highly lethal kidney cancer defined by biallelic SMARCB1 loss and afflicting predominantly young individuals of African descent who carry the sickle cell trait. Platinum-based chemotherapy was until recently the mainstay of RMC treatm …

18.07.2026

Abstract A045: Clinical benefit of MAPK inhibition in appendiceal adenocarcinoma

Abstract Background: Appendiceal adenocarcinomas (AA) are exceptionally rare malignancies that exhibit high rates of fatal peritoneal metastases with few effective treatment options. AAs have frequent MAPK signaling variants targetable with tyrosine kinase inhibitors. However, th …

18.07.2026

Abstract B005: A patient-centered approach to rare cancer research and biobanking

Abstract Rare cancers, defined as those affecting fewer than 40,000 people annually in the United States, collectively account for 20-25% of all cancer cases worldwide. Patients with rare cancers often face delayed diagnosis, limited treatment options, and few opportunities to pa …

18.07.2026

Abstract A007: Hsp27 Mediates Sensitivity to Gemcitabine through Mitophagy Regulation in Osteosarcoma

Abstract Osteosarcoma (OS) is the most common primary malignant bone tumor in children, comprising approximately 3% of all childhood cancers. Metastatic OS remains a clinical challenge largely due to pulmonary metastases, the main cause of death in these patients. Gemcitabine (GC …

18.07.2026

Abstract PR002: Breaking Barriers in Rare Cancer Research: Patient-Partnered Research via Social Media as a Model for Generating Evidence in Granulosa Cell Tumor of the Ovary

Abstract Background: Granulosa cell tumors (GCT) of the ovary account for ∼ 5% of malignant ovarian cancers. As with many rare cancers, the evidence base for treatment is weak, and conventional research approaches face serious barriers: small patient populations, geographic dispe …

18.07.2026

Abstract A050: The top functional driver of brain metastasis carries zero somatic mutations in 1,879 patients: class-aware multi-modal integration exposes the blind spot in sequencing-based target discovery

Abstract Purpose: Brain metastasis affects 20% to 40% of patients with solid tumors and is associated with a median survival of less than 12 months. Current genomic profiling primarily focuses on somatic mutations, assuming the primary drivers of central nervous system colonizati …

18.07.2026

Abstract A044: Dissecting the developmental trajectory of DICER1 syndrome-associated sarcoma with genetically engineered mouse models

Abstract DICER1 syndrome, also known as DICER1-related tumor predisposition, encompasses a spectrum of malignancies mainly in children and young adults, affecting lung, gynecologic tract, kidney and other organs. Most of these tumors are sarcomas, exhibiting histological and mole …

18.07.2026

Abstract B039: Genomic and epigenomic complexity underlies barrett’s esophagus progression to adenocarcinoma

Abstract Esophageal adenocarcinoma (EAC) is a highly lethal malignancy with rising incidence and poor survival, and is increasingly recognized as a rare but aggressive cancer subtype with limited therapeutic options. Barrett’s esophagus (BE), the only known precursor, progresses …

18.07.2026

Abstract B041: 5-Base cfDNA Fragmentomics Reveals Cancer-Associated Alterations in Gallbladder Cancer

Abstract Background: Gallbladder cancer (GBC) is a highly aggressive malignancy that is typically diagnosed at advanced stages due to nonspecific symptoms and a lack of screening strategies. Prognosis remains poor, highlighting the need for sensitive, noninvasive biomarkers. Liqu …

18.07.2026

Abstract A026: AI-Enabled Digital Pathology and Multi-Omics Integration for Cell-Type–Resolved Biomarker Discovery in Environment-Associated Cancers

Abstract Rare cancers present persistent challenges in biomarker discovery and clinical translation due to limited sample availability, histopathologic heterogeneity, and fragmented molecular data. To overcome these barriers, we developed an artificial intelligence (AI)-driven in …

18.07.2026

Abstract IA011: Chromatin and cancer: from mechanisms to emerging therapies

Abstract Genes that encode subunits of SWI/SNF (BAF) chromatin remodeling complexes are mutated in over 20% of cancers. Among these are several types of pediatric cancer including rhabdoid tumors, neuroblastoma, leukemias and medulloblastoma as well as many types of adult cancers …

18.07.2026

Abstract A004: Voltage and calcium dynamics determine Tir-induced pyroptosis in triple-negative breast cancer cells

Abstract Bioelectricity and calcium (Ca2+) dynamics are key regulators of cancer cell behaviour; they influence proliferation, migration, and invasion. Transient Ca2+ influx through ion channels alters membrane potential (Vm), generating dynamic bioelectric activity. Pathogenic b …

18.07.2026

Abstract IA013: Targeting the Undruggable: Immunotherapy Directed Against the DNAJB1::PRKACA Fusion in Fibrolamellar Carcinoma

Abstract Fibrolamellar carcinoma (FLC) is a rare liver cancer of children and young adults driven by the recurrent DNAJB1::PRKACA fusion, an oncogenic driver that has proven largely inaccessible to conventional small-molecule inhibition because of its essential kinase activity an …

18.07.2026

Abstract PR001: The CCDI-COG Molecular Characterization Initiative (MCI) in rare pediatric cancers

Abstract Background: Rare pediatric cancers encompass a broad range of diagnoses, including both adult-onset carcinomas that rarely arise in children and very rare diagnoses unique to childhood. Although each individual diagnosis is exceedingly uncommon, rare tumors collectively …

18.07.2026

Abstract B050: Deciphering Rare Patterns of Dual Drug Resistance in metastatic castration resistant prostate cancer through Machine Learning–Based ctDNA Methylation and CTC Transcriptomics

Abstract Purpose: Despite the clinical utility of androgen receptor pathway inhibitors (ARPIs) and taxanes, a rare and highly aggressive subset of metastatic castration-resistant prostate cancer (mCRPC) exhibits inevitable dual resistance. The epigenetic drivers behind this treat …

18.07.2026

Abstract A028: mirAI: Computational prioritization of allele-selective synthetic microRNAs for KRAS G12D-driven cancers

Abstract Background: KRAS G12D is a frequent oncogenic driver in pancreatic ductal adenocarcinoma and other difficult-to-treat tumor contexts, yet direct allele-selective targeting remains challenging. RNA-based strategies that preferentially suppress mutant rather than wild-type …

18.07.2026

Abstract B048: Nasser’s Express Insertion Technique (NEIT): A Simplified and Effective Approach to Cervical Cancer Intracavitary Brachytherapy Without Anesthesia for Resource-Limited Settings, Operational Disruptions, and Patients Unfit for Anesthesia

Abstract Purpose: To introduce NEIT (Nasser’s Express Insertion Technique), a simplified, effective, and well-tolerated intracavitary (IC) brachytherapy insertion technique performed at the CT simulation table using finger-guidance, without the need for anesthesia, sedation, spec …

18.07.2026

Abstract PR004: A comprehensive pan-sarcoma single-cell transcriptomic meta-analysis reveals shared molecular programs across subtypes

Abstract Background: Sarcomas are rare malignancies that encompass diverse histologic subtypes, despite their shared mesenchymal origins. Given their rarity, completing large-scale studies that aim to elucidate sarcoma biology and derive meaningful therapeutic advancements remain …

18.07.2026

Abstract A023: Inhibition of GPR68 induces ferroptosis in diffuse intrinsic pontine gliomas

Abstract Background: Diffuse Intrinsic Pontine Glioma (DIPG) is a highly aggressive pediatric brainstem tumor with limited treatment options and dismal prognosis. Previously, we showed that Ogremorphin (OGM), a specific GPR68 inhibitor, induced ferroptosis in glioblastoma multifo …

18.07.2026

Abstract A036: Risk stratification of females with diabetes mellitus: A-to-I editing of GABRA3 under ADAR-1 mediated activity in pancreatic ductal adenocarcinoma

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) incidence is rising on an unprecedented scale in women, with the highest increases in younger and minority populations in the last two decades. GABRA3, an X-linked GABA-A receptor subunit, is biallelically expressed in …

18.07.2026

Abstract B047: Managing Suspected Leptomeningeal and Multifocal Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach in a Guideline Gray Zone

Abstract Background: Renal cell carcinoma (RCC) most often metastasizes to the lung, bone, liver, and brain. Although osseous disease is common, concurrent mandibular, dural, and suspected leptomeningeal involvement is rare and complicates management. Calvarial invasion with dura …

18.07.2026

Abstract A015: Targeting polyamine metabolism to overcome PARP inhibitor resistance in Colorectal Cancer

Abstract Resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) presents a major challenge in colorectal cancer (CRC) treatment. PARP plays a dual role in DNA repair and cellular metabolism, and its inhibition disrupts key DNA damage response pathways. However, CRC cells of …

18.07.2026

Abstract B046: Visualizing viral evasion of PRRs: A review of live cell imaging and confocal microscopy techniques

Abstract During the initial stage of viral defense, the host maintains vital sentinels through Pattern recognition receptors called RIG-I-like receptors, including RIG-I and MDA5. The successful viral infection and propagation depend on various advanced strategies developed by vi …

18.07.2026

Abstract B052: The MRA Melanoma Biorepository: A centralized, broadly accessible resource for rare acral and mucosal melanoma research

Abstract Research progress in rare melanoma subtypes, including acral and mucosal melanoma, has been hampered by the limited availability of patient-derived specimens. Individual institutions often collect small numbers of these rare tumors, and inter-institutional sharing of pat …

18.07.2026

Abstract A030: Functional precision medicine targeting polyresistant cancer stem cells in high-grade serous ovarian cancer

Abstract High-grade serous ovarian cancer (HGSOC) carries one of the worst prognoses of any gynecologic malignancy, with over 80% of patients relapsing within 24 months of first-line platinum-taxane chemotherapy and ultimately succumbing to resistant disease. A central driver of …

18.07.2026

Abstract A043: Paracrine remodeling of normal fibroblasts into glioblastoma-associated states: An immune-enriched stromal model of GBM

Abstract Background: Cancer-associated fibroblasts (CAFs) are central orchestrators of tumor progression, stromal remodeling, and immune evasion in glioblastoma. While tumor-derived secretomes can induce CAF-like phenotypes, it remains unknown whether therapy resistance reprogram …

18.07.2026

Abstract B036: The Rare Ovarian Cancer Collaborative Analytics (ROCCA) platform: Advancing research through a federated data network

Abstract Background: Rare ovarian cancers account for 15-20% of ovarian cancer cases, yet research progress is often hindered by fragmented, small datasets and siloed institutional data. This is particularly evident in rare disease research, where individual institutions are unab …

18.07.2026

Abstract B008: A trend and ethical analysis of rare pediatric cancer research funding priorities; why certain pediatric cancers receive more research funding than others

Abstract Background: Pediatric cancer research funding is limited and unevenly distributed across cancer subtypes. Although funding agencies cite disease burden as a guiding principle, prior evidence suggests weak alignment between burden and allocation. This raises concern that …

18.07.2026

Abstract IA005: Shifting phenotype of kinase fusion driven gliomas by Lorlatinib

Abstract Unlike adult glioblastoma, infantile high grade gliomas are often driven by a single gene fusion. In most cases, these are fusions to the kinase domain of receptor tyrosine kinases such as Alk, Ros1 and Trk. The first line therapy for Alk and Ros1 fusion gliomas is Crizo …

18.07.2026

Abstract A016: Single-nuclear RNA sequencing of retroperitoneal liposarcoma reveals progenitor cells of dedifferentiated liposarcoma in well-differentiated liposarcoma

Abstract Given the worse prognosis of dedifferentiated liposarcoma (DDLPS) compared to well-differentiated liposarcoma (WDLPS), it is imperative to understand how WDLPS tumors degenerate into DDLPS. Based on prior studies, we hypothesized that DDLPS progenitor cells can be found …

18.07.2026

Abstract B029: Immunotherapy with autologous dendritic cells in the complex treatment of malignant gliomas – results

Abstract Malignant gliomas are the most common primary brain tumor. Despite the variety of modern treatments, it is still a fatal disease with an extremely poor prognosis. The use of immunotherapy as a technique for the treatment of malignant tumors has great promise, retraining …

18.07.2026

Abstract A013: Prolonged survival in unresectable primary squamous cell carcinoma of the pancreas treated with multimodal therapy despite absence of actionable genomic drivers

Abstract Primary squamous cell carcinoma (SCC) of the pancreas is an exceptionally rare malignancy without established treatment guidelines. A systematic review published in 2017 reported a dismal prognosis and median overall survival of 7 months.1 Genomic characterization has no …

18.07.2026

Abstract IA004: Functional Precision Oncology in Rare Cancers: From Biobank to Drug Discovery

Abstract Rare cancers collectively account for ∼25% of all cancer diagnoses yet remain underserved due to limited biological understanding, a lack of preclinical models, and challenges associated with conducting clinical trials. Overcoming these barriers requires both the develop …

18.07.2026

Abstract A048: Decoding tumor seeding in retinoblastoma: The genomic clues from aqueous humor liquid biopsy

Abstract Retinoblastoma (RB) is a rare pediatric malignancy in which tumor biopsy is contraindicated due to risk of extraocular spread. Consequently, clinical management relies on imaging and phenotypic features, limiting insight into the molecular drivers of disease progression …

18.07.2026

Abstract A021: Surface and global proteome profiling identifies ROR2 and other surface proteins as actionable immunotherapy targets in osteosarcoma

Abstract Objective: Osteosarcoma (OS) is the most common primary bone cancer affecting children and young adults, with an incidence of roughly 4.4 per million in the United States. While the survival rate of patients diagnosed with localized OS is ∼65%, this decreases to ∼20% for …

15.07.2026

KRAS on Empty: Lipid Oxidation Blockade Reveals a Metabolic Achilles’ Heel in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the United States, driven by its aggressive biology and high metastatic incidence at diagnosis. With a 5-year survival rate of just 8%, PDAC remains one of the most lethal cancers. Mutant KRAS, …

15.07.2026

Oncogenic KRAS Promotes Extracellular DNA Clearance to Drive Immunosuppression in Colorectal Cancer

Cellular turnover and death result in shedding of DNA into the extracellular space. In the context of cancer, the constant turnover of cancer cells leads to the release of tumor-derived DNA (tDNA) into the circulation. Circulating tDNA (ctDNA) provides molecular insights into the …

15.07.2026

Retraction: Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells

12.05.2026

Soluble Uric Acid Drives CD8+ T-cell Exhaustion by Inducing KSR1-Mediated MAPK Hyperactivation

Abstract T-cell exhaustion in the tumor microenvironment undermines antitumor immunity and limits immunotherapy efficacy. Further defining the metabolic triggers of this dysfunctional state could provide therapeutic targets for circumventing immunosuppression. In this study, we i …

08.05.2026 · 4 Zitationen

ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer

Abstract The tumor microenvironment (TME) actively contributes to pancreatic ductal adenocarcinoma (PDAC) pathogenesis through dynamic bidirectional tumor–stroma interactions. In this study, we demonstrated that ATM-deficient tumor epithelium reprograms the TME in a genotype-spec …

07.05.2026 · 1 Zitationen

Arginine Deprivation of ASS1-Deficient Cancers Drives Mistranslation and Shared Neoepitope Production

Abstract Arginine biosynthesis is frequently suppressed in cancer because of the loss of argininosuccinate synthase 1 (ASS1) expression, rendering cancer cells reliant on extracellular arginine. This feature has driven the development of systemic arginine-depleting strategies, wh …

05.05.2026

CellFuse Enables Multimodal Integration of Single-Cell and Spatial Proteomics Data for Systems-Level Analysis in Cancer

Abstract Analysis of tumors using single-cell and spatial modalities is critical to advance our understanding of cancer. The growth of technologies that enable these studies provides an increasing number of single cell datasets. Integrating such data across studies will increase …

04.05.2026 · 2 Zitationen

Cancer-Associated Fibroblasts Promote Epithelial–Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer

Abstract Pancreatic ductal adenocarcinoma (PDAC) carries an extremely poor prognosis, in part resulting from cellular heterogeneity that supports overall tumorigenicity. Cancer-associated fibroblasts (CAF) are key determinants of PDAC biology and response to systemic therapy, and …

04.05.2026

Targeting DOT1L Reactivates HERV-K to Drive Cell-Autonomous and Paracrine Senescence in Adenocarcinoma of the Esophagogastric Junction

Abstract Emerging evidence implicates human endogenous retroviruses (HERV) in cellular senescence and stemness suppression, suggesting that they may also play a role in tumor cell senescence. In this study, we identified the histone methyltransferase disruptor of telomeric silenc …

29.04.2026 · 4 Zitationen

KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer

Abstract Pancreatic ductal adenocarcinoma (PDAC) is characterized by frequent KRAS mutations, which activate the MAPK pathway to promote PDAC progression. In this study, we explored metabolic vulnerabilities of PDAC by assessing initial metabolic reprogramming upon ERK inhibition …

22.04.2026 · 1 Zitationen

ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis

Abstract Brain metastasis in patients with breast cancer represents a terminal disease stage, with a median survival typically measured in months. Tumors that colonize the brain must adapt to its unique microenvironment, such as high acetate levels. Primary brain tumor cells enha …

21.04.2026

Targeting DNA Polymerase Epsilon Induces Tumor Clearance and Activates an NF-κB–Mediated Inflammatory Response in Triple-Negative Breast Cancer

Abstract Breast cancer remains the second leading cause of cancer-related mortality among women, with triple-negative breast cancer (TNBC) exhibiting a particularly poor 5-year prognosis. In this study, we have demonstrated that among genetic and pharmacologic perturbations targe …

19.04.2026

Mutant KRAS Suppresses DNA Sensing by Remodeling Membrane Tension to Clear Extracellular Tumor DNA

Abstract Extracellular tumor-derived DNA (tDNA) has emerged as an important biomarker for cancer diagnosis and monitoring. A better understanding of the mechanisms controlling the abundance of tDNA could help improve biomarker and treatment strategies. In this study, we identifie …

02.07.2026

Abstract LT10: Targeting post-transcriptional mechanisms of tumour persistence

Abstract Quiescent (G0) cancer cells are a sub-population of reversible, non-proliferating cells that survive aggressive clinical therapies and cause cancer persistence. While transcriptional changes have been extensively studied in cancers, we find that 50% of gene expression ch …

02.07.2026

Abstract P54: Information Processing Through Feedback and Feed-Forward Loops in Epithelial–Mesenchymal Transition in Cancer Metastasis

Abstract Network motifs, such as feedback loops, feed-forward loops (FFLs) and their higher-order arrangements known as hypermotifs, serve as fundamental building blocks that orchestrate cellular decision-making networks in cancer. In the context of Epithelial-Mesenchymal Transit …

02.07.2026

Abstract P58: A Novel ALK-R-Spondin-Wnt Signaling Axis in Neuroblastoma: Insights from In Silico And In Vitro Analysis

Abstract Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase implicated in the pathogenesis of several cancers, including anaplastic large cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma. While ALK activation typically occurs through its lig …

02.07.2026

Abstract P71: EZH2 Inhibition Overcomes Radiotherapy Resistance in Radioresistant Head and Neck Cancers (HNCs) by Modulating Heterochromatin-Mediated Epigenetic Silencing

Abstract Radiotherapy is a primary treatment modality for head and neck cancer patients. However, tumour recurrence following radiotherapy and the existing knowledge gap in radioresistance mechanisms pose a major clinical challenge that leads to poor treatment responses. Our prev …

02.07.2026

Abstract P68: Photocatalytic Ferroptosis Induction in KRAS-Mutant CRC via BiVO4-Silica Nanoparticles

Abstract Purpose: KRAS mutations are prevalent in colorectal cancer (CRC) and are associated with resistance to conventional therapies. Recent studies suggest that KRAS-mutant cancers exhibit increased vulnerability to ferroptosis, a non-apoptotic form of cell death driven by iro …

02.07.2026

Abstract P75: THE NEGATIVE IMPACT OF DELAYED INTER-CYCLE CHEMOTHERAPY ADMINISTRATION ON NEUTROPHIL-TO-LYMPHOCYTE RATIO IN CERVICAL CANCER PATIENTS

Abstract Background: Delayed initiation of chemotherapy increases the incidence of mortality in patients with cancer. Currently, more than half of cervical cancer patients experience an inter-cycle delay. However, there is no adequate evidence regarding the effect of inter-cycle …

02.07.2026

Abstract P104: Exploring the Therapeutic Potential of a Novel Peptide Targeting Lysophosphatidic Acid Receptor-3 (LPAR3) in Ovarian Cancer

Abstract Background: Lysophosphatidic acid (LPA), an onco-lipid, is reported to be elevated in the tumour microenvironment in ovarian cancer. The binding of LPA to its cognate receptor LPAR3 leads to the activation of the MAPK, PI3K signalling pathways, resulting in the prolifera …

02.07.2026

Abstract P83: LOW DOSE MEDICAL DIAGNOSTIC RADIATION, A RISK FACTOR FOR COLON CARCINOGENESIS?

Abstract Every day, 500 000 patients worldwide undergo radiological examinations using CT scans. These procedures account for nearly 75% of the collective effective dose received by patients. The associated cancer risk is particularly relevant for colon cancer, where a dose/risk …

02.07.2026

Abstract LT02: Aggressive B-cell lymphomas retain ATR-dependent determinants of T-cell exclusion from the Germinal Center Dark Zone

Abstract Diffuse large B-cell lymphomas (DLBCLs) with a dark zone (DZ)-like transcriptional profile correlate with poor outcomes to rituximab-based chemoimmunotherapy, but the mechanisms underlying this resistance remain unclear. We hypothesize that DZ-like DLBCLs retain immune-e …

02.07.2026

Abstract P26: Targeting Lactate-Induced Pyrimidine Biosynthesis Sensitizes Liver Cancer Cells to Ferroptosis

Abstract Hepatocellular carcinoma (HCC) is a prevalent and aggressive liver malignancy closely associated with the tumor microenvironment (TME), where stromal components significantly contribute to disease progression. Among these components, hepatic stellate cells (HSCs) play a …

02.07.2026

Abstract P15: Context-aware foundation model of bulk transcriptomics for interpretable analysis of transcriptional dynamics and treatment response in AML

Abstract While language models extract linguistic structures from text, similar approaches can uncover biological rules from genetic patterns. Though these methods have shown promise in single-cell analysis, bulk transcriptomics remains underexplored despite offering distinct cli …

02.07.2026

Abstract P60: Intra-tumor heterogeneity in colorectal cancer tumoroids during normal growth and under treatment

Abstract There are currently many treatments available for colorectal cancer (CRC), yet around a million people still die from this disease each year. Recently, the presence of distinct phenotypic subpopulations within tumors has gained interest as a potential source of drug resi …

02.07.2026

Abstract P33: Tumor transcriptome deconvolution identifies genes associated with metastatic progression in colorectal cancer

Abstract Most late-stage colorectal cancer (CRC) patients experience lethal metastasis, often to the liver. However, the molecular mechanisms that drive metastatic progression and adaptation to new tissue environments remain challenging to study in patients. To investigate molecu …

02.07.2026

Abstract P80: Unveiling Precision Targets of PD-1 Blockade Hyperprogression in Cervical Adenocarcinoma via Longitudinal Single-Cell and Spatial Monitoring

Abstract Cervical adenocarcinoma, a significant subtype of cervical cancer, exhibits variable responses to immune checkpoint inhibitors, with some patients experiencing hyperprogressive disease (HPD) characterized by accelerated tumour progression. The molecular and cellular mech …

02.07.2026

Abstract P48: MULTIMODAL DATA INTEGRATION FOR A PAN-CANCER ASIAN COHORT OF EXCEPTIONAL RESPONDERS AND HYPER-PROGRESSORS TO IMMUNOTHERAPY HIGHLIGHTS UTILITY OF BIOMARKERS

Abstract While cancer immunotherapy has become an important treatment option, heterogenous responses to immune checkpoint inhibitor (ICI) treatment across diverse cancer types remain a significant clinical challenge. The SUPER (Singapore Translational Cancer Consortium (STCC) Uni …

02.07.2026

Abstract P09: Functional Dissection of NK Cell Evasion Mechanisms in TP53 -Inactivated Acute Myeloid Leukemia

Abstract Introduction: TP53 mutations occur in 30% of relapsed/refractory AML patients and are associated with poor prognosis, therapy resistance, and immune dysfunction. While TP53 mutations have been shown to induce T cell exhaustion and impair adaptive immunity, their impact o …

02.07.2026

Abstract P31: FGFR Inhibitor, Erdafitinib, Reshapes Prostate Cancer Skeletal Metastases via Modulation of Cancer-Stemness and Tumor-Bone Interface

Abstract Background: Castration-resistant prostate cancer (CRPC) bone metastases lack curative therapies. Fibroblast growth factor receptor (FGFR) signaling is implicated in bone physiology, cancer stemness and therapy resistance. Previously, we demonstrated Dovitinib, a multi-ty …

02.07.2026

Abstract P93: Multi-Cancer Screening Using AI-Enhanced Canine Olfactory Detection: Interim Results from a Multi-Center Breath Analysis Study in India

Abstract Background: Early cancer detection remains a critical challenge in global healthcare. Breath is an ideal first-tier screening matrix: non-invasive, sampleable outside clinics, and rich in volatile organic compound (VOC) signatures generated by tumor metabolism. We develo …

02.07.2026

Abstract P87: Drug-induced Hyperactivation of the oncogene KRAS induces ferroptosis in G12-mutant KRAS Pancreatic Ductal Adenocarcinoma (PDAC)

Abstract Pancreatic Ductal Adenocarcinoma (PDAC) has a dismal prognosis and limited treatment options. With ∼90% of PDAC cases harboring KRAS mutations, targeting KRAS has been a major therapeutic focus. However, its small size and high affinity for GTP present challenges for dir …

02.07.2026

Abstract P67: n-Butylidenephthalide Induces Ferroptosis in ALDH+ Cancer Stem Cells of High-Grade Serous Ovarian Cancer

Abstract Type II high-grade serous ovarian cancer (HGSOC) represents approximately 80% of all ovarian cancer cases, with cancer stem cells (CSCs) contributing to tumor metastasis and chemoresistance. n-Butylidenephthalide (BP), a compound with known anti-tumor activity, was evalu …

02.07.2026

Abstract P49: Target PRMTs to Overcome Cancer Immune Resistance

Abstract Hyperactivated protein arginine methyltransferases (PRMTs) are implicated in human cancers. Genetic screens and other preclinical studies reveal tumor intrinsic PRMTs can suppress T-cell mediated antitumor immune responses, highlighting the possibility of combining PRMT …

02.07.2026

Abstract P14: Lgr5+ and Lgr6+ Cells as Prognostic Markers and Therapeutic Targets in Esophageal Squamous Cell Carcinoma (ESCC)

Abstract Esophageal squamous cell carcinoma (ESCC) is the world’s 7th most common malignancy, yet survival remains dismal owing to late detection, frequent relapse, and a lack of targeted therapies. While Wnt signalling is commonly dysregulated in ESCC, the specific roles of its …

02.07.2026

Abstract P56: Prospective Functional Personalised Oncology For Metastatic Breast Cancer Patients Identifies Effective PI3K Inhibitors-based Combinations

Abstract Breast cancer (BC) is the major cause of cancer-related death in women, with metastatic BC patients having a dismal 5-year survival rate of about 20%. The advent of functional precision oncology, leveraging on patient-derived models and functional assays, can provide pat …

02.07.2026

Abstract P82: An ATP–P2Y2–Integrin Signaling Axis Underlies the Persistent Stability of Oncogenic EGFR Mutants in non-small cell lung cancer (NSCLC)

Abstract Activating mutations in the epidermal growth factor receptor (EGFR) gene are key oncogenic drivers in NSCLC. While EGFR tyrosine kinase inhibitors (TKIs) have revolutionized the treatment landscape, resistance inevitably emerges—often through secondary or tertiary EGFR m …

02.07.2026

Abstract P102: Molecular Landscape, Subtypes, and Therapeutic Vulnerabilities of Central Nervous System Solitary Fibrous Tumors

Abstract Solitary fibrous tumors (SFTs) of the central nervous system (CNS) are rare, aggressive mesenchymal neoplasms with high recurrence and metastasis rates. Here, we perform a comprehensive multi-omics analysis of 189 cases of CNS SFTs integrating 94 whole genome sequencing, …

02.07.2026

Abstract P72: From Papilloma to Carcinoma: Unravelling the Transcriptomic Reprogramming in Malignant Transformation of Sinonasal Inverted Papilloma

Abstract BACKGROUND & OBJECTIVES: Inverted papilloma (IP) is a benign yet locally aggressive sinonasal lesion, characterized by frequent disease recurrence and potential for malignant transformation, most commonly into squamous cell carcinoma (SCC). While clinical management of I …

02.07.2026

Abstract P10: Early Immunosuppressive Landscape Shaped by BRCA1/p53 Loss in Early Pre-Malignant Mammary Glands Permits Tumor Development

Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options and poor prognosis. The early pre-malignant events that lead to TNBC remain elusive, largely due to a lack of tractable models that recapitulate stepwise tumor initiation in a …

02.07.2026

Abstract P69: Covalent Inhibition of CLIC1: A Novel Strategy for Anti-Cancer Drug Discovery

Abstract Human Chloride Intracellular Channel 1 (CLIC1) is frequently overexpressed in various tumors, where it plays a critical role in cancer cell survival by recycling vitamin C and protecting against oxidative stress. This crucial function makes targeting CLIC1's enzymatic ac …

02.07.2026

Abstract P88: Hydrogel-Supported Cryopreserved Colorectal Cancer (CRC) Explants for Evaluation of Immunotherapy

Background: The heterogeneous tumor microenvironment (TME) in colorectal cancer (CRC) critically influences drug response, with Microsatellite Instability (MSI) and Microsatellite Stability (MSS) subtypes exhibiting distinct TMEs. While MSI tumors often respond to immunotherapy, …

02.07.2026

Abstract P107: Gelsolin Promotes Resistance to 5-Fluorouracil in Colorectal Cancer through TFEB-dependent autophagy

Abstract Despite advances in colorectal cancer management using a 5-Fluorouracil (5-FU)-based regime, recurrence after chemotherapy is the barrier to effective clinical outcomes for these patients. Accumulating evidence suggests regulators of actin cytoskeleton play critical role …

02.07.2026

Abstract P73: The Spatial Organization of Lymphoma Cells with MYC-BCL2 Co-Expression Shapes the Immune Microenvironment and Determines Survival After Chemoimmunotherapy

Abstract Introduction: MYC and BCL2 co-expression defines double-expressor lymphoma (DEL), a subtype of diffuse large B-cell lymphoma (DLBCL) associated with poor prognosis. However, its clinical utility is limited by inconsistent scoring thresholds and a possible protective role …

02.07.2026

Abstract P78: Identification of Novel Non-Coding RNAs and Phytochemicals for Targeting Different Cell Death Mechanisms in Triple-Negative Breast Cancer

Abstract Triple-Negative Breast Cancer (TNBC) is an aggressive and heterogeneous subtype of breast cancer characterized by the absence of estrogen, progesterone, and HER2 receptors, which limits the effectiveness of current targeted therapies. Emerging evidence highlights the cru …

02.07.2026

Abstract P94: Cross-Talk of Hepatic Innate Immune Cells in Maintaining Liver Health and Shaping Metastatic Susceptibility

Abstract Up to 50% of patients undergoing treatment for malignancies develop liver metastases during the course of their disease. In the United States and Europe, liver metastases are more prevalent than primary liver cancer. Tissue-resident immune cells are pivotal regulators of …

02.07.2026

Abstract P81: Hsa_circ_0116796 as a novel regulator and potential therapeutic target in hepatocellular carcinoma

Abstract Background: Hepatocellular carcinoma (HCC) is among the leading causes of cancer-related mortality worldwide, exhibiting a poor prognosis due to its high metastatic potential and lack of effective diagnostic and prognostic markers. Non-coding RNAs (ncRNAs), including mic …

02.07.2026

Abstract P106: SELECTIVE CYTOTOXICITY IN KRAS-MUTANT CANCER CELLS THROUGH COORDINATED STABILIZATION OF KRAS AND ITS UPSTREAM REGULATORS USING SMALL MOLECULE DRUG

Abstract KRAS is one of the most frequently mutated oncogenes in cancer, driving tumorigenesis and resistance to therapy. However, its smooth, shallow surface and lack of deep binding pockets have historically made it difficult to target with small molecules. Our lab identified M …

02.07.2026

Abstract P110: DPYD Overexpression Promotes Malignant Phenotypes in Glioblastoma Through Enhanced Proliferation and Migration

Abstract Introduction: Glioblastoma (GBM) is a highly aggressive brain tumor driven by metabolic reprogramming. Dihydropyrimidine Dehydrogenase (DPYD), a key enzyme in pyrimidine catabolism, is linked to cancer metabolism, but its role in GBM is unclear. This study examined the c …

02.07.2026

Abstract P101: Investigating the Role of Hypoxia-Mediated Metabolic Dysregulation in Immune Evasion in Pancreatic Ductal Adenocarcinoma (PDAC)

Abstract Pancreatic ductal adenocarcinoma (PDAC) is known for its poor prognosis, with a 5-year survival rate of less than 10%, primarily due to late-stage diagnosis and the absence of reliable early biomarkers. The tumour's poor vascularization and hypoxic microenvironment drive …

02.07.2026

Abstract P39: Development and In Vitro Evaluation of PLGA-PEG Nanoparticles Encapsulating a Cdc42 Inhibitor for Targeted Colorectal Cancer Therapy

Abstract Background: CASIN, a Cdc42 inhibitor, can suppress the growth and metastasis of colorectal cancer cells but is limited by rapid clearance and poor bioavailability. In this study, we developed PLGA-PEG-COOH nanoparticles to encapsulate CASIN, aiming to improve its deliver …

02.07.2026

Abstract P74: Poly-Aneuploid Prostate Cancer Cells Exhibit Enhanced HIF-1α, RhoA-Mediated Motility and Aerotaxis Under Hypoxia

Abstract While metastasis accounts for the majority of cancer-related deaths, the mechanisms by which rare subpopulations of cancer cells complete the metastatic cascade remain poorly understood. Emerging evidence implicates poly-aneuploid cancer cells (PACCs), a subpopulation th …

02.07.2026

Abstract P45: Disruption of mTORC2 Activity by Pdcd4–Rictor Binding Attenuates Tumor Growth in NSCLC

Abstract Programmed cell death 4 (Pdcd4) is a tumor suppressor frequently downregulated in various cancers, including breast, colon, liver, lung, pancreas, prostate, and skin. It inhibits tumor initiation, proliferation, invasion, and metastasis. Biochemically, Pdcd4 suppresses p …

02.07.2026

Abstract P01: Investigating the Early-stage Colorectal Cancer Liver Metastasis Microenvironment to Discover Novel Macrophage Molecular Targets

Abstract Colorectal cancer (CRC) is the second-leading cause of cancer deaths in Singapore for both men and women, accounting for more than 4000 deaths between 2016 and 2020. Up to 50% of patients diagnosed with CRC eventually develop liver metastasis, which is the spread of the …

02.07.2026

Abstract P55: Targeted Delivery of Cdc42 Inhibitor CASIN to Colorectal Cancer Cells via Nucleolin-Binding Aptamer-Functionalized PLGA-PEG Nanoparticles

Abstract Background: Systemic inhibition of Cdc42 effectively suppresses the growth and metastasis of colorectal cancer but is associated with substantial side effects. To minimize these adverse effects, we have developed PLGA-PEG nanoparticles functionalized with DNA aptamers, e …

02.07.2026

Abstract P03: Chemotherapy-Induced CD70 Expression Enhances Anti-Tumor Immunity and CAR-T Cell Efficacy in Acute Myeloid Leukemia

Abstract Introduction: Acute myeloid leukemia (AML) has largely evaded clinical benefit from immunotherapeutic approaches, with current CAR-T therapies targeting CD123 and CD33 showing limited activity and significant cytopenia due to shared antigen expression with normal hematop …

02.07.2026

Abstract P111: DISTINCT EXPRESSION OF AKT ISOFORMS IN TRIPLE NEGATIVE BREAST CANCERS AND ROLES OF AKT ISOFORMS IN CISPLATIN SENSITIVITY

Abstract AKT, a serine threonine kinase, exists in three different isoforms and is known for regulating several biological processes including tumorigenesis. In this study, we investigated the expression and net effect of the individual isoforms in triple negative breast cancers …

02.07.2026

Abstract P76: α-Arrestin ARRDC3 Regulates TNF-α-Mediated Signaling Through TNFR1 in Triple Negative Breast Cancer

Abstract Triple negative breast cancers (TNBC) account for 10-20% of all breast cancer diagnoses in the United States and are noted for their aggressive reoccurrences and complex molecular heterogeneity. Although the mainstay of TNBC treatment is chemotherapy and radiation therap …

02.07.2026

Abstract P96: Oxygen Nanobubbles as Theranostic Agents: In Vivo Evaluation of Contrast Properties and Oxygen Delivery

Abstract Hypoxia is a common feature of the tumor microenvironment and can significantly impair the efficacy of standard cancer therapies. Both microbubbles and nanobubbles, containing perfluorocarbon and/or air, are already widely used as effective contrast agents in ultrasound …

02.07.2026

Abstract P34: PREDICTING BRAIN METASTASIS THROUGH TUMOR-DERIVED EXTRACELLULAR VESICLES: ADVANCING THE SEED AND SOIL PARADIGM

Abstract Background and Objective: Brain metastasis is a devastating complication in advanced cancers, particularly in breast cancer, where it significantly reduces patient survival. Despite its clinical relevance, early detection remains a challenge due to the absence of reliabl …

02.07.2026

Abstract P40: Novel Monoclonal Antibody Kills Lymphoma Cells Via LFA-1/ICAM-1 Dependent, Antibody-Mediated Cellular Cytotoxicity

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin’s lymphoma. DLBCL patients undergo a first line immunochemotherapy regimen, termed R-CHOP. Unfortunately, approximately 40% of treated patients eventually relapse, or are non-responsiv …

02.07.2026

Abstract P118: Interleukin-Inflammatory Cancer-Associated Fibroblast Educate IL1B TAMs that Correlate with Recurrence and Chronic Inflammation

Abstract Tumour-associated macrophages (TAMs) are key in shaping the tumour microenvironment, often synergizing with cancer-associated fibroblasts (CAFs) to drive angiogenesis, immune suppression and exclusion. While single-cell omics has revealed a heterogeneous spectrum of TAMs …

02.07.2026

Abstract P32: Integrative Transcriptomic and Deep Learning Model Identifies Anti-Cancer Peptides Targeting KIF2C in Breast Cancer

Abstract Breast cancer is the most diagnosed cancer and a leading cause of cancer-related death among women worldwide. Drug resistance is a major challenge, contributing to treatment failure and disease progression. Anti-cancer peptides (ACPs), small protein fragments, offer a pr …

02.07.2026

Abstract P105: GPER1 (G-protein Coupled Estrogen Receptor 1): A Molecular Target for Prostate Cancer Chemoprevention

Abstract Incidence of Prostate Cancer (PCa), the 2nd most common cancer in men, is projected to increase by two-fold in 2040 and will pose as a potential healthcare burden. PCa pathogenesis involves a long latency period offering opportunities for chemoprevention. GPER1, a membra …

02.07.2026

Abstract P119: Senescent Cell-Derived Extracellular Vesicles Distinctly Impede Tumor Recurrence by Antitumor Immune Response and Function

Abstract Triple-negative breast cancers (TNBC), associated with poor prognosis and high tumour recurrence, are often-treated with taxanes in first-line treatment regimens. However, acquired disease resistance can often set in, hampering clinical efficacy. Senescent cells represen …

02.07.2026

Abstract LT01: Spatial Phenotypes Ascribed to Cancers with Extreme Resistance (SPACER) in HR+ HER2- Metastatic Breast Cancer – a Multi-Institutional Use-Case Study of the Translational Research Integration and Support Platform by the Singapore Translational Cancer Consortium (STCC)

Abstract Background & Objectives: Despite advances in breast cancer treatment, there remains a critical need for reliable predictive biomarkers to guide treatment selection for hormone receptor positive (HR+) breast cancer. To address this gap, we conducted a retrospective study …

02.07.2026

Abstract P28: Metastatic Capabilities in Breast Cancer Cells are Potentiated by Resistance Against Membrane Damage Through Dysregulated Membrane Phospholipid Profiles and Annexin-Mediated Repair

Abstract During cancer metastasis, invading cancer cells are required to navigate through various biophysical barriers. In the process of intravasation, circulation and extravasation, cancer cells which successfully overcome and survive these tremendous biophysical stressors can …

02.07.2026

Abstract P103: Large-Scale Integrative Analysis Identifies Expression-Based Predictors of EGFR-TKI Response

Abstract Lung adenocarcinomas patients harboring classical mutations in the epidermal growth factor receptor (EGFR), notably Exon 19 deletions and L858R insertions, are typically treated with tyrosine kinase inhibitors (TKIs) as first-line therapy. While these tumours initially r …

02.07.2026

Abstract LT07: EPIGENETIC VULNERABILITIES DRIVE SURVIVAL OF DRUG-TOLERANT PERSISTERS AND REVEAL THERAPEUTIC OPPORTUNITIES IN AML

Abstract Acute myeloid leukemia (AML) presents significant therapeutic challenges despite advances in targeted therapies, primarily due to acquired resistance. In AML, relapse is frequently driven by drug-tolerant persisters (DTPs), a small subpopulation of cells that survive the …

02.07.2026

Abstract P04: Extracellular Cartography Reveals Immunomodulatory Axes in Colorectal Cancer Tumor Microenvironment

Abstract The tumor microenvironment (TME) orchestrates immune evasion and therapeutic resistance in colorectal cancer (CRC), particularly in microsatellite stable (MSS) tumors that exhibit poor responses to immunotherapy. While the cellular component of the TME has been extensive …

02.07.2026

Abstract P114: Dissecting the Carcinogenesis Mechanisms of Aristolochic Acid in Cholangiocarcinoma

Abstract Aristolochic acid (AA) is a potent mutagen found in commonly consumed herbal remedies, causing mutational signature (SBS22) that results in oncogenic transformation of tissues including that of hepatobiliary and genitourinary origins. However, the mechanistic role of AA …

02.07.2026

Abstract P29: STAT3-Mediated Immune Dysfunction And BMI-Stratified Therapeutic Windows in Obesity-Associated Pancreatic Cancer

Abstract Background: Obesity increases pancreatic ductal adenocarcinoma (PDAC) incidence and aggressiveness by impairing antitumor immunity, yet mechanistic insights remain limited. We hypothesized that STAT3 integrates obesity-induced metabolic and immune dysfunctions, creating …

02.07.2026

Abstract P17: Escape From Therapy-Induced Senescence Drives ABCB1-Mediated Drug Resistance And Evades Aneuploidy Surveillance

Abstract Successful anti-cancer therapy relies on tumor cell killing or senescence induction where cells cease proliferating. However, although senescence initially causes tumor suppression, it can also contribute to tumor recurrence via paracrine tumorigenic action of the senesc …

02.07.2026

Abstract P61: Turning Back TIME: Leveraging an Improved Humanized Mouse Model to Dissect the Tumor Immune Microenvironment and Guide Immunotherapy in Soft Tissue Sarcoma

Abstract Humanized mouse models are critical for studying cancer immunology, but traditional models often fail to fully recapitulate human immune complexity, particularly underrepresenting natural killer (NK) cells. To address this, we developed a humanized mouse model with impro …

02.07.2026 · 1 Zitationen

Abstract P02: Vascularised Lymphoid Organoids Recreate Tertiary Lymphoid Structures for Quantitative Tumour-Immune Studies

Abstract Tertiary lymphoid structures (TLS) are temporary immune cell clusters that form in non-lymphoid tissues during chronic inflammation and cancer. Their presence has been associated with better patient outcomes, especially within tumors, and a stronger response to immunothe …

02.07.2026

Abstract P23: A deep-learning model for quantifying circulating tumour DNA from the density distribution of DNA-fragment lengths

Abstract Background: Frequent, low-cost ctDNA profiling promises real-time therapy monitoring and economical triage of scarce volume plasma samples. Yet, current methods either require tumour-informed deep-sequencing or plateau at a ∼3% limit of detection (LoD) when tumour-naïve …

02.07.2026

Abstract P46: Discovery of Highly Brain Penetrable Antimitotic Agents for the Treatment of Breast Cancer Brain Metastasis

Abstract Background and unmet medical need: Among the four major breast cancer metastasis sites (lung, bone, liver, and brain), patients with breast cancer brain metastasis (BCBM) have very limited therapeutic options, poor quality of life, and low overall survival rates. In fact …

02.07.2026

Abstract P86: A drug repurposing screen identified efficacious topoisomerase II (TOP2) inhibitors against mutant KRAS-driven colon cancer metastasis

Abstract Background: Colorectal cancer (CRC) is the third most common malignancy worldwide. Mortality is largely due to limited treatment options for patients who present with advanced disease. Oncogenic mutations in KRAS occur in approximately 30-50% of CRC, driving tumor progre …

02.07.2026

Abstract P115: Modulation Of Long Non-Coding RNAs In Triple-Negative Breast Cancer Cells By Tocotrienol-rich Fraction from Palm Oil

Abstract Breast cancer is the leading cause of cancer-related mortality among women worldwide. Triple-negative breast cancer (TNBC), representing ∼15% of cases, disproportionately contributes to this burden due to its aggressive growth, absence of targeted therapies, and high rat …

02.07.2026

Abstract LT04: EcDNA-borne PVT1 Fusions Stabilize Transcripts and Enhance MYC Oncogenic Functions

Abstract Oncogene amplifications on extrachromosomal DNA (ecDNA) are common in malignant cancers and contribute to drug resistance. By integrating 17,578 whole genome sequencing and 10,908 RNA-seq data from Genomics England (GEL), The Cancer Genome Atlas (TCGA), and Cancer Cell L …

02.07.2026

Abstract P116: Epigenetic Regulation of Sox21 in Brain Tumor

Abstract Epigenetic dysregulation plays a pivotal role in the pathogenesis of brain tumors, contributing to aberrant gene expression and malignant progression. The transcription factor Sox21, a member of the SRY-related HMG-box (SOX) family, has been implicated in neural differen …

02.07.2026

Abstract P18: Functional Consequences of Structural Variants Arising from Extracellular Domain Mutations in EGFR

Abstract Background: Epidermal growth factor receptor (EGFR) is an oncogene frequently mutated in cancers. Around half of Asian non-small cell lung cancer (NSCLC) tumours harbour activating EGFR mutations, the most prevalent variants being exon19 deletion and L858R point mutation …

02.07.2026

Abstract P22: Decoding ecDNA in Breast Cancer: From Patient-Derived Models to AI-Enhanced Clinical Detection

Abstract Extrachromosomal DNA (ecDNA) drives oncogene amplification and therapy resistance across cancers, yet its role in breast cancer requires more comprehensive mechanistic understanding. We developed comprehensive ecDNA breast cancer models including patient-derived cell lin …

02.07.2026

Abstract P41: Potential role of LCN2, MMP9 and LCN2/MMP9 complex as plausible biomarkers of Oral Squamous Cell Carcinoma (OSCC)

Abstract Background: OSCC is a significant health problem in LMICs including India, and has poor outcome due to lack of diagnostic marker. We identified 135 dysregulated candidate proteins in the saliva of OSCC patients using LCMS, of which Lipocalin 2(LCN2) and Matrix Metallopro …

02.07.2026

Abstract P91: Development of CEACAM6-Targeted Single-Domain Antibody-Functionalized Liposomal Doxorubicin for Targeted Therapy of Lung Cancer Brain Metastases

Abstract Brain metastases in non-small cell lung cancer (NSCLC) pose a critical treatment hurdle due to the blood–brain barrier’s (BBB) restriction on drug delivery. While liposomal doxorubicin improves circulation and reduces toxicity, it lacks active targeting ability to reach …

02.07.2026

Abstract P64: Methylation Mesa Define Functional Regulatory Elements for Targeted Gene Demethylation and Activation

Abstract Aberrant DNA methylation, in regions such as gene promoters, is considered an epigenetic hallmark of many cancers, contributing to tumorigenesis by means of transcriptionally silencing tumor suppressor genes. However, DNA methylation and mRNA expression correlations are …

02.07.2026

Abstract P12: Bystander activation drives CD8+ T cells response in Lymphoma-associated Hemophagocytic Lymphohistiocytosis

Abstract Hemophagocytic lymphohistiocytosis (HLH) is a fulminant disease characterized by overwhelming inflammatory response leading to dismal outcomes. Amongst patients with secondary HLH, lymphoma-associated HLH has the worst outcome. While aberrant activation of cytotoxic CD8+ …

02.07.2026

Abstract P30: Q-omics: smart data mining through ontology-derived gene network modelling

Abstract Q-omics (https://qomics.io) is an AI-powered omics data mining platform designed to help cancer researchers and oncologists identify tumor-specific targets, prognostic biomarkers, and underlying mechanisms—without requiring bioinformatics expertise. The platform integrat …

02.07.2026

Abstract P50: IQGAP1-YAP-IQGAP2 Axis: Modulators Of Stemness, Resistance And Relapse Dynamics

Abstract Breast cancer continues to be the foremost cause of cancer-related deaths among women, driven by high rates of therapy resistance and relapse, largely due to the persistence of cancer stem cells (CSCs). Despite advances in targeted therapies, the ERK signalling pathway r …

02.07.2026

Abstract LT05: How EGFR Mutations Shape Lung Cancer in Never-Smokers

Abstract Lung cancer is classically linked to tobacco, yet in East Asia, a striking proportion arises in never-smokers—accounting for up to 48% of cases in Singapore. Paradoxically, these lung cancers in never-smokers (LCINS), often driven by EGFR mutations, exhibit a lower tumou …

02.07.2026

Abstract P97: SOLID STRESS ACTIVATED IL-6/JAK/STAT3 PATHWAY TO INCREASE BREAST CANCER CELL MIGRATION AND INVASION

Abstract While tumour cells are known to respond to biochemical signals, the influence of physical and mechanical cues is increasingly more recognised. Solid stress arises from tumour expansion, where growing tumour masses and surrounding tissue exert equal and opposite forces on …

02.07.2026

Abstract P62: Liposarcoma Clonal Complexity: A Multi-Modal Single-Cell and Genomic Analysis

Abstract Introduction: Liposarcomas are rare mesenchymal malignancies that remain poorly characterized at single-cell resolution, limiting insights into tumor identity and heterogeneity. While MDM2 and CDK4 amplifications are hallmark diagnostic features, current clinical tools s …

02.07.2026

Abstract P08: ESTABLISHMENT AND CHARACTERISATION OF LIPOSARCOMA-DERIVED CELLS AS RELEVANT PRE-CLINICAL MODELS FOR TARGET DISCOVERY

Abstract Background: Pre-clinical models that encompass disease heterogeneity are limited for liposarcoma research. We aim to establish and characterise matched liposarcoma-derived tumours and liposarcoma cells cultured in vitro. More importantly, we aim to identify drug suscepti …

02.07.2026

Abstract P25: MS CETSA deep functional proteomics uncovers novel DNA repair programs leading to Gemcitabine resistance

Abstract Mechanisms for resistance to cytotoxic cancer drugs are dependent on dynamic changes in the biochemistry of cellular pathways, information which is hard to obtain at the systems level. Here we use a deep functional proteomics implementation of the Cellular Thermal Shift …

02.07.2026

Abstract P59: Targeting TGF-β signaling pathway to reverse immune checkpoint blockade resistance in hepatocellular carcinoma

Abstract Immune checkpoint blockade (ICB) therapies have reshaped the treatment paradigm across various cancer types. In hepatocellular carcinoma (HCC), the combination of anti-PD-L1 and anti-VEGF, approved as new first-line treatment, has shown improved overall survival. However …

02.07.2026

Abstract P44: Transposable Element Patterns Across Genetic Ancestries in Prostate Cancer Patients

Abstract Introduction: Prostate cancer (PCa) is a significant burden to men with African ancestry, however, the mechanism of how ancestry contributes to aggressive PCa in these patients is not well understood. We have identified differences in endogenous retrovirus (ERV) expressi …

02.07.2026

Abstract P63: Oxidative Metabolism and One-Carbon Networks Enable Survival of Colon Cancer Cells in Glucose-Deprived Conditions

Abstract Colon cancer cells possess remarkable metabolic adaptability, allowing them to survive under changing nutrient conditions. While this adaptive response is critical for tumor progression, the mechanistic underpinnings remain poorly characterized. Here, we investigate how …

02.07.2026

Abstract P108: Colorectal cancer cells grown in vitro as spheroids show a response to the first-line chemotherapy-based combination drug, FOLFOXIRI

Abstract Background: Colorectal cancer (CRC) is a major public health concern by being the third most diagnosed and second most lethal cancer globally. Although complete surgical resection of the tumor and its metastatic sites improves overall survival in patients with CRC, appro …

02.07.2026

Abstract P05: Comprehensive Analysis of BAP1 Germline Variants

Abstract Germline mutations in the BRCA1-associated protein 1 (BAP1) gene are linked to various hereditary cancer syndromes, particularly BAP1 tumor predisposition syndrome. However, the effects of these mutations on cellular biology and their roles in disease predisposition are …

02.07.2026

Abstract P57: Molecular Underpinnings of Obesity-related Oesophageal Adenocarcinoma (OAC)

Abstract Background: The global rise in obesity has been paralleled with increasing incidence of obesity-associated cancers, including OAC. While epidemiological studies have shown a strong link between obesity and increased risk of OAC, the underlying mechanism remains poorly un …

02.07.2026

Abstract P42: SEROTONIN RECEPTOR 5-HT2A AS A POTENTIAL TARGET FOR HCC IMMUNOTHERAPY

Abstract While recent clinical trials of combination immunotherapies for hepatocellular carcinoma (HCC) have shown promising clinical efficacy and survival improvements breakthroughs, there is still much room for further improvement. A key limiting factor for HCC immunotherapy is …

02.07.2026

Abstract P92: C11ORF68 is a repressor of inflammatory response under normal and replication stress conditions

Abstract Introduction: Unresolved replication stress (RS) or DNA damage, and inflammation often lead to genomic instability – a feature of many diseases including cancer. Therefore, understanding the molecular foundation of these phenomena is crucial for identifying potential bio …

02.07.2026

Abstract P70: Exploring cancer stem cell regulators and its mechanisms using CRISPR-activation based screening

Abstract Cancer stem cells (CSCs) potentially possess multiple mechanisms of resistance to therapies and contribute to cancer initiation and progression. However, effective therapies that target CSCs have not yet been developed, as underlying mechanisms of stemness maintance, dif …

02.07.2026

Abstract LT06: Dual Inhibition of Protein Degradation and Nuclear Export Uncovers Molecular Dependencies in Gliomas

Abstract High-grade glioma (HGG), including glioblastoma (GBM), remains one of the most aggressive and therapeutically resistant brain malignancies, with limited effective treatment options. While numerous clinical trials have explored molecularly targeted therapies, the intrinsi …

02.07.2026

Abstract P19: CellTopo quantifies tissue structure and organization in solid tumors

Abstract Highly structured tissues in human gut, breast, and lymphoid organs maintain precise cellular organization that enables their functions. In cancer, tissue structure becomes progressively dysregulated which promotes tumour progression and therapeutic resistance. Despite c …

02.07.2026

Abstract P20: PIM inhibition potentiates TRAIL apoptosis in renal cell carcinoma

Abstract Renal cell carcinoma (RCC) cases are on the rise globally. RCC tumors’ acquired resistance to current RCC therapies necessitates the identification of novel therapeutic strategies and biomarkers. Oncogenic PIM1 kinase is overexpressed and associated with worse clinical o …

02.07.2026

Abstract P95: PDCD11, Enriched in Cancer cell-Derived Extracellular Vesicles, Promotes Immunosuppressive Macrophage Polarization and Tumor Immune Evasion in HBV related Hepatocellular Carcinoma

Abstract Background: Chronic hepatitis B is the main cause of hepatocellular carcinoma (HCC) increasing worldwide. In addition to liver residing cells, the infiltrating immune cells in the tumor microenvironment (TME) promotes initiation, progression, and metastasis of HCC. Withi …

01.07.2026

Editor’s Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib

01.07.2026

Editor’s Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity

01.07.2026

MIF–CD74 Signaling Defines a Brain-Specific Immune Vulnerability in Metastasis and Neurologic Disease

Brain metastases represent a major clinical challenge in systemic cancer, as current treatments are rarely curative and neurologic morbidity dominates patient outcomes. Increasing evidence suggests that the brain functions as a distinct, partially orthogonal ecosystem in which th …

01.07.2026

Editor’s Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells

01.07.2026

Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference

Abstract The 17th Annual Frontiers in Cancer Science (FCS) conference (2025) highlighted the convergence of multiomics, computational biology, and ancestry-specific genomics to advance proactive cancer care. Key insights included the role of epigenetic plasticity in maintaining t …

01.07.2026

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer

01.07.2026

ARF beyond p53: Shaping the Pancreatic Tumor Microenvironment

ARF (p14ARF) is a tumor suppressor classically known for stabilizing and activating p53. In this issue of Cancer Research, Ferreira and colleagues provide insights into the role of ARF in the development of pancreatic ductal adenocarcinoma, showing its p53-independent tumor micro …

22.04.2026

A Conserved Enhancer Locus in Extrachromosomal DNA and Homogeneously Staining Regions Activates MYC Transcription in Group 3 Medulloblastoma

Abstract MYC is amplified on extrachromosomal DNA (ecDNA) or homogeneously staining regions (HSR) in group 3 medulloblastoma (G3-MB), conferring a poor prognosis. A better understanding of the mechanisms underlying MYC expression in ecDNA and HSRs could be leveraged to develop im …

20.04.2026

Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic Vulnerabilities

Abstract Acquired resistance limits the therapeutic efficacy of KRAS-MAPK inhibitors in pancreatic ductal adenocarcinoma (PDAC). As transcriptional plasticity and epithelial-to-mesenchymal transition (EMT) have been implicated in resistance, we sought to study the molecular mecha …

20.04.2026

Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma

Abstract In pancreatic ductal adenocarcinoma (PDAC), irinotecan (1μmol/L) chemotherapy triggers a dual-phase autophagy process that drives drug resistance. Although mTOR and autophagy exert suppressive effects on each other, coactivation of mTOR and autophagy has been observed wh …

17.04.2026

UFMylation Suppresses Hepatocellular Carcinoma Metastasis by Inhibiting β-Catenin–Driven Hybrid EMT and NK Cell Evasion

Abstract Hepatocellular carcinoma (HCC) is a deadly malignancy marked by frequent metastasis and recurrence. Despite therapeutic advances, HCC metastasis and immune evasion remain major hurdles to effective treatment. In this study, by analyzing clinical HCC specimens, we found t …

15.06.2026

Editor’s Note: Inhibition of NF-κB–Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma

15.06.2026

DPY30 Sticks a Fork in PDAC Immunity

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited therapeutic options and poor responsiveness to immune checkpoint blockade (ICB). Emerging evidence links genome instability and replication stress to the activation of cyclic GMP–AMP …

15.06.2026

Editor’s Note: Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53

22.04.2026

Ciliated Cells Drive Critical STING-Mediated Tumor Suppression in the Fallopian Tube Epithelium

Abstract Mitigating DNA damage in the fallopian tube epithelium (FTE) is essential for preventing tubo-ovarian high-grade serous carcinoma (HGSC). In this study, we demonstrated that the stimulator of interferon genes (STING) is abundantly expressed in the ciliated cells of the F …

21.04.2026

Stress Tested: Aging Rewires Tumors for Metastatic Spread through Activation of the Integrated Stress Response

Aging is a major risk factor for cancer incidence and mortality; however, its effect on tumor evolution and metastatic progression remains incompletely understood. A recent study by Patel and colleagues published in Nature reveals a paradoxical role for aging in cancer biology: A …

01.06.2026

Editor’s Note: B-Cell Receptor Translocation to Lipid Rafts and Associated Signaling Differ Between Prognostically Important Subgroups of Chronic Lymphocytic Leukemia

01.06.2026

Editor’s Note: Transglutaminase Interaction with α6/β4-Integrin Stimulates YAP1-Dependent ΔNp63α Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation

15.05.2026

Editor’s Note: The Myc–miR-17∼92 Axis Blunts TGFβ Signaling and Production of Multiple TGFβ-Dependent Antiangiogenic Factors

15.05.2026

Editor’s Note: Myc-Transformed Epithelial Cells Down-Regulate Clusterin, Which Inhibits Their Growth in Vitro and Carcinogenesis in Vivo

15.05.2026

Editor’s Note: Stat1-dependent Induction of Tumor Necrosis Factor-related Apoptosis-inducing Ligand and the Cell-Surface Death Signaling Pathway by Interferon β in Human Cancer Cells

15.05.2026

Abstract ND06: ECI830, a potent and highly selective CDK2 inhibitor, for the treatment of HR+/HER2− breast cancer and CCNE1 -amplified tumors

Abstract Cyclin-dependent kinases (CDKs) are a group of serine/threonine kinases that play a crucial role in regulating cell cycle progression. Over the past decade, CDK4/6 inhibitors such as ribociclib have significantly improved outcomes in patients with HR+/HER2− breast cancer …

15.05.2026

Abstract ND09: Discovery of CID-078, a first-in-class oral macrocycle cyclin A/B-RxL inhibitor, for the treatment of cancers with RB1 loss or hyperactivated E2F

Abstract Dysregulation of the RB-E2F pathway is a hallmark of many human cancers resulting in uncontrolled transcription of genes required for DNA replication, S-phase progression, and mitotic entry. Genetic alterations that disrupt RB pathway control, such as loss of the tumor s …

15.05.2026

Abstract ND04: EPI-326: A novel mutation-independent and normal tissue-sparing EGFR bispecific antibody that degrades EGFR for the treatment of EGFR-driven solid tumors

Abstract EGFR is an oncogenic driver in lung, head and neck, and colorectal cancers, but clinical success has been limited by EGFR having multiple oncogenic forms, acquired drug resistance, and on-target/off-tumor dose-limiting toxicities such as rash and diarrhea. A therapeutic …

15.05.2026

Abstract ND11: Discovery and Preclinical Characterization of a Novel ENPP3-Targeted ADC, JNJ-89862175 to treat Advanced Solid Tumors

Abstract Antibody Drug Conjugates (ADC) are a clinically validated therapeutic modality for solid tumors relying on an antibody that targets a tumor-specific antigen to internalize and deliver cytotoxic agents directly to the tumor. ENPP3 (ectonucleotide pyrophosphatase/phosphodi …

15.05.2026 · 5 Zitationen

Abstract CT021: Preliminary safety and clinical activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC)

Abstract Background: Patients (pts) with previously treated advanced NSCLC have a high unmet medical need, with a median reported overall survival (OS) of <1 year. KRAS G12D mutations occur in approximately 4% of pts with NSCLC, for which there is currently no approved RAS-target …

15.05.2026

Abstract ND10: Discovery of AMX-883: an orally bioavailable, novel degrader of BRD9 as a karyotype-independent pro-differentiation agent for the potential treatment of AML

Abstract The discovery and characterisation of AMX-883, an orally bioavailable, highly potent and selective degrader of Bromodomain-containing protein 9 (BRD9) will be described. Acute myeloid leukaemia (AML) is commonly characterized by a block in the differentiation of myeloid …

15.05.2026

Abstract CT103: Ciltacabtagene autoleucel in high-risk smoldering myeloma: Results from the CAR-PRISM trial

Abstract Background: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, is approved for patients with relapsed/refractory multiple myeloma after 1 line of therapy. In the CAR-PRISM trial, we hypothesi …

15.05.2026

Abstract ND12: Development of IPN01203, a dual T cell agonist activating Vβ6/Vβ10 TCR-expressing T cells

Abstract Selective activation of T cells expressing specific TCR Vβ components presents a promising clinically validated strategy for the treatment of advanced metastatic cancers. IPN01203 is a bi-specific antibody designed to activate and expand T cells expressing Vβ6/Vβ10 TCRs, …

15.05.2026

Abstract ND08: Discovery and development of a CD30 dual-payload ADC that combines MTI and Top1i to overcome drug resistance

Abstract Since the 1960s combination therapy has been practiced to address drug resistance in cancer patients. Initially utilizing multiple chemotherapeutic agents, approaches have evolved to include chemotherapeutics combined with a biologic or, more recently, multi-biologic reg …

15.05.2026

Abstract ND03: TNG961: A selective oral molecular glue degrader of HBS1L for the treatment of FOCAD-deficient cancers

Abstract Loss of tumor suppressor genes frequently results in co-deletion of neighboring genes, generating tumor-specific collateral vulnerabilities. On chromosome 9p21, deletion of CDKN2A/B commonly extends to loss of the adjacent MTAP gene creating a known dependency on PRMT5. …

15.05.2026

Abstract CT004: Safety of prolonged checkpoint inhibitor exposure in alveolar soft part sarcoma (ASPS) patients

Abstract Immune checkpoint inhibitors (ICIs) are often stopped after 2 years (yrs) because studies have shown no overall survival benefit beyond 2 yrs and prolonged exposure has the potential to produce late-onset adverse events (AEs). However, questions remain about optimal trea …

15.05.2026

Abstract ND07: TRI-611, a potent, selective, CNS-penetrant ALK molecular glue degrader for the treatment of ALK-fusion protein positive non-small cell lung cancer

Abstract While lung cancer remains the leading cause of cancer deaths worldwide, our understanding of genetic drivers of certain lung cancer subtypes has enabled significant progress in precision medicine approaches. Therapeutic inhibition of Anaplastic Lymphoma Kinase (ALK) rece …

15.05.2026

Abstract ND05: A First-in-Class Human Sialidase-Armed Anti-B7-H3 Antibody that Enhances Innate and Adaptive Antitumor Immune Responses

Abstract Tumor hypersialylation, overexpression of sialoglycans on cancer cell surfaces, plays a critical role in cancer progression by suppressing both innate and adaptive anti-tumor immunity. Previously, we demonstrated that an untargeted engineered human sialidase enzyme exhib …

15.05.2026

Abstract ND02: AZD8359: A novel CD8-biased T cell engager designed to deliver a wider therapeutic window in prostate cancer

Abstract Prostate cancer remains a major global burden, ranking second in incidence among men, and outcomes are particularly poor once disease progresses to metastatic castration resistance. Six-transmembrane epithelial antigen of the prostate 2 (STEAP2) is a metalloreductase pre …

15.05.2026 · 1 Zitationen

Abstract CT037: A first-in-human phase 1 trial of a novel claudin 6 (CLDN6)-targeting antibody drug conjugate (ADC) QLS5132 in patients (pts) with platinum-resistant ovarian cancer (PROC)

Abstract Background: QLS5132 is a highly selective ADC composed of a humanized anti-CLDN6 hIgG1 antibody and a novel topoisomerase-1 inhibitor as cytotoxic payload via a hydrophilic cleavable linker LK1b, with a drug-to-antibody ratio of 8. QLS5132 showed an expanded therapeutic …

15.05.2026

Abstract NG02: Residual breast cancer cells co-opt SOX5-driven endochondral ossification to maintain dormancy

Abstract Breast cancer remains the leading cause of cancer-related mortality among women globally. While significant advances in diagnostics and targeted treatment strategies have rendered primary tumors largely curable, approximately 30% of patients develop recurrent disease. Th …

15.05.2026

Abstract NG05: Mechanisms by which mRNA vaccines augment responses to immune checkpoint blockade

Abstract Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but do not produce durable responses in most patients. Personalized cancer vaccines have been proposed as tools to sensitize tumors to ICIs, but are limited by cost and manufacturing time. …

15.05.2026

Abstract CT188: Intralesional PD-1 blockade for oral cancer prevention: First-in-class phase 1 trial

Abstract Oral premalignant lesions affect 5% of the global population with transformation rates of 1-8% in mild-moderate dysplasia and up to 36% in severe dysplasia. Current management via surgical excision yields 30-40% recurrence despite negative margins, with cumulative functi …

15.05.2026 · 2 Zitationen

Abstract CT020: Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in advanced non-small cell lung cancer (NSCLC) previously treated with or without a KRAS G12C inhibitor: Results from a phase 1/2 study

Abstract Background: Elisrasib is a next-generation KRAS-G12C inhibitor (G12Ci) designed to improve target engagement (TE) efficiency and overcome growth factor-induced nucleotide exchange. This unique MoA distinguishes elisrasib from first-generation G12Ci and has led to robust …

15.05.2026

Abstract NG08: Cancer-restricted cryptic antigens: Novel targets for next-generation T cell-based therapies

Abstract Emerging evidence suggests that cancer cells aberrantly translate regions of the genome outside of annotated open reading frames (ORFs), leading to human leukocyte antigen class I (HLA-I) presentation of cryptic peptides. These non-canonical HLA-I bound peptides (ncHLAp) …

15.05.2026

Abstract ND01: Development of NEO-811, a molecular glue degrader of ARNT (HIF-1β) with potent single agent activity in ccRCC

Abstract Inactivation of Von Hippel Lindau (VHL) occurs in up to 90% of patients with clear cell renal cell carcinoma (ccRCC), leading to constitutive activation of hypoxia inducible factors, HIF-1⍺ and HIF-2⍺, and triggering a pro-tumorigenic transcriptional program (e.g., VEGF, …

17.04.2026

Abstract LB039: Orally bioavailable BCL6 degrader HSK47977 featuring a novel CRBN ligand demonstrates potent antitumor activity and synergy with BCL2 inhibition in NHL

Abstract The B-cell lymphoma 6 (BCL6) transcriptional repressor is a proto-oncogene pivotal in diffuse large Bcell lymphoma (DLBCL) and follicular lymphoma (FL). In normal B cells, BCL6 is essential for germinal-center (GC) initiation and maintenance. In DLBCL and FL, BCL6 is one …

17.04.2026

Abstract CT286: Toward personalized atezolizumab dosing by therapeutic drug monitoring

Abstract Background: Currently, intravenous atezolizumab has 3 FDA-approved dosing regimens; 840 mg every 2 weeks or 1,200 mg every 3 weeks or 1,680 mg every 4 weeks which yield steady-state concentrations > 10-fold above the stated minimum effective concentration (MEC) of 6 µg/m …

17.04.2026

Abstract CT217: OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS/BRAF wild-type metastatic colorectal cancer

Abstract Background: Approximately 50% of patients diagnosed with metastatic colorectal cancer (mCRC) are wild-type for KRAS, NRAS, and BRAF (RAS/BRAF WT). Standard initial therapy for left-sided RAS/BRAF WT mCRC is doublet chemotherapy (FOLFOX or FOLFIRI) combined with anti-EGFR …

17.04.2026

Abstract CT140: Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)

Abstract Background: Few effective treatment options for advanced NSCLC are available following frontline immune checkpoint inhibitor (ICI)-based therapy. The randomized, phase II Lung-MAP S1800A study of RP versus SOC for pts with NSCLC previously treated with ICI demonstrated b …

17.04.2026

Abstract LB198: Targeting galectin-1 overcomes paclitaxel resistance in esophageal squamous cell carcinoma

Abstract Resistance to paclitaxel poses a major obstacle in esophageal squamous cell carcinoma (ESCC) treatment. A better understanding of the mechanisms underlying paclitaxel resistance could help identify prognostic biomarkers and improved therapeutic strategies. In this study, …

17.04.2026

Abstract CT124: Interim results of a phase I clinical trial evaluating Fas ligand (FasL) blocking antibody M3T01 in adults with advanced treatment-refractory solid tumors

Abstract Background: FasL expressed on tumor endothelial cells, macrophages, and activated T cells contributes to apoptosis of tumor-specific T cells and impaired tumor infiltration by T cells. In preclinical models, blockade of FasL/Fas signaling results in enhanced T cell infil …

17.04.2026

Abstract CT036: A first-in-human study result of a novel EGFR-targeted antibody drug conjugate (ADC) in patients with advanced nasopharyngeal carcinoma (NPC) (SYS6010-001-NPC)

Abstract Background: SYS6010 is a novel EGFR-targeted ADC, consisting of a humanized anti-EGFR mAb linked to a topoisomerase I inhibitor (JS-1) via a glycine̶̶-glycine-phenylalanine-glycine tetrapeptide linker (DAR = 8). This phase I study (ChiCTR2300072141) evaluated SYS6010 in …

17.04.2026

Abstract LB392: Associations between perceived costs and rewards of sun protection and sun safety practices among high school students

Abstract Objectives: Adolescents frequently engage in behaviors that increase ultraviolet radiation (UVR) exposure, elevating their lifetime risk for skin cancer. This study examined cross-sectional associations between high school students’ perceptions of the costs of UVR protec …

17.04.2026

Abstract LB227: Adipokine adipsin promotes breast cancer progression by inducing adipocyte maturation

Abstract Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related death among women worldwide. Despite advances in diagnosis and treatment, advanced-stage metastatic breast cancer remains difficult to cure. Adipocytes have long been recognized …

17.04.2026

Abstract CT035: CTEP #10355 A phase 1 trial of DS-8201a and olaparib in HER2-expressing malignancies: Results from dose escalation

Abstract Background: DS-8201a is a HER2-targeting antibody drug conjugate with a topoisomerase 1 (topo1) inhibitor payload. Preclinical evidence suggests that inhibiting PARP can potentiate topo1 inhibitor-induced DNA damage and cytotoxicity. However, the clinical activity of com …

17.04.2026

Abstract CT213: A phase I/II study to evaluate EP0031 (lunbotinib), a next-generation selective RET inhibitor, as monotherapy and in combination with chemotherapy, in patients with advanced RET-fusion-positive NSCLC

Abstract Background: EP0031 (lunbotinib, A400), a first-in-class, next-generation selective RET inhibitor (SRI), has broad potency against common RET alterations, including resistance mutations, and has greater potency, antitumor activity, and CNS penetration/activity compared wi …

17.04.2026

Abstract SY20-02: Cancer genes beyond chromosomes

Abstract Cancer patients face an extraordinary challenge when oncogenes unleash themselves from chromosomes. Extrachromosomal DNA (ecDNA) are large, megabase-sized circular episomes containing oncogenes and regulatory DNA elements. EcDNAs have a remarkable transcriptional advanta …

17.04.2026

Abstract LB497: Portraits of clonal landscape and mutational signature in primary tumors and matched lung metastatic model of osteosarcoma

Abstract Objective: The development of lung metastasis following primary tumor diagnosis, resection and chemotherapy remain a significant hurdle in the treatment of osteosarcoma. Research indicates that the metastatic progression of osteosarcoma is driven by clonal evolution wher …

17.04.2026

Abstract CT206: Larotrectinib (L) in patients (pts) with solid tumors with NTRK1/2/3 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Abstract Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohort of pts with solid tumors with NTRK1/2/3 amp treated with L are reporte …

17.04.2026

Abstract LB406: Active RAS inhibition intercepts pancreas cancer in mice

Abstract Cancer interception is a clinical approach to eliminate pre-malignant lesions, distinct from approaches to treat invasive cancer, but effective strategies in pancreatic ductal adenocarcinoma (PDAC) remain to be identified. Conceptually, interception strategies should tar …

17.04.2026

Abstract LB354: Pharmacologic TSC2 inhibition sensitizes acute myeloid leukemia to proteasome inhibition via mTORC1 mediated mitochondrial catastrophe

Abstract Introduction: mTORC1 activity is widely regarded as oncogenic; however, under therapeutic stress, suppression of mTORC1 can promote adaptive survival programs and contribute to drug resistance. Despite extensive efforts to inhibit mTORC1, pharmacologic strategies to tran …

17.04.2026

Abstract CT065: Preliminary safety, pharmacokinetics and pharmacodynamics of SGR-3515, a Wee1/Myt1 dual inhibitor from an ongoing Phase 1 study in participants with advanced solid tumors (SGR-3515-101)

Abstract Introduction: SGR-3515 is an oral, small molecule co-inhibitor targeting Wee1 and Myt1 kinases, which play a crucial role in regulating cell cycle and are synthetic lethal based on preclinical data. SGR-3515 has shown preclinical antitumor activity superior to single tar …

17.04.2026

Abstract LB154: Anti-GARP reverts immune suppression and extends overall survival in a MASH-HCC murine model resistant to anti-PDL1+anti-VEGFA therapy

Abstract Background and Aims: Atezolizumab (anti-PDL1) plus bevacizumab (anti-VEGFA) (atezo+bev) is one first-line standard-of-care (SOC) treatment for advanced hepatocellular carcinoma (aHCC) with objective responses in ∼30% of cases. Clinical benefit is hindered in non-viral HC …

17.04.2026

Abstract LB350: Discovery and characterization of ABK-EGFR-1, a 4th generation EGFR C797S Inhibitor with excellent selectivity and brain penetration

Abstract Introduction: The EGFR C797S mutation is a clinically validated mechanism of resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) and is estimated to occur in approximately 51,000-146,000 cases annually worldwide. Currently, no approved therapies specifi …

17.04.2026

Abstract CT227: Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01

Abstract Background: GP2 is a biologic nine amino acid peptide of the HER2/neu protein delivered in combination with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) that stimulates an immune response targeting HER2/neu expressing cancers, the combination known as GLSI-1 …

17.04.2026

Abstract LB268: Preclinical development of 3H-10000, a novel vedotin antibody-drug conjugate for treatment of FGFR2b-expressing cancers

Abstract FGFR2b overexpression across multiple cancer types promotes dysregulated tyrosine kinase activation and results in tumor progression and unchecked malignance with exciting potential for targeted therapies in solid tumors. 3H-10000 is a novel vedotin antibody-drug conjuga …

17.04.2026

Abstract LB477: Neoadjuvant chemotherapy induces clinically distinct spatial remodeling of the tumor microenvironment in PDAC

Abstract Neoadjuvant chemotherapy (NACT) followed by surgical resection is increasingly becoming the standard treatment paradigm for pancreatic ductal adenocarcinoma (PDAC). However, post-surgical therapeutic strategies remain largely unguided by tumor. To address this critical g …

17.04.2026

Abstract CT092: A Phase 1a/1b, first-in-human study of an ADC targeting ADAM9 (DB-1317) in participants with selected advanced or metastatic solid tumors

Abstract Background: A disintegrin and a metalloprotease 9 (ADAM9) is highly expressed in several cancer types and its expression level correlates with a suppressive tumor microenvironment, metastasis, and poor prognosis, making it a promising therapeutic target. DB-1317 is an an …

17.04.2026

Abstract CT051: From preclinical models to first-in-human evaluation of STC-1010 immunotherapy in unresectable advanced colorectal cancer

Abstract Background: Colorectal cancer (CRC) is the third most common cancer worldwide and the second leading cause of cancer death. It comprises two biological subtypes: microsatellite-stable (MSS, 85-95%) and microsatellite-instable (MSI-H) tumors. While MSI-H tumors respond to …

17.04.2026

Abstract CT143: Resolved hematological toxicities associated with anti-CD47 agents using a bispecific design involving an optimized anti-CD47 arm: A clinical proof of concept study

Abstract Anti-CD47 agents, including anti-CD47 antibodies and signal regulatory protein alpha (SIRPα)/Fc fusion proteins, have been seen to be associated with hematological toxicities/adverse events (AEs) in multiple clinic trials. These AEs are believed to be driven by the expre …

17.04.2026

Abstract LB490: Preclinical evaluation of the nectin-4 antibody-drug conjugate MK-3120 (SKB410) in a panel of solid-tumor patient-derived xenograft models

Abstract Despite clinical success of some antibody-drug conjugates (ADCs), much remains unknown about what ultimately drives tumor response. Therefore, identification and preclinical testing of selection biomarkers to enrich for responders is critical. MK-3120 (SKB410) is a necti …

17.04.2026 · 1 Zitationen

Abstract CT028: Results of first-in-human, Phase 1 study of KSQ-001EX, an autologous tumor infiltrating lymphocyte therapy engineered to inactivate the SOCS1 gene, in patients with select advanced solid tumors

Abstract KSQ-001EX is an engineered TIL (eTIL) therapy with CRISPR/Cas9-mediated inactivation of SOCS1, a negative regulator of cytokine signaling and T cell function. SOCS1 was identified in a series of genome-wide in vivo screens where inactivation of SOCS1 strongly enhanced th …

17.04.2026 · 1 Zitationen

Abstract CT222: Obrixtamig (BI 764532) in patients with relapsed/refractory delta-like ligand 3 (DLL3) high-expressing extrapulmonary neuroendocrine carcinoma (epNEC): trial in progress of the dose expansion part of the Phase II DAREON-5 trial

Abstract Background: Patients with relapsed/refractory extrapulmonary neuroendocrine carcinoma (epNEC) have poor outcomes with currently available therapies. Delta-like ligand 3 (DLL3) is expressed on the surface of many epNEC cells, offering a promising therapeutic target. Obrix …

17.04.2026

Abstract LB057: Repurposing statins for locally advanced esophageal adenocarcinoma: Integrating scRNAseq, organoid based high throughput drug screening, and patient level clinical data

Abstract Introduction: Overcoming chemoresistance remains a significant challenge in esophageal adenocarcinoma (EAC). Drug repurposing has gained interest for its potential to identify new uses for approved drugs, with advantages including lower costs, established safety, and acc …

17.04.2026

Abstract LB258: Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T cell exhaustion and reinvigorates antitumor immunity

Abstract LAG3 is a critical inhibitory receptor that is highly enriched on exhausted T cells within the tumor microenvironment (TME), where it functions as a key driver of T cell exhaustion—an archetypal barrier to robust antitumor immunity. In a colon cancer model, we identified …

17.04.2026

Abstract LB187: KRAS-MAPK signaling adaptation underlies acquired resistance to wild-type IDH1 inhibition in pancreatic ductal adenocarcinoma

Abstract Background: Wild-type isocitrate dehydrogenase 1 (IDH1), a cytosolic NADP+-dependent enzyme is upregulated in pancreatic ductal adenocarcinoma (PDAC), where it supports redox balance and metabolic homeostasis. Pharmacologic inhibition of IDH1 induces metabolic stress, su …

17.04.2026

Abstract LB440: Quantitative Systems Pharmacology (QSP) enables research and translation of AMP01, a novel next generation anti PD1 bispecific that amplifies and redirects endogenous IL15 to PD1 high expressing T Cells, maximizing efficacy and therapeutic index

Abstract Background: Safe and efficacious dosing of clinically validated cytokines is exciting but remains elusive. The primary challenge has been therapeutic index (TI), i.e. providing sufficient cytokine tumor exposure while minimizing exposure elsewhere to avoid systemic immun …

17.04.2026

Abstract LB329: Overcoming the blood-brain barrier to potentiate GD2-CAR T therapy using P-selectin-targeted nanomedicine

Abstract Pediatric brain tumors are the leading cause of cancer-related death in children, and high-grade malignancies such as diffuse intrinsic pontine glioma (DIPG) and medulloblastoma (MB) remain intractable. DIPG is inoperable due to its brainstem location and diffuse infiltr …

17.04.2026

Abstract LB101: Whole-genome sequencing reveals distinct mutational mechanisms across endometrial cancer subtypes

Abstract Uterine corpus endometrial carcinoma (UCEC) is among the most prevalent gynecologic malignancies worldwide and represents a growing public health burden, particularly in high-income countries. Despite advances in clinical management, UCEC mortality continues to rise, wit …

17.04.2026

Abstract CT007: A phase 2 study of tislelizumab (TIS) + investigational agents as first-line (1L) treatment in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Abstract Background: Despite the use of anti-programmed cell death protein-1 (PD-1)/programmed cell death protein ligand-1 (PD-L1) monotherapy in HNSCC, not all patients (pts) experience a durable response or prolonged survival; thus, there is an unmet need for novel treatment co …

17.04.2026

Abstract CT223: AACR Adaptive Biomarker-Driven Organ Preservation Trial in GE Adenocarcinomas (AACR-ADOPT-GEA)

Abstract Background: Localized gastroesophageal adenocarcinomas (GEA) are molecularly heterogeneous and often exhibit limited sensitivity to current systemic therapies. The 5-year survival rate with standard perioperative chemotherapy is ∼40%, and only ∼15% of patients achieve a …

17.04.2026

Abstract LB131: The communal process through which prostate cancer survivors and their partners affect each other's diets: A qualitative descriptive study

Abstract Introduction: This qualitative descriptive study explored the communal processes (i.e., dyadic communication and collaborative action) through which prostate cancer (PCa) survivors and their partners shaped each other’s diets. Methods: Dyads of PCa survivors and their pa …

17.04.2026

Abstract LB281: Loss of ERK pulsatility drives transformation of colonic organoids through collapse of Akt-mediated signaling insulation

Abstract Colonic stem cells (CSCs) reside within spatially organized niches exposed to a gradient of growth factor signals, including EGF secreted by stromal cells at the crypt base. Despite this gradient, CSCs exhibit paradoxical signaling patterns that deviate from canonical li …

17.04.2026

Abstract LB199: High-plex spatial transcriptomics reveals triplatin-induced DNA damage signaling and tumor-fibroblast niche reprogramming in pancreatic cancer PDX models

Abstract Background: With an estimated 67,440 cases anticipated in 2025, the fight against Pancreatic ductal adenocarcinoma (PDAC) is still challenging. PDAC is characterized by an extensive desmoplastic stroma rich in glycosaminoglycans (GAGs) that hinders chemotherapy and promo …

17.04.2026

Abstract CT268: Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL)

Abstract Background: Despite recent advancements in NHL therapies, many patients experience disease progression or relapse. Agents with novel mechanisms of action and combination strategies are needed to improve clinical outcomes. B-cell lymphoma 6 (BCL6) is a master transcriptio …

17.04.2026

Abstract LB333: Synergistic antitumor efficacy and clinical translation of a novel dual-payload TROP2 ADC KH815 in combination with a PD-L1/VEGF bispecific antibody

Abstract Background: Although Anti PD-(L)1-VEGF have shown substantial progress in cancer treatment, many patients still do not benefit from immune checkpoint inhibitor (ICI) monotherapy. To overcome resistance and enhance clinical efficacy, combination strategies with antibody-d …

17.04.2026

Abstract LB390: Genetic risk of prostate cancer: Insights from the Prostate Cancer Sequencing Consortium

Abstract Inherited susceptibility plays a critical role in prostate cancer (PCa) risk. Using large biobank and case-control datasets, we evaluated the contribution of both common variants and rare germline pathogenic variants (PVs) to overall PCa risk. The Prostate Cancer Exome S …

17.04.2026

Abstract LB049: DAC-002, a novel IKZF1/3 MGD-CD38 degrader-antibody conjugate for MM treatment

Abstract Introduction: Immunomodulatory drugs (IMiDs), which degrade Ikaros family zinc finger proteins 1 and 3 (IKZF1/3), have shown promising efficacy in the treatment of multiple myeloma (MM). Notably, since IKZF1/3 are essential transcription factors (TFs) for the differentia …

17.04.2026

Abstract CT032: ABO2203, a messenger RNA encoding a CD3×CD19 T cell engager, for relapsed/refractory B cell non-Hodgkin lymphoma: Preliminary results from first-in-human study

Abstract Background: While protein-based T cell engagers (TCEs) show promise for hematologic malignancies, challenges remain in safety, efficacy, and durability. ABO2203 provides a novel strategy as a first-in-class, lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA) enco …

17.04.2026

Abstract LB222: MRD Express: Rapid, scalable, and high-performance custom target enrichment for minimal residual disease monitoring

Abstract Detection of minimal residual disease (MRD) via liquid biopsy offers a high-sensitivity alternative to conventional radiographic imaging, enabling early detection of molecular relapse within clinically actionable decision windows. To achieve the necessary analytical sens …

17.04.2026

Abstract CT290: NTS071-101: A phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of NTS071 in patients with advanced solid tumors harboring a TP53 Y220C mutation

Abstract Background: The TP53 gene encodes a tumor suppressor that binds to DNA and transcriptionally activates a network of target genes responsible for cell-cycle checkpoint, apoptosis, DNA repair, and other cellular processes. The normal function of p53 protein is inactivated …

17.04.2026 · 1 Zitationen

Abstract CT063: An EphA2-targeting Bicycle Drug Conjugate (BDC), BT5528, in combination with nivolumab in patients (pts) with advanced solid tumors: Results from a Phase 1/2 study

Abstract Background: BT5528 is a BDC® comprising a bicyclic peptide targeting EphA2 linked to MMAE via a cleavable linker. EphA2 is overexpressed in various solid tumors and is correlated with poor clinical outcomes. Earlier EphA2-targeted therapies were associated with significa …

17.04.2026 · 1 Zitationen

Abstract CT230: STRIDE regimen of tremelimumab and durvalumab as non-operative management strategy of microsatellite instability-high (MSI-H) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): Final results of the cohort 2 of INFINITY study by GONO GI

Abstract Background: In resectable GAC/GEJAC, MSI-H is associated with improved survival and potential lack of benefit from chemotherapy. Pre-operative immune-checkpoint inhibitors (ICIs) achieve high rates of pathological response and promising disease-free and overall survival …

17.04.2026 · 1 Zitationen

Abstract CT302: The safety, tolerability, and efficacy of HS-10504 in patients with EGFR mutation-positive locally advanced or metastatic NSCLC: Initial results from a first-in-human phase 1 study

Abstract Background: The EGFR C797S mutation is a major resistance mechanism following third-generation EGFR tyrosine kinase inhibitors (TKIs) treatment in EGFR-mutant NSCLC, with no clinically validated and accessible target therapies. HS-10504 is a novel, potent, and highly sel …

17.04.2026

Abstract LB070: Discovery of Helicon peptides that selectively degrade the agonist-bound androgen receptor (ARON) in prostate cancer

Abstract Prostate cancer (PCa) remains largely driven by the androgen receptor (AR) even in castration-resistant settings where AR signaling is maintained through various genetic mechanisms including mutations in the androgen binding pocket and amplifications in the AR locus lead …

17.04.2026

Abstract LB010: First-line (1L) trastuzumab deruxtecan (T-DXd) regimens in advanced HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Exploratory analysis of baseline HER2-related biomarkers in DESTINY-Gastric03 (DG-03) Part 2

Abstract Background: DG-03 Part 2 showed promising antitumor activity for 1L T-DXd regimens in advanced HER2+ GCs. We report concordance rates between local and central HER2 IHC results, and ORRs according to baseline HER2-related biomarkers, in DG-03 Part 2. Methods: DG-03 (NCT0 …

17.04.2026

Abstract NG09: Overcoming aging-driven barriers to effective immunotherapy in pancreatic cancer

Abstract Background: Immunotherapies such as immune checkpoint inhibitors (ICIs) and cancer vaccines have transformed the treatment of several cancers, yet pancreatic ductal adenocarcinoma (PDAC) remains largely refractory. PDAC has a dismal 5-year survival rate of ∼13%, and ther …

17.04.2026

Abstract LB006: Prostate cancer phenotypes determined from circulating tumor DNA associate with outcomes to 177Lu-PSMA-617 therapy

Abstract Background: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease with a major unmet clinical need to identify therapeutics that extend survival and biomarkers that predict treatment responses. The prostate-specific membrane antigen (PSMA) radioliga …

17.04.2026

Abstract LB062: DEM301, a novel bifunctional ADC with potent immunomodulatory activity for potential use in difficult to treat colorectal malignancies

Abstract Background: DEM301 is a first-in-class antibody-drug conjugate (ADC) targeting DEM-TXX, a novel target expressed in gastrointestinal (GI) malignancies. DEM301 consists of an afucosylated humanized monoclonal antibody conjugated to a topoisomerase I (TOP-1) inhibitor. We …

17.04.2026

Abstract CT271: Clinical trial in progress: BCC021 Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors

Abstract Background: Pediatric patients with recurrent neuroblastoma (NB), Ewing sarcoma (ES), and other rare sarcomas have a poor prognosis with a clear need for more effective therapies. These cancers exhibit high CSNK2A1 expression and Casein Kinase 2 (CK2) activity, which pro …

17.04.2026

Abstract LB463: Exploring the molecular landscape of ovarian cancer through immunohistochemistry multi-marker prevalence screening

Abstract Ovarian cancer (OVCA), and particularly its most aggressive form, highgrade serous ovarian cancer (HGSOC), presents a major challenge to women's health worldwide. Standard treatments include cytoreductive surgery and platinumbased chemotherapy, which can achieve initial …

17.04.2026

Abstract LB438: Decoding therapy-induced rewiring of the tumor microenvironment networks to overcome drug resistance through multiscale mechanistic pathway crosstalk analysis

Abstract Therapy resistance in pancreatic cancer is driven by multicellular pathway crosstalks within the tumor microenvironment (TME) that amplify desmoplasia and immune dysfunction. The TME networks that mediate these crosstalks are rewired under therapeutic pressure, but how t …

17.04.2026

Abstract LB071: Combination of isorhapontigenin and FSP1 inhibitor suppresses triple negative breast cancer cell progression

Abstract Breast cancer is the most frequently diagnosed cancer in women with an estimated 316,950 new cases and 42,170 deaths in the United States in 2025. Approximately 15% of all breast cancers are diagnosed as a malignant subtype known as triple negative breast cancer (TNBC; E …

17.04.2026

Abstract LB367: Novel non saccharide glycosaminoglycan mimetic inhibit colorectal cancer stem cells by selectively targeting key tyrosine kinase receptors

Abstract Introduction: Unique sulfated non-saccharide glycosaminoglycan mimetic (NSGM) of heparin hexasaccharide (HS06), G2.2, selectively inhibited CSCs via inhibition of specific tyrosine kinase receptors, resulting in selective activation of p38 mitogen-activated protein kinas …

17.04.2026

Abstract LB095: Chromosomal weak links in cancer: A/B compartment rewiring coupled to global DNA methylation alterations in gastric tumorigenesis

Abstract Three-dimensional genome organization into A/B compartments constrains gene regulation, mutation rate, and epigenetic stability. However, how cancer-associated global DNA methylation alterations intersect with higher-order chromatin architecture to generate chromosomal v …

17.04.2026

Abstract LB334: Patient-derived 3D tumor models integrated with AI-driven treatment matching for target discovery and personalized therapy

Abstract Many cancer therapies show strong preclinical activity yet fail clinically due to inadequate experimental models. Conventional 2D cultures lack physiological relevance because they cannot reproduce the complex tumor-stromal-immune interactions or the biomechanical cues t …

17.04.2026

Abstract LB181: Quantitative deep mutational scanning (qDMS) enables accurate predictions of clinical drug resistance in CML

Abstract Targeted BCR-ABL inhibitors have turned chronic myeloid leukemia (CML) from a debilitating disease into a manageable condition, yet patients continue to acquire mutations within the ABL1 gene that confer drug resistance and drive treatment failure. While existing clinica …

17.04.2026

Abstract CT087: Phase I/II FIH study of IPN60300, a first-in-class ADC targeting ITGA2, to assess the safety, tolerability, PK, biomarkers, immunogenicity and antitumor activity in adults with locally advanced solid tumors

Abstract Background: Integrin alpha-2 (ITGA2), a component of the heterodimeric transmembrane receptor integrin α2/β1, plays a key role in cell adhesion and transduction. Although ITGA2 is expressed at low levels across normal tissues, it is notably overexpressed in various solid …

17.04.2026

Abstract LB210: Obesity with and without cardiometabolic risk factors, biomarkers, and incident obesity-related cancer: The Women’s Health Study

Abstract Obesity is an established risk factor for at least 13 types of cancers, yet the role of obesity-related cardiometabolic risk factors and biomarkers in mediating this relationship remains unclear. We classified 37,540 Women’s Health Study participants as obese (body mass …

17.04.2026 · 2 Zitationen

Abstract CT215: RASolve 301: A Phase 3 study of daraxonrasib (RMC-6236) vs. docetaxel in patients with previously treated RAS-mutant NSCLC

Abstract Background: Previously treated non-small cell lung cancer (NSCLC) patients represent a significant unmet medical need. After patients have received platinum-based chemotherapy and/or immune checkpoint inhibitors, docetaxel monotherapy is often the mainstay of treatment, …

17.04.2026 · 2 Zitationen

Abstract CT015: Clinical outcomes by genomic markers and ctDNA dynamics with perioperative nivolumab (NIVO) for resectable NSCLC from CheckMate 77T

Abstract Background: In the phase 3 CheckMate 77T study, perioperative NIVO demonstrated statistically significant and clinically meaningful EFS benefit vs placebo (PBO) in patients (pts) with resectable NSCLC. Here, we report comprehensive analyses of EFS by tumor genomic altera …

17.04.2026

Abstract SY29-01: Tracing the eco-evolutionary path of tumors to understand cancer

Abstract Tracing the eco-evolutionary path of tumors to understand cancer “Cancer is no more a disease of cells than a traffic jam is a disease of cars. A lifetime of study of the internal-combustion engine would not help anyone understand our traffic problems.”David W. Smithers, …

17.04.2026

Abstract LB155: Durable anti-tumor immunity through in vivo CAR T cell engineering using the RetroT all-RNA genome integration platform

Abstract Adoptive T cell therapies have transformed the treatment of hematologic malignancies, yet broader application remains constrained by ex vivo manufacturing, viral gene delivery, and genome-editing approaches that introduce double-strand breaks (DSBs) and associated genoto …

17.04.2026

Abstract LB412: Reprogramming immunity: Personalized T cell approaches in gastric cancer

Abstract Gastric cancer (GC) is the fourth most common malignancy and a leading cause of cancer-related deaths worldwide. While PD-1/PD-L immunotherapy has become part of the standard of care, only a fraction of patients responds. Therefore, there is a strong rationale to explore …

17.04.2026

Abstract LB435: Large-scale foundation model-based PDX model selection and cancer subtype assignment

Abstract Introduction. Patient-derived xenograft (PDX) models preserve patient-specific tumor biology and clinical heterogeneity; however, selecting PDX models in the context of clinical and preclinical datasets is challenging due to varied criteria and characteristic differences …

17.04.2026

Abstract LB489: A comparative analysis of paired normal, primary, and metastatic breast cancer organoids derived from core-needle biopsies

Abstract Background: Patient-derived organoids (PDOs) are emerging as clinically relevant ex vivo models that preserve the histology, immunophenotype, and genomic landscape of source tissues. However, generating PDOs from low-abundance core-needle biopsy (CNB) samples, especially …

17.04.2026 · 1 Zitationen

Abstract SY30-03: Reversing brain tumor immunotolerance: A new therapeutic approach for childhood brain tumors

Abstract Brain tumours kill more children than any other cancer. Although immunotherapies have proved effective against treatment-resistant adult cancers and some leukamias, they have proved less effective against brain tumours. This is due in part to a poor understanding of how …

17.04.2026

Abstract CT244: Taletrectinib in tyrosine kinase inhibitor (TKI)-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC): Updated data from TRUST-I and TRUST-II

Abstract Background: Taletrectinib is a next-generation, CNS-active, selective ROS1 TKI approved by the US FDA for the treatment of patients (pts) with locally advanced/metastatic ROS1+ NSCLC. In two Phase 2 studies, TRUST-I (NCT04395677) and TRUST-II (NCT04919811), taletrectinib …

17.04.2026

Abstract CT285: Design and rationale of DOMISOL, a first-in-human Phase I/II study of DT-7012 (NCT06819735) in advanced solid tumors

Abstract Background: CCR8 has recently emerged as a promising target in the treatment of solid tumors. DT-7012, a novel anti-CCR8 monoclonal antibody, distinguishes itself from competitors through its binding properties and optimized effector functions. These characteristics sugg …

17.04.2026

Abstract LB312: SOX2-driven stemness as a key determinant for long-term maintenance of pre-treatment patient-derived organoids in esophageal squamous cell carcinoma

Abstract Background: Patient-derived organoids (PDOs) provide an advanced in vitro model that faithfully recapitulates tumor heterogeneity than conventional two-dimensional cultures. A major advantage of PDOs is their ability to directly link experimental findings with clinical t …

17.04.2026

Abstract CT210: Occupational cancer screening in firefighters: A pilot randomized study of whole-body screening modalities

Abstract Background: The International Agency for Research on Cancer has concluded that occupational work as a firefighter is carcinogenic. Given the higher risk of multiple cancer types in firefighters, providing evidence-based preventive health services including recommendation …

17.04.2026

Abstract LB230: A prospective immunological analysis of head and neck squamous cell carcinoma in humans

Abstract Head and neck squamous cell carcinoma (HNSCC) is characterized by poor prognosis, with the 5-year survival rate being less than 50% for advanced HNSCC. Despite improvements in treatments, approximately half of HNSCC patients will recur. Clinical evidence suggests that pa …

17.04.2026

Abstract LB277: The p53-Reprimo-Hippo-YAP-p73 pathway: An extrinsic apoptosis mechanism for tumor suppression

Abstract The p53 tumor suppressor gene is the most commonly mutated gene in human cancer and plays a central role in tumor suppression. We have identified and characterized the molecular function of several novel p53 target genes, including Noxa, AEN, FUCA1, IER5, and PHLDA3 (Sci …

17.04.2026

Abstract CT256: A Phase II chemo/immunotherapy study using metronomic gemcitabine, doxorubicin, docetaxel and nivolumab for advanced angiosarcoma (NCT04535713): An interim analysis

Abstract Background: Advanced angiosarcoma is a rare and aggressive sarcoma which is most often fatal, with a median progression free survival of 4-6 months on standard therapy. Therefore, innovative treatment regimens are urgently needed. Methods: Endpoints: Primary: Progression …

17.04.2026

Abstract LB014: HSPBP1 9 bp insertion mutation concurrent with pro-apoptosis and NF-κB genomic integrity predicts response to bortezomib-mediated proteasome inhibition in recurrent glioblastoma treated in NCT03643549 trial

Abstract Resistance to cytotoxic therapy in glioblastoma (GBM) is largely driven by DNA repair mechanisms. Proteasome inhibition may sensitize tumors through suppression of NF-κB survival signaling and MGMT transcription. However, biological mechanisms that modulate tumor-intrins …

17.04.2026

Abstract LB085: Claudin-1 modulates the melanoma immune microenvironment to promote tumor growth and is a candidate therapeutic target for advanced melanoma

Abstract Malignant cutaneous melanoma is a highly aggressive cancer responsible for the majority of skin cancer-related deaths with increasing prevalence world-wide. While early-stage melanoma can be efficiently treated by surgery, the treatment of advanced melanoma with immune c …

17.04.2026

Abstract LB331: First-line (1L) trastuzumab deruxtecan (T-DXd) + rilvegostomig (rilve) + fluoropyrimidine (FP) in HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) Part 4 arm A results

Abstract Background: T-DXd monotherapy is approved in several countries for advanced HER2+ GC/GEJA after an indicated HER2-directed regimen. 1L rilve (a monovalent, Fc-reduced, bispecific IgG1 antibody against PD-1 and TIGIT receptors) + chemotherapy showed encouraging efficacy a …

17.04.2026

Abstract LB068: Oral fulvestrant nanoparticles deliver high, sustained exposure: An alternative to IM injection

Abstract Background: Fulvestrant, a selective estrogen receptor degrader (SERD) for ER⁺ breast cancer, is available only as a monthly intramuscular (IM) injection in a viscous formulation that can be painful, and no oral product is available. Oral fulvestrant could improve conven …

17.04.2026

Abstract LB208: The role of pks-positive bacteria in colorectal cancer

Abstract The gut epithelium is a dynamic environment engaged in constant crosstalk with trillions of microbes, including bacteria, viruses, fungi, and archaea, that collectively shape host health and disease. Among these are Enterobacteriaceae that carry the polyketide synthase ( …

17.04.2026

Abstract SY23-01: Lineage tracing of the intercellular transfer of mitochondria during cancer progression

Abstract The nervous system plays a pivotal role in cancer biology, and pathological investigations have consistently linked intratumoral nerve density to cancer aggressiveness and metastasis. However, the precise impact of cancer-associated neurons on cancer cell biology and the …

17.04.2026

Abstract LB182: CTC/cfDNA biomarker-guided precision medicine to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma

Abstract Background/Aim: Immune checkpoint inhibitors (ICs) have improved survival outcomes in advanced hepatocellular carcinoma (HCC), but most HCC patients experience treatment resistance. Thus, we aimed to stratify HCC patients to target therapy-resistant TICs and identify res …

17.04.2026

Abstract LB405: Novel brain-penetrant BRAF paradox breaker HSK42360 demonstrates promising antitumor activity in patients with BRAF-mutant glioma

Abstract Background: BRAF V600E is one of the most frequent BRAF mutations across human cancers. It is present in various gliomas, including pediatric low-grade gliomas (LGG, ∼20%), pediatric high-grade gliomas (HGG, ∼5-15%), and adult glioblastomas (∼5%). Although BRAF inhibitor …

17.04.2026

Abstract CT117: Phase 1 study of HRS-6209, a highly selective CDK4 inhibitor, in patients with advanced solid tumors

Abstract Background: This first-in-human, open-label, multicenter, dose-escalation and dose-expansion phase 1 study evaluated the safety, pharmacokinetics (PK), and preliminary efficacy of HRS-6209, a highly selective CDK4 inhibitor, in patients (pts) with advanced solid tumors. …

17.04.2026

Abstract CT246: An ensemble multi-omics framework for chemo de-escaltion NSCLC patients with PD-L1-low/negative disease in the PEOPLE phase II trial (NCT03447678)

Abstract Advanced non-small cell lung cancer (NSCLC) patients with PD-L1-low/negative expression face uncertainty regarding optimal treatment selection, as some derive meaningful benefit from pembrolizumab monotherapy while others require chemotherapy escalation. This study lever …

17.04.2026

Abstract LB163: Spatial analysis of head and neck cancer reveals two ecosystems with distinct modes of epithelial-to-mesenchymal transition

Abstract Background: Single-cell RNA sequencing has revealed diverse malignant programs in head and neck squamous cell carcinoma (HNSCC), including partial epithelial-to-mesenchymal transition (p-EMT), a state linked to invasion and poor outcome. However, how p-EMT is spatially o …

17.04.2026

Abstract LB103: Whole-genome sequencing of driver-negative renal cell carcinoma with African ancestry identifies MET structural variations missed by targeted panel sequencing

Abstract Clear cell renal cell carcinoma (ccRCC) is more prevalent in patients with European (EUR) ancestry, whereas non-clear cell subtypes, such as papillary renal cell carcinoma (pRCC), are more common in patients with African (AFR) ancestry. ccRCC is primarily driven by biall …

17.04.2026

Abstract LB415: Nanobody:STING agonists reprogram the tumor microenvironment and improve adoptive cell therapy for solid tumors

Abstract Adoptive cell therapy (ACT) has shown curative potential in hematologic malignancies but remains largely ineffective in solid tumors due to an immunosuppressive tumor microenvironment (TME) that limits T cell infiltration, activation, and persistence. Pharmacologic activ …

17.04.2026 · 1 Zitationen

Abstract CT195: Fast-manufactured, low IL-2-dependent FAST-TIL for the treatment of advanced melanoma in asian patients: Median 6-month follow-up data from a phase I clinical trial

Abstract Background: FAST-TIL (HS-IT101) is an innovative autologous tumor-infiltrating lymphocyte (TIL) therapy product developed using a fully enclosed, automated platform. It features minimal dependence on IL-2, requires very small amounts of starting tumor tissue (<0.05 g), a …

17.04.2026

Abstract CT138: Preliminary delayed-type-hypersensitivity immune response results from open-label arm of on-going Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01

Abstract Background: This Phase III trial is a prospective, randomized, double-blinded, multi-center study (NCT05232916) in HLA-A*02 patients at approximately 140 sites in the US and Europe. A third non-randomized arm of approximately 250 non-HLA-A*02 patients is now fully enroll …

17.04.2026

Abstract CT111: Phase 0 intratumoral microdevice study of FX-909 in bladder cancer demonstrates on-target anti-tumor activity and immune modulation, enhanced in combination with anti-PD-1

Abstract INTRODUCTION: Luminal advanced urothelial carcinoma (UC), defined by high PPARG expression, represents ∼65% of UC cases and is associated with poor clinical outcomes1,2. FX-909, a first-in-class oral PPARG inhibitor, demonstrated early clinical activity and acceptable sa …

17.04.2026

Abstract LB355: ICP-B794, a B7H3-targeting ADC with a novel linker-payload, demonstrated superior anti-tumor activity and large therapeutic window in preclinical studies

Abstract The B7H3-targeted antibody-drug conjugates (ADCs) have shown encouraging clinical efficacy in the treatment of multiple solid tumors. Here, we present a new B7H3-ADC, ICP-B794 created based on a novel linker-payload platform, which was able to overcome the resistant of c …

17.04.2026

Abstract LB261: ProTCE-PSMA, a novel therapeutic PSMA/CD3 prodrug for prostate cancer

Abstract Over the past decade, T-cell engagers (TCEs) have demonstrated impressive efficacies and reshaped the therapeutic landscape for blood cancers. However, the application of TCEs in solid tumors is still facing hurdles, such as CRS, on-target off-tumor toxicity and immunoge …

17.04.2026

Abstract LB170: scVarID: Linking somatic variants to single-cell transcriptomes to reveal early cancer-associated cell states

Abstract Identifying how somatic variants reshape gene expression at single-cell resolution is essential for understanding cancer initiation and evolution, yet joint measurement of DNA and RNA in the same cell remains technically demanding. Single-cell RNA sequencing (scRNA-seq) …

17.04.2026

Abstract LB476: Combined inhibition of transcription initiation and histone deacetylation triggers blood cancer cell death

Abstract Introduction: Blood cancer cells, including acute-myeloid-leukaemia (AML), exhibit exquisite dependency on the transcriptional and epigenetic networks that sustain oncogenic-transcriptomes, and are acutely sensitive to drugs targeting transcriptional and epigenetic regul …

17.04.2026

Abstract CT061: A phase I study of the type II ROS1 TRK inhibitor ANS03 in ROS1 fusion-positive lung cancers

Abstract Background: ROS1 tyrosine kinase inhibitors (TKIs) are highly effective in ROS1-positive non-small cell lung cancer (NSCLC), but acquired resistance remains a challenge, particularly solvent front (SF) mutations like G2032R and D2033N, and the central beta sheet (Cβ6) mu …

17.04.2026

Abstract LB077: Natural killer (NK) cell therapies for breast cancer brain metastasis

Abstract Breast cancer brain metastasis (BCBM) is a devastating stage of breast cancer with no effective treatment options. There is a growing interest in immunotherapies to treat brain metastasis, given that immune cells can enter the brain while many conventional therapies are …

17.04.2026

Abstract CT082: A phase 1b/2 study of toripalimab and nadunolimab for the treatment of chemotherapy-refractory metastatic microsatellite stable (MSS) colorectal cancer (CRC)

Abstract Background: MSS CRC accounts for more than 90% of all metastatic CRC cases. For these patients, there are few systemic therapeutic options beyond chemotherapy, most of which have response rates under 10% despite significant toxicities. Conventional immunotherapy with PD- …

17.04.2026

Abstract CT283: Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in patients with peritoneal-only metastasis from pancreatic ductal adenocarcinoma

Abstract Background: Patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) and peritoneal metastasis are currently treated with standard systemic therapy. However, peritoneal-only metastasis represents a “regional” subtype of stage IV PDAC, and in select patients there …

17.04.2026

Abstract LB269: Mechanistic insights into the pharmacology of CDR609 support high potential as a targeted immunotherapy

Abstract Colorectal cancer (CRC) remains a leading cause of mortality, and patients with metastatic or chemoresistant disease still lack effective long-term treatment options. The majority of CRC tumors are microsatellite-stable (MSS), immunologically “cold” and respond poorly to …

17.04.2026

Abstract CT052: Proof of mechanism from a phase 1, single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LRK-4189 in healthy subjects

Abstract Background: Cancer cells maintain fitness by developing survival adaptations that foster escape from intrinsic and extrinsic cell death under stress. Phosphatidylinositol 5-phosphate 4-kinase, type II, gamma (PIP4K2C) is a lipid kinase associated with poor outcomes in se …

17.04.2026

Abstract LB119: An integrated DNA methylation-based and multidimensional risk factor model for predicting breast cancer progression

Abstract Background: Breast cancer remains a leading cause of cancer-related mortality, with approximately 20-30% of patients with early-stage disease developing metastatic recurrence. Conventional serum tumor markers, such as CA15-3 and CEA, have limited sensitivity for monitori …

17.04.2026

Abstract CT209: DiscovHER PAN-206: Phase 2 tumor-agnostic study of zanidatamab in patients with previously treated human epidermal growth factor receptor 2-overexpressing solid tumors

Abstract Background: Tissue-agnostic HER2 targeting is a rational, precision-oncology approach for treating HER2-expressing tumors due to the protein’s expression across multiple tumor types and potential oncogenic role. Zanidatamab, a dual HER2-targeted bispecific antibody, is a …

17.04.2026

Abstract LB441: Towards a platform PBPK-QSP model for first-in-human dose selection of GenSci139, a potential best-in-class EGFR×HER2 bispecific ADC, in patients with cancer

Abstract Background: GenSci139 is a novel bispecific ADC (BsADC) targeting both EGFR and HER2 by carrying a cleavable linker conjugated to a topoisomerase I inhibitor as payload. Preclinical studies have showed broad-spectrum efficacy in different tumors models. To support first- …

17.04.2026

Abstract CT126: Results of phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors

Abstract Introduction: V-domain Ig Suppressor of T-cell Activation (VISTA) is an immune checkpoint regulator found on tumor, myeloid, and other immune cells. Its presence has been shown to enhance tumor growth, create an immunosuppressive microenvironment and may potentially cont …

17.04.2026

Abstract CT130: Initial results from a phase 1 study of PHST001, a macrophage activating anti-CD24 antibody, in patients with advanced/metastatic solid tumors

Abstract Background: Macrophages are the most abundant immune cell in tumors and can phagocytose tumor cells and promote broad anti-tumor immunity. However, phagocytosis can be blocked by macrophage checkpoints, also known as ‘don’t eat me’ signals. One such signal is CD24 which …

17.04.2026

Abstract CT084: A Phase 1b/2a study to evaluate the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma patients (mCRC): Evidence of lower incidence and severity of CIPN events

Abstract Background: Dysregulated sphingolipid metabolism is common to many cancer types, including mCRC, and leads to elevated concentrations of gangliosides (GM3), lactosylceramides (LacCer), glucosylceramides (GluCer) and sphingosine-1-phosphate (S1P) and lower concentration o …

17.04.2026

Abstract LB220: Can dietary calcium prevent myeloma onset

Abstract Multiple myeloma (MM) is the second most common blood cancer. It remains an incurable disease due to relapsing and developing treatment resistance. Treatment resistance and disease progression are not solely due to intrinsic MM characteristics but are also fostered by al …

17.04.2026

Abstract CT145: A phase II, multicenter, open-label study (COMPASSION-26) of cadonilimab, a PD-1/CTLA-4 bispecific antibody,combined with chemotherapy (chemo) as first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC)

Abstract Background: PDAC is a highly lethal malignancy, with approximately 80% of patients presenting with unresectable locally advanced or metastatic disease at diagnosis. Prognosis for advanced PDAC remains poor, with limited treatment options. Cadonilimab, a PD-1/CTLA-4 bispe …

17.04.2026

Abstract LB395: Potential survival benefits from early detection: Development and results of a multi-cancer simulation model

Abstract The rapid development of blood-based or liquid-biopsy cancer screening tests may change the landscape of how cancer screening is performed. Statistical models that study optimal screening strategies are usually of a single cancer type. We present the development of a mul …

17.04.2026

Abstract CT180: Safety and efficacy of pucotenlimab combined with standard chemotherapy regimens in the preoperative treatment of pediatric patients with intermediate or high-risk rhabdomyosarcoma: A phase I/II study

Abstract Background: Rhabdomyosarcoma is the most common soft tissue sarcoma in pediatric populations, and intermediate or high-risk cases are associated with poor prognosis and limited therapeutic options. In this study, we aimed to evaluate the safety and efficacy of preoperati …

17.04.2026

Abstract CT078: First-in-human phase I study of UCL70802, a LACO-Stim armored Anti-CD70 CART cell therapy, in patients with metastatic clear cell renal cell carcinoma (mccRCC)

Abstract Background: UCL70802 is a novel autologous CART product engineered to co-express an anti-CD70 CAR and a Lymphocyte-APC-Co-stimulator (LACO-Stim) molecule, designed to target CD70-positive tumors through dual mechanisms: direct tumor lysis via CAR engagement and systemic …

17.04.2026

Abstract LB127: Drivers and patterns of disease progression as a novel schema for risk stratification in metastatic non-small cell lung cancer

Abstract Background: Targeted therapy (TT) and immunotherapy (IO) have transformed the systemic therapy (ST) landscape for non-small cell lung cancer (NSCLC), but overall prognosis remains poor. Select organ metastases may be predictive of decreased survival; however, the fundame …

17.04.2026

Abstract LB028: LN019, a novel HER2-targeting affibody-drug conjugate, demonstrates superior antitumor efficacy compared to T-DXd in xenograft models

Abstract Affibody, distinguished by its compact three-helix structure, offers significant advantages over conventional monoclonal antibodies, such as superior tissue penetration kinetics, picomolar binding affinity, and efficient production via prokaryotic expression. Leveraging …

17.04.2026

Abstract LB191: Decoding metastasis and therapy resistance in sarcomatoid bladder cancer

Abstract Sarcomatoid bladder cancer represents an extreme manifestation of tumor plasticity, characterized by rapid metastatic progression and limited durability of systemic therapies. Increasing evidence implicates that epithelial-mesenchymal transition (EMT) underlies this aggr …

17.04.2026

Abstract LB162: Twistcgp pipeline: A portable, open-source workflow for comprehensive genomic profiling in translational oncology

Abstract Comprehensive genomic profiling (CGP) panels are widely used in translational studies & clinical trials to support patient stratification, exploratory biomarker analysis, & retrospective molecular characterization. However, secondary analysis & reporting workflows are of …

17.04.2026

Abstract NG04: BMAL2 is a KRAS-driven master regulator of hypoxic adaptation and EMT in pancreatic ductal adenocarcinoma

Abstract Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive human malignancies, with a five-year survival rate below 15%. In contrast to several other solid tumors where chemotherapy, radiotherapy, and immune checkpoint blockade have significantly improved outco …

17.04.2026

Abstract LB011: Exploratory biomarker analysis of the phase 3 RATIONALE 305 trial: First-line (1L) tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT for advanced gastric cancer/gastro-oesophageal junction adenocarcinoma (GC/GEJC)

Abstract Background: In the randomised phase 3 RATIONALE 305 trial (NCT03777657), patients (pts) with advanced GC/GEJC treated with 1L TIS + CT had significantly improved overall survival (OS) vs PBO + CT. We present exploratory biomarker and molecular subtyping results from RATI …

17.04.2026 · 1 Zitationen

Abstract LB414: Updated clinical efficacy and translational biomarker analysis of tumor infiltrating lymphocyte therapy (LM103) in metastatic melanoma

Abstract Background: Tumor-infiltrating lymphocytes (TIL) adoptive therapy has shown clinical efficacy for metastatic melanoma refractory to anti-PD-1 therapy. This phase I clinical trial evaluated the safety and efficacy of TILs (LM103) in advanced Chinese patients (pts) with me …

17.04.2026

Abstract LB022: Cutting-edge, drug-free targeted cancer therapeutic: Smart folate-conjugated copolymer intrinsically disables the YAP/TAZ-HIPPO oncoproteins and abrogates pancreatic cancer progression and metastasis

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is driven by intrinsic chemoresistance and adaptive survival pathways, including the Hippo/YAP axis and hypoxic signaling. Systemic cytotoxic therapy is limited by severe toxicity and poor tumor penetration. Recent adva …

17.04.2026

Abstract LB371: Prospective investigation of the blood metabolome to identify risk biomarkers for biliary tract cancer

Abstract Biliary tract cancer (BTC) is a group of rare and aggressive malignancies; most (∼80%) patients are diagnosed with metastatic disease, which has a five-year survival rate of 3%. A better understanding of BTC etiology and biology is critical for designing cost-effective p …

17.04.2026

Abstract LB466: Scalable, digitally enabled FISH workflows for high-confidence HER2 and genomic biomarker assessment in precision oncology

Abstract Fluorescence in situ hybridization (FISH) is a widely used cytogenetic method for detecting gene amplification, deletions, and structural alterations in solid tumors. Its single-cell resolution and high specificity make it essential for assessing biomarkers such as HER2 …

17.04.2026

Abstract LB279: Tumor-targeted bispecific antibodies effectively inhibit oncogenic pathways while minimizing toxicity

Abstract Oncogenic signaling pathways are key drivers of cancer progression, but their inhibition has been difficult due to dose-limiting toxicities in normal tissues. Aberrant Wnt signaling, a major oncogenic pathway in colorectal cancer (CRC) and pancreatic ductal adenocarcinom …

17.04.2026

Abstract LB024: Preclinical profile and first-in-human study design of KHN922, a novel dual-payload HER3-targeted ADC, for advanced solid tumors

Abstract HER3 (human epidermal growth factor receptor 3) is highly expressed in various solid tumors , where it drives tumor progression and confers therapy resistance through heterodimerization with EGFR or HER2. Although the single-payload HER3-targeted ADC patritumab deruxteca …

17.04.2026

Abstract LB283: Oncogenic WNT/β-catenin signaling reduces MAPK signaling to suppress broad gene expression and promote colorectal cancer progression

Abstract Background: The WNT-β-catenin-APC signaling axis is the most mutated pathway in colorectal cancer (CRC). Two of the most commonly lost proteins in early colorectal tumorigenesis are the hormone ligands (guanylin and uroguanylin) for the tumor suppressor, guanylate cyclas …

17.04.2026

Abstract CT241: Phase 2 window of opportunity trial of pyrimethamine in locoregionally advanced head and neck squamous cell carcinoma

Abstract Background: Constitutive activation of the NRF2 stress response pathway is a common occurrence in head and neck squamous cell carcinomas (HNSCC), promoting metabolic reprogramming, immune evasion, and resistance to radiation therapy. Through integrative omics, we identif …

17.04.2026

Abstract CT219: A randomized, double-blind, placebo-controlled Phase 2 study of mifomelatide (TCMCB07) in patients with newly diagnosed metastatic colorectal cancer undergoing chemotherapy: The Paradox Trial

Abstract Background: Cachexia is a complex metabolic disorder characterized by involuntary weight loss, anorexia, and fatigue. It affects many patients with cancer and is associated with reduced chemotherapy tolerance, diminished quality of life, and reduced overall survival (OS) …

17.04.2026

Abstract CT090: Pilot study of an implantable microdevice for in situ evaluation of drug response in patients with pancreatic cancer

Abstract Background: Standard of care for both early and late-stage pancreatic ductal adenocarcinoma (PDAC) depends in part on effective multi-agent chemotherapy, yet fewer than half of patients respond to their therapy. Although gene expression profiling has identified transcrip …

17.04.2026

Abstract CT304: Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial) a Phase 1b 2a study-Interim analysis

Abstract Background: Narmafotinib (AMP945) is a highly potent and selective inhibitor of Focal Adhesion Kinase (FAK). FAK is a non-receptor tyrosine kinase over-expressed in pancreatic cancer (PCa), where it contributes to cell survival, proliferation, migration, chemoresistance …

17.04.2026

Abstract LB213: Clinician perspectives on weight stigma highlight opportunities to improve preventive cancer screenings for patients with obesity

Abstract Background: Obesity increases cancer risk and impairs cancer survival. Patients with obesity may be less likely to receive cancer screenings that reduce cancer morbidity and mortality. Weight stigma may represent an under-recognized barrier to participation in cancer scr …

17.04.2026

Abstract CT185: A phase 1 trial of M3814 (peposertib) in combination with lutetium 177 DOTATATE for metastatic well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Abstract Background: Radiolabeled SSA, Lu-177 DOTATATE is a beta-emitting radionuclide, currently used for SSTR positive GEP-NETS. Despite favorable progression free survival (PFS) and safety profile, next generation of radioligand therapy trials must seek improvement in PFS and …

17.04.2026

Abstract LB484: Evaluation of immune-checkpoint inhibitor-induced pneumotoxicity using a patient-derived alveolar organoid and PBMC co-culture model

Abstract Immune-checkpoint inhibitors (ICIs), such as Pembrolizumab (anti-PD-1) and Atezolizumab (anti-PD-L1), have revolutionized oncology. However, their use is frequently limited by immune-related adverse events (irAEs), with checkpoint inhibitor-pneumonitis (CIP) being one of …

17.04.2026

Abstract LB454: Complete restoration of p53 in p53 mutant cancers through co-delivery of p53 siRNA and mRNA using a targeted LNP platform

Abstract p53, the "Guardian of the Genome," maintains cellular integrity by inducing cell cycle arrest or apoptosis. While p53 mRNA delivery is an emerging therapeutic approach, its efficacy is often limited to p53-null backgrounds. In p53-mutant cancers, the effectiveness of wil …

17.04.2026

Abstract LB003: Integrated computational design and cDNA display selection enable cyclic peptide radiopharmaceutical ligand discovery

Abstract Despite their small size, cyclic peptides offer a desirable balance of binding affinity and biological specificity, making them attractive scaffolds for radiopharmaceuticals and peptide-based theranostics. However, identifying novel cyclic peptide ligands suitable for po …

17.04.2026

Abstract CT299: Dirozalkib versus crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): Results from the multicenter, randomized, open-label phase 3 trial

Abstract Background: Dirozalkib is a novel, highly selective inhibitor of anaplastic lymphoma kinase (ALK). This open-label, multicenter, randomized, phase 3 study (NCT05204628) was to evaluate the efficacy and safety of dirozalkib versus crizotinib in patients (pts) with advance …